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Pituitary adenylate cyclase-activating polypeptide (PACAP), a member of the 
secretin/glucagon/vasoactive intestinal peptide family, which is expressed throughout 
the nervous system, binds to the PACAP-specific G-protein-coupled receptor family 
members to promote both neuronal differentiation and survival. Although the PACAP 
receptor is known to activate its effector protein, adenylate cyclase (AC), and thus 
enhance cAMP generation, the molecular mechanism utilized by the receptor to 
activate AC is lacking. In addition, plasma membrane lipid rafts/caveolae 
microdomains, which are enriched in cholesterol and glycosphingolipids, mediate 
many intracellular signaling cascades leading to a variety of biological outcomes. The 
aim of this study is to elucidate the role of lipid rafts/caveolae in PACAP-induced 
neuritogenesis and the pertinent signaling pathways in PC12 cells. 
 
 The current study shows that PACAP induces neurite outgrowth in PC12 cells by 
induction of translocation of the PACAP type 1 receptor, PAC1R, into caveolin-
enriched Triton X-100-insoluble microdomains, leading to stronger PAC1R-AC 
interaction and elevated cAMP production. Moreover, it has been demonstrated that 
translocation of PAC1R is blocked by various treatments that selectively disrupt 
caveolae and, as a result, intracellular cAMP level is decreased and consequently the 
PACAP-induced neurite outgrowth retarded. In contrast, addition of exogenous 
ganglioside GM1 to the cells shows the opposite effects. In addition, the distribution 
 xvii 
of the downstream effector protein Rap1 which is activated upon cAMP elevation 
favors the detergent-insoluble fraction upon PACAP induction. Rap1 regulates the 
PACAP-induced neurite outgrowth through modulating the GSK3 activity and 
subsequent ERK1/2 phosphorylation. These results therefore identify the PACAP-
induced translocation of its G-protein-coupled receptor and Rap1 into lipid 
rafts/caveolae, where both AC and the regulating G-proteins reside, as the key 
molecular events in activating AC and inducing cAMP-mediated differentiation of 
PC12 cells. In addition, PACAP-elicited Rap1 and Ras activation accounted for the 
sustained and transient activation of downstream ERK1/2 activation and neurite 
extension. At the same time, PKC and Ca2+ mobilization collaborated with cAMP 
pathways on PACAP signaling by regulating GSK3 and ERK1/2 activity. ERK1/2 
translocated to nucleus and activated the transcription factors CREB and Elk, which 
is an essential transcriptional requirement for the effective cell differentiation.  
 
These results therefore demonstrate novel lipid rafts/caveolae-mediated signaling 
cascades induced by PACAP in PC12 cells. Moreover, this study shows that lipid 
rafts/caveolae microdomains regulated the PACAP-stimulated differentiation in PC12 
cells as a platform to gather related signaling molecules upon ligand-receptor binding. 
Specifically, it demonstrates that the PAC1 receptor and downstream Rap1 protein 
preferably shift to the rafts fraction once activated, which initiated and transduced the 
signaling cascades. It also indicates that the integrity of lipid rafts/caveolae is of 
importance for the efficient neuritogenesis in PC12 cells. This study should therefore 
 xviii 
shed light on the better understanding of the underlying mechanisms of 
neuritogenesis process, particularly in the neurodegenerative diseases, which may 

















CHAPTER 1.  INTRODUCTION 
 
Elucidation of the underlying molecular and cellular basis of neuronal differentiation 
has been greatly facilitated by cell culture models. The cell line PC12 was cloned 
from rat adrenal pheochromocytoma, and it was the first cell line that was 
characterized based on its capacity to cease proliferation and extend branching 
varicose processes (ie. differentiation) when exposed to nerve growth factor (NGF), 
the first known neurotrophin (Greene and Tischler 1976; Levi-Montalcini 1965). In 
addition to NGF, it has been reported that many other cellular factors such as growth 
factors (e.g. platelet-derived growth factor: PDGF and fibroblast growth factor: FGF), 
hormones and neurotransmitters could also initiate multiple signaling pathways that 
converge on specific cellular targets, resulting in neurite extension and competence 
for neuronal excitability in PC12 cells (Vaudry et al. 2002a). Based on its ability to 
differentiate toward sympathetic neurons after exposure to different cellular factors, 
PC12 cells have been extensively used as a useful in vitro model for the investigation 








1.1. PC12 cell differentiation and signaling pathways 
 
1.1.1. NGF pathway  
 
Over the past 30 years, the effects of NGF on PC12 cell differentiation have been 
extensively investigated (Lange-Carter and Johnson 1994; Angelastro et al. 2000; 
Huang et al. 2001; Vaudry et al. 2002a; Lee et al. 2005). NGF-stimulated PC12 cells 
cease division, extend neurites, express neuronal specific markers, and become 
electrically excitable (Tischler and Greene 1975; Greene and Tischler 1976). In PC12 
cells, the multiple effects induced by NGF appear to be mediated by at least two 
distinct signaling cascades, the Ras/ERK pathway that mediates differentiation and 
the AKT-PI3 kinase pathway that enhances survival. Differentiation signaling in 
PC12 cells induced by NGF through the receptor tyrosine kinase (RTK), TrkA, is 
well known (Chao et al. 1995). Upon binding to NGF, the receptor TrkA is activated 
and autophosphorylates itself on Tyr-490, a step which is required for Shc association 
and subsequent activation of the Ras-ERK signaling cascades. This then leads to 
activation of Elk-1 dependent gene transcription and neurite outgrowth (Yoon et al. 
1997). Significant progress has been made in the identification of the intracellular 
signaling intermediates that are involved in transducing neurotrophin NGF-mediated 
neuronal differentiation. However, certain aspects still need to be definitely clarified. 
For instance, the Ras/ERK cascade has been demonstrated to be both necessary and 
sufficient for differentiation of PC12 cells stimulated by NGF (Klesse et al. 1999). 
 3 
However, it was also reported that NGF activates the ERK pathway through not only 
transient activation of Ras family proteins (Qui and Green 1992; Marshall 1995), but 
also sustained activation of Rap1, which in turn induces sustained activation of B-Raf, 
and subsequently the ERKs (York et al. 1998; 2000). Recently, Sun et al. (2006) 
suggested that NGF induces neuronal differentiation of PC12 cells through sustained 
activation of M-Ras, one of the isoforms of Ras protein, rather than through sustained 
activation of Rap1 (Sun et al. 2006). Nevertheless, NGF signaling pathways remains 





















   
 
Fig 1.1. Schematic diagram of singaling pathways of NGF-dependent PC12 cell 
differentiation. Ras and Rap1 (or M-Ras) -dependent signaling are thought to account for 
immediate and sustained neurite outgrowth effect induced by NGF respectively.  
 
Gene transcription











1.1.2. Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) 
pathway 
 
Following the identification of the neuronal differentiation function of NGF, several 
reports including Deutsch and Sun (1992), Hernandez et al. (1995) and Vandry et al. 
(2002) have all shown that treatment of PC12 cells with pituitary adenylate cyclase-
activating polypeptide (PACAP) also induces neurite outgrowth and inhibits cell 
proliferation. The following paragraphs provide a summary of the published works. 
 
1.1.2.1. Pituitary adenylate cyclase-activating polypeptide (PACAP) 
 
PACAP was originally isolated from an extract of ovine hypothalamus on the basis of 
its ability to stimulate cAMP formation in rat pituitary cells (Miyata et al. 1989). It 
belongs to a family of peptide hormones that includes secretin, glucagon, growth 
hormone-releasing factor, and vasoactive intestinal peptide (VIP), and acts via three 
G-protein-coupled receptors (Harmar et al. 1998). PACAP is the most ancient and 
conserved member of the VIP/glucagon superfamily. In the last few decades, PACAP 
has been identified in many vertebrate species, including human (Hosoya et al. 1992; 
Ohkubo et al. 1992), sheep (Miyata et al. 1989), rat (Ogi et al. 1990), mouse (Okazaki 
et al. 1995), chicken (McRory et al. 1997), lizard (partial sequence in Pohl and Wank 
1998), frog (Chartrel et al. 1991), salmon (Parker et al. 1993,), catfish (McRory et al. 
1995), stargazer (Matsuda et al. 1997), and stingray (Matsuda et al. 1998).  
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The sequence of PACAP is evidently well conserved during evolution from 
protochordate to mammals, indicating that it is involved in the regulation of primary 
biological events. There are two isoforms of PACAP: PACAP-27 and PACAP-38.    
These represent alternatively processed forms of a precursor protein that share a 
common N-terminal 27 amino acids.  PACAP-27 is the more ancient form whereas 
the vertebrate PACAPs are present as both a 38-amino acid form and a truncated 27-
amino acid form. Both forms exhibit substantial amino acid sequence homology with 
VIP (Miyata et al. 1990) (Fig 1.2). Moreover, the three-dimensional structure of 
PACAP also exhibits prominent similarities with those of other members of the 
VIP/glucagon family (Braun et al. 1983; Gronenborn et al. 1987; Wray et al. 1993). 
 
  PACAP-38       NH2-KNKVRQKYRKGLVAALYKKVAMQKRYRSYSDTFIGDSH  
    PACAP-27                  NH2-LVAALYKKVAMQKRYRSYSDTFIGDSH  
   VIP                       NH2-NLISNLYKKVAMQKRLRTYNDTFVADSH 
 
Fig 1.2. Amino acid sequences of the different isoform of PACAP and VIP in human. 
The amino acid sequences in VIP which are identical with PACAPs are highlighted.  
 
                      
PACAP is widely distributed in the central nervous system (CNS) and peripheral 
tissues and has been implicated in a broad range of biological processes including 
reproduction, development, growth, cardiovascular, respiratory, digestive functions, 
immune responses, and modulation of circadian rhythms (Vaudry et al. 2000). The 
major form of PACAP in all tissues is PACAP-38, with the highest concentration 
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found in the hypothalamus, cerebral cortex, hippocampus, posterior pituitary, testes, 
and adrenal gland (Arimura 1998). In several in vitro and in vivo models of cerebral 
ischemia, PACAP-38 has potent neurotrophic and neuroprotective effects (Reglodi et 
al. 2000; Uchida et al. 1996; Vaudry et al. 2000). PACAP acts as a hypothalamic 
hormone, neurotransmitter, neuromodulator, and neurotrophic factor that may play an 
important role during brain development and in learning and memory processes. It 
has been demonstrated that PACAP-38, when administered intra-cerebroventricularly 
at very low dosages, improves memory in rat (Sacchetti et al. 2001). In the 
developing CNS, PACAP expression decreases the number of mitotic cells and 
enhances neuroblast differentiation (Lu and Dicicco-Bloom 1997). In the adult brain, 
PACAP regulates neurotransmitter release, inhibits apoptosis (Uchida et al. 1996; 
Anderson and Curlewis 1998) and is neuroprotective. It reacts to injury, inflammation 
and may have neural oncogenetic functions through involvement in proliferation/ 
differentiation processes.  
 
 The neurotrophic and neurite-inducing action of PACAP was first observed in PC12 
cells in 1992 (Deutsch and Sun 1992). Initiation of neurite outgrowth occurred within 
4-8 h after the addition of PACAP-38 to cultured PC12 cells (Lazarovici et al. 1998). 
Since then, this cell line has been extensively used as a model to investigate the 
signaling pathways involved in PACAP-induced cell differentiation and survival. The 
neurite-inducing activity of PACAP-38 is markedly more robust than that observed 
for PACAP-27 in PC12 cells (Deutsch and Sun 1992). There is clear evidence that 
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PACAP exerts pleiotropic effects on multiple types of cells. However, many 
questions remain unanswered with regards to the molecular mechanisms involved in 
PACAP’s effect on proliferation, migration, differentiation, and apoptosis.  
 
Interest in the molecular mechanisms of PACAP-induced neuronal differentiation is 
especially intense because it represents the prototype for G-protein-coupled receptor 
(GPCR)-mediated neurotrophins (Waschek et al. 1998; Beaudet et al. 2000; Vaudry 
et al. 2000; Nicot et al. 2002). NGF, on the other hand, was extensively used as a 
model for neurodevelopmental processes through the function of tyrosine kinase 
receptors, (Sofroniew et al. 2001; Torocsik et al. 2002; Glebova and Ginty 2004. 
These two neurotrophic agents therefore induce neuronal differentiation through 
distinct receptors and different transduction pathways. They can however synergize to 
promote the neuronal differentiation and prolong phosphorylation of ERK1 and 2, 
which are required for the induction of neurite outgrowth (Kao et al. 2001; Sakai et al. 
2004). The signal transduction pathways responsible for mediating PACAP-induced 
neuronal differentiation are not as clearly understood as the NGF-mediated pathway, 
and their elucidation could reveal fundamentally novel mechanisms responsible for 






1.1.2.2. PACAP receptors and PACAP receptor type I (PAC1R) 
 
Two classes of PACAP binding sites have been characterized on the basis of their 
relative affinities for PACAP and VIP. Type I binding sites, which were originally 
characterized in the anterior pituitary and hypothalamus, exhibit high affinities for 
both PACAP-38 and PACAP-27 (Kd  0.5 nM) and much lower affinities for VIP 
(Kd > 500 nM) (Cauvin et al. 1990; Gottschall et al. 1990, 1991; Lam et al. 1990; 
Suda et al.1992). Type II binding sites, which are abundant in various peripheral 
organs including the lung, duodenum, and thymus, however possess a similar affinity 
for PACAP and VIP (Kd  1 nM) (Gottschall et al. 1990; Lam et al. 1990). 
According to their relative affinity for PACAP and VIP, three PACAP receptors have 
been cloned, and were termed PAC1R, VPAC1R, and VPAC2R receptors 
respectively by the International Union of Pharmacology (Harmar et al. 1998). 
Among these, PAC1R is a PACAP-specific receptor, whereas the VPAC receptors 
exhibit a similar affinity for both PACAP and VIP (Harmar et al. 1998). 
 
PAC1R was first cloned from a pancreatic acinar carcinoma cell line (Pisegna and 
Wank 1993) and was subsequently cloned from humans (Ogi et al. 1993; Pisegna and 
Wank 1996), bovine (Miyamoto et al.1994), rat (Hashimoto et al. 1993; Hosoya et al. 
1993; Morrow et al. 1993; Spengler et al. 1993; Svoboda et al. 1993), and mouse 
(Hashimoto et al. 1996b) sources. The PAC1R cDNA encodes a 495-amino acid 
polypeptide with seven putative transmembrane domains. It belongs to the G-protein-
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coupled receptor (GPCR) superfamily, and exhibits a high degree of sequence 
identity with the glucagons, secretin and calcitonin receptor cDNAs (Pisegna and 
Wank 1993). Indeed, PAC1R is the only endogenous GPCR that could stimulate 
neurite outgrowth in PC12 cells (Tristan et al. 2003). Multiple receptor isoforms are 
generated by alternate splicing of the PAC1R mRNA. The splice variants are 
determined by the absence (short variant) or presence of either one or two cassettes 
consisting of 28 (hip or hop1 variant) or 27 (hop2 variant) amino acids (Journot et al. 
1994). The presence of the hip cassette stimulates adenylyl cyclase (AC) only but not 
phospholipase C (PLC), while the presence of the hop cassette enables activation of 
both AC and PLC, suggesting that the various cassettes are involved in different 
second messenger coupling. In the brain and pituitary, the short variant is the most 
abundant form, whereas the hop variant predominates in the testes and adrenal gland 
(Spengler et al. 1993). Similarly, a variant of the receptor lacking the fourth and fifth 
exons encoding sequence in the extracellular domain has been described in 
hypothalamus and pituitary. This short splice variant of PAC1R is characterized by a 
21-amino acid deletion in the N-terminal extracellular region (Pantaloni et al. 1996; 
Dautzenberg et al. 1999). The existence of this 21-amino acid sequence influences the 
receptor’s ligand binding selectivity for the PACAP-38 and PACAP-27 isoforms and 
determines the relative potencies of the two peptides in stimulating PLC. Another 
PACAP receptor variant termed PAC1R transmembrane domain (TM) IV has been 
cloned in the rat cerebellum and differs from the short variant of the PAC1R by 
discrete sequence substitutions located in TMs II and IV (Chatterjee et al. 1996). 
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Surprisingly, activation of PAC1R TM IV has no effect on AC or PLC activity, but 
causes calcium influx through L-type voltage-sensitive calcium channels (Chatterjee 
et al. 1996). Other variants of the type I PACAP receptor have also been described 
(Svoboda et al. 1993; Chatterjee et al. 1996), as well as alternative splicing of the 5'-
untranslated region (5’UTR) (Chatterjee et al. 1997). The complex pattern of 
alternative splicing (as shown in Fig 1.3) modulates its ligand binding and signaling 
properties, resulting in the fine modulation of PACAP physiological effects (Nicot 












Fig 1.3. A. Putative topology of PAC1 receptor variant amino acid residues. 
Alternative splicing in the PAC1R region encoding the amino-terminal extracellular domain 
and third cytoplasmic loop generates multiple isoforms of the PACAP-selective PAC1 
receptor. The presence or absence of two 83 or 84-base pair exons in the region encoding the 
third cytoplasmic loop produces receptor variants with the HIP (green) and/or HOP (dark 
blue) cassettes. Alternative splicing of exons 4 (21 nucleotides) and 5 (42 nucleotides) 
encodes a 21-residue fragment (yellow) or 5’ untranslated region (5’UTR) (light blue) in the 
extracellular domain of the receptor, producing either short or 5’UTR isoforms. Another 
PAC1R variant TM4 differs from short variant of PAC1R by discrete sequence substitution in 
TM2 and 4.  
A, 
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Fig 1.3. B.  Schematic diagram of PAC1 isoforms. PAC1 isoforms that differ in either 
the extracellular N-terminal domains or transmembrane domains (TMs) II and IV or the IC3 



























5’UTR S TM4 HIP HOP1/2 3’UTR
5’UTR S 3’UTRTM4 HIP HOP2
5’UTR S 3’UTRTM4 HIP HOP1
5’UTR S TM4 3’UTR
HIP5’UTR S TM4 3’UTR
HOP15’UTR S TM4 3’UTR




PAC1R is actively expressed in different parts of neuroepithelia from early 
developmental stages and in various brain regions during prenatal and postnatal 
development. In the adult, it exists predominantly in the CNS (most abundantly in the 
olfactory bulb, thalamus, hypothalamus, the dentate gyrus of the hippocampus and 
granule cells of the cerebellum) (Spengler et al. 1993). The presence of PAC1R has 
also been reported in various components of the immune system (Delgado et al. 
1996a; Pozo et al. 1997), the cardiovascular system (Gagnon et al. 1994; Adamou et 
al. 1995; Wei and Mojsov 1996a, b; Wong et al. 1998) and a number of tumor cells 
such as rat pancreatic acinar AR4-2J (Buscail et al. 1990), medullary carcinoma 6/23 
cell line (Vertongen et al. 1994) as well as the human neuroblastoma cell line NB-OK 
(Cauvin et al.1990; Vertongen et al. 1997a). The latter suggest a possible involvement 
of PACAP in oncogenesis. Functional PACAP receptors including PAC1R have also 
been identified in PC12 cells (Watanabe et al. 1990).  
 
The wide distribution of PACAP and PACAP receptors has led to several studies 
aimed at determining the pharmacological effects and biological functions of the 
peptide. Analysis of the dynamic interactions of the PACAP with its receptor PAC1R 
would be rudimental for understanding of the molecular mechanism of the many 
biological events PACAP is involved in. Furthermore, as PACAP peptides and the 
PACAP receptors are found to be localized in areas affected by neurodegenerative 
diseases such as Alzheimer’s disease, it may make the investigation of the peptide 
and its receptors more meaningful in terms of the comprehensive understanding of, 
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and hence more effective prevention, intervention and therapy of these 
neurodegenerative diseases. 
 
1.1.2.3. Neurotrophic signaling induced by PACAP  
 
PAC1R is known to be positively coupled to the adenynyl cyclase (AC), PLC and 
calcium signaling pathways (Hernandez et al. 1995). It can also activate other 
signaling molecules such as phospholipase D (McCulloch et al. 2001) and Ras 
(Osipenko et al. 2000). Activation of three PACAP receptors by PACAP typically 
leads to a Gs-mediated cAMP elevation (Arimura 1998). 
 
It has been recently shown that PACAP-induced differentiation of rat neural stem 
cells (NSCs) into astrocytes involves the cAMP/protein kinase A (PKA) pathway 
(Vallejo and Vallejo 2002), while it promotes NSC proliferation via the PAC1R/PKC 
pathway (Mercer et al. 2004). Thus, it has been suggested that PKC or PKA is 
involved in PACAP-promoting signal propagation leading to either proliferation or 
differentiation of neural progenitor cells. However, studies on the PACAP signaling 
pathways have yielded conflicting findings: It was reported that PACAP induced 
neurite outgrowth in PC12 cells by increasing cAMP levels (Gunning et. al. 1981), 
while others suggested that PACAP stimulated both the cAMP and PLC pathways in 
immature cerebellar granule cells (Basille et al. 1995). PACAP has also been reported 
to be dependent on PKC but not cAMP-PKA and Ras in inducing neurite outgrowth 
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in PC12 cells (Lazarovici et al. 1998).  The downstream effect of PACAP on the 
neurite outgrowth is mediated through ERK, a mitogen-activated protein kinase 
(MAPK), phosphorylation of which is similar to, but distinct from that of NGF 
signaling (Barrie et al. 1997; Lazarovici et al. 1998; Vaudry et al. 2002b). 
Furthermore, although NGF (which signals through TrkA) and PACAP pathways 
may activate several common cellular signaling components, their ultimate effects on 
gene transcription and cellular phenotype differ substantially (Lazarovici et al. 1998; 
Vaudry et al. 2002). For example, NGF increases CREB-responsive gene expression 
through both CREB response element (CRE) and serum response element (SRE) 
(Bonni et al. 1995), while PACAP increases neuropeptide genes expression through 
cAMP and calcium signaling pathways (Vandry et al. 2002). In addition, the intensity 
and duration required for the neurite outgrowth differ in a stimulus-dependent fashion. 
The small GTPases Ras- and Rap1-dependent signaling through ERK are thought to 
account for immediate and sustained effects on neurite outgrowth in TrkA-mediated 
pathways (Qui and Green 1992; York et al. 2000). However, the mechanism of ERK 
activation in PACAP-induced pathways is still a matter of debate, as some reports 
indicate that ERK activation requires the PKC pathway (Barrie et al. 1997), while 
others suggest that cAMP elevation is involved in the stimulation of ERK (Hernandez 
et al. 1995; Vaudry et al. 2002b). It is also possible that PKA, PKC and Ca2+ are all 
necessary for ERK activation by PACAP in neuronal cells (Bouschet et al. 2003). In 
addition, it was suggested that PAC1R triggers neuronal differentiation of the PC12 
cell line via ERK1/2 activation by transiently activating Ras and inducing the 
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sustained GTP-loading of Rap1, which is similar to NGF pathway (Bouschet et al. 
2003). These different results on the activation of ERK and neuronal differentiation 
could be explained by the fact that several signaling pathways, including PKA, PKC 
and the small GTP-loading protein Rap1, may synergize to activate ERK (Bouschet 
et al. 2003). Alternatively, this could be due to the specific availability of signaling 
intermediates in different cell lines. In addition, whether the different effects observed 
were due to PC12 cells cultured in different conditions, ie. in normal serum 
concentrations or in low serum in which most ERK studies have been conducted 
(Barrie et al. 1997; Bouschet et al. 2003), are matters which need further clarification. 
The precise molecular events during PACAP-induced neurite outgrowth and the 
molecular mechanisms of PAC1R signaling in this regard therefore remain to be fully 
elucidated. A particular important and interesting aspect of PACAP signaling at the 
plasma membrane is the membrane microdomains-mediated clustering and 
organization of receptors and adaptor complexes. The following sections discuss this 
aspect in more detail. 
 
1.2. Lipid rafts, caveolae and caveolins  
 
Lipid rafts and caveolae are microscopic structures which discovery had changed the 
way we think about signaling events across cell membranes. These membrane 
microdomains are small platforms enriched in sphingolipids and cholesterol in the 
lipid bilayer. They are proposed to exist as laterally segregated regions of cell 
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membranes that form as the result of selective affinities between certain lipids and 
membrane proteins. The enriched sphingolipids and cholesterol in these domains act 
to compartmentalize membrane proteins, separating different biochemical functions 
(Simons and Ikonen 1997). Caveolae, a unique subset of lipid rafts, are invaginations 
of the plasma membrane characterized by the presence of the caveolin protein 
(Anderson 1998). It has been suggested that lipid rafts act in the sorting and 
subsequent transport of sphingolipids, cholesterol and certain membrane proteins. On 
the other hand, caveolae have been implicated in clathrin-independent endocytosis as 
well as in cholesterol efflux. Many signaling molecules are enriched in lipid rafts and 
caveolae, implicating these microdomains as platforms for assembly and launching of 
multi-molecular signaling cascades.  
 
In addition, the importance of lipid raft/caveolae signaling in the pathogenesis of a 
variety of conditions such as Alzheimer's disease, Parkinson's disease, prion diseases, 
systemic lupus erythematosus, HIV, cardiovascular disease as well as cancer has 
come to light in recent years (Simons and Ehehalt 2002; Quest et al. 2004). These 
specific membrane domains are therefore interesting targets for pharmacological 






1.2.1. The concept and definition of lipid rafts  
 
The original concept of lipid rafts was used to provide an explanation for the directed 
transport of cholesterol from the trans-Golgi to the plasma membrane, formally 
developed in 1997 by Simons and colleagues (Ikonen and Simons 1997). In 1998, this 
concept was further related to the liquid-liquid immiscibility observed within model 
membranes between the liquid ordered phase (Lo phase) and the liquid disordered 
phase (Ld or L phase) (Rietveld and Simons 1998).  Although the exact cause 
remains uncertain, this immiscibility is thought to arise as a result of free energy 
minimisation of the two phases. 
 
One of the original definitions of lipid rafts is that they differed from the rest of the 
plasma membrane in being specifically enriched in cholesterol and 
glycosphingolipids. They are resistant to non-ionic detergents, such as Triton X-100 
or Brij-98 at low temperatures (e.g. 4 °C). When detergent is added to cells, it has 
been hypothesised that the fluid part of membrane liquid will dissolve, while the lipid 
rafts will remain intact and can be extracted. Based on their composition and 
detergent resistance, lipid rafts have also been referred to as detergent-insoluble 
glycolipid-enriched complexes (GEMs), detergent-insoluble glycosphingolipid-
enriched membranes (DIGs), detergent resistant membranes (DRMs) or cholesterol-
enriched membranes (CEMs) (Dietrich and Jacobson 1999). However, the raft 
concept has long been controversial, largely because it has been difficult to prove 
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definitively that rafts exist in living cells. Several studies with improved methodology, 
such as electron microscopy, florescence resonance energy transfer (FRET) and 
photonic force microscopy, have dispelled most of the doubts that rafts are detergent-
induced artifacts, but rather exist as dynamic microdomains in the membrane of 
living cells (Brown and London 1997; Harder et al. 1998; Pralle et al. 2000; Varma 
and Mayor 1998; Friedrichson and Kurzchalia 1998; Wilson et al. 2000). Lipid rafts 
have indeed been established as critical structures for a variety of cellular processes 
(Andrew et al. 2004). 
 
1.2.2. The definition of caveolae  
 
Caveolae are specialized lipid rafts that are present in many different cell types 
(Anderson 1998). These were first described in the 1950s by Palade and Yamada 
based on their characteristic morphology as 50–80 nm diameter flask-shape 
invaginations observed by electron microscopy of thin sections (Palade 1953; 
Yamada 1955). Further study shows that caveolae assume a variety of shapes, 
including flat, vesicular, and tubular, as patches of membrane with these properties 
are dynamic domains that assume different shapes depending on their activity in the 
cell. For instance, flat caveolae that contain caveolin-1 have a striated coat, and 
become flask shaped during internalization (Smart et al. 1994). They can be either 
open at the cell surface or closed off to form a unique endocytic/exocytic 
compartment. In the 1990s, a series of studies provided evidence for the existence of 
 19 
plasma membrane microdomains enriched in glycosphingolipids, cholesterol, GPI-
linked proteins and certain intracellular signaling proteins (e.g. Src family kinases) 
(Simons and Ikonen 1997). The structure, function, and molecular composition of 
caveolae are dependent on the phase properties of a unique set of membrane lipids. 
Resident molecules freely move in and out of caveolae during their lifetime. 
Purification methods using the caveolae marker protein caveolin established a few 
criteria for the identification these membrane domains, which includes (i) resistance 
to solubilization by Triton X-100 at 4 °C (Sargiacomo et al. 1993) (ii) a light buoyant 
density (Smart et al. 1995) and (iii) richness in glycosphingolipids, cholesterol, and 
lipid-anchored membrane proteins. The function of caveolae may include cholesterol 
transport (Smart et al. 1996b), protocytosis (Anderson 1998), signal transduction 
(Anderson 1998; Li et al. 1996a), and processes that lead to tumor suppression 
(Galbiati el al. 1998). 
 
Due to the similar lipid composition among lipid raft, caveolae and flattened caveolae, 
they are co-purified as low density, detergent-insoluble membrane particles. This had 
contributed to some confusion in the literature with regards to their identity. The 
distinction among them is still vague, thus making it difficult to define which cellular 
functions are attributable to rafts and which to caveolae. For example, because 
cholesterol-modifying drugs such as cyclodextrins and filipin remove cholesterol 
from plasma membrane rafts and caveolae, these reagents cannot distinguish between 
the signaling events that occurring in these compartments. To avoid such confusions, 
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the use of the term "caveolae" is generally reserved for morphologically defined cell 
surface invaginations (containing caveolins), as originally proposed. Since caveolae 
are considered to be a subfamily of lipid rafts, lipid rafts and caveolae can indeed be 
described under a unified concept in many instances. 
 
1.2.3. The composition of lipid rafts/caveolae 
 
It is well known that lipid rafts/caveolae have a specific lipid composition and is 
enriched in lipid-modified proteins, as well as in receptors and signal-transducing 
molecules. A more detail description of these components is given below. 
 
1.2.3.1. Proteins in lipid rafts/caveolae 
 
There are three categories of raft-associated membrane proteins: those mainly found 
in the rafts, those present in the liquid-disordered phase, and those in an intermediate 
state of flux, moving in and out of rafts. Constitutive raft residents include 
glycophosphatidylinositol(GPI)-anchored proteins, doubly acylated proteins, such as 
tyrosine kinases of the Src family, G subunits of G proteins, endothelial nitric oxide 
synthase (eNOS), cholesterol-linked and palmitate-anchored proteins like Hedgehog 
(Jeong and McMahon 2002), and transmembrane palmitoylated proteins such as 
influenza virus hemaglutinin and -secretase (BACE) (Simons and Toomre 2000). 
This association can at least be partially attributed to the acylated, saturated tails of 
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both the tyrosine kinases and the GPI-anchored proteins, which matches the 
properties of sphingolipids more than the rest of the membrane (Simons and Ikonen 
1997). Indeed, proteins modified with either GPI or fatty acids are found to be 
enriched in lipid rafts/caveolae fractions (Sargiacomo et al. 1993; Smart et al. 1995). 
Mutations that abolish either the GPI-anchor addition (Keller et al. 1992; Ritter et al. 
1995) or fatty acid acylation (Robbins et al. 1995; Shenoy-Scaria et al. 1994) shift the 
protein to other fractions, suggesting that these two different covalent modifications 
are responsible for targeting proteins with a wide range of biochemical activities to 
the lipid rafts. When the GPI-anchored complement inhibitor protein CD59 is inserted 
into the promonocyte cell U937, it is initially dispersed in the membrane but becomes 
clustered after a brief period. The clustered molecules are active in cell signaling, 
whereas unclustered CD59 are inactive (van den Berg et al. 1995). Raft targeting is 
therefore correlated with functional activity. 
 
While these proteins tend to continuously present in lipid rafts, there are others that 
associate with lipid rafts only when the protein is activated. Some membrane proteins 
are regulated raft residents and have a weak affinity for rafts in the unliganded state. 
After binding to a ligand, they undergo a conformational change and/or become 
oligomerized and may therefore increase their affinity for rafts (Harder et al. 1998). 
Some examples of these include B cell receptors (BCRs), T cell receptors (TCRs), 
and an enzyme called CD39 (Horejsí et al. 1999; Matko and Szollosi  2002; 
Papanikolaou et al. 2005; Petrie et al. 2000). When bound to their ligands, certain 
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receptors move into lipid microdomains in the outer leaflet of the plasma membrane 
lipid bilayer. These domains are coupled to microdomains in the inner leaflet that 
contain signaling kinases, which become activated and initiate signaling cascades 
(Pierce 2002). Other proteins are completely excluded from rafts, such as transferrin-
receptor (Shogomori and Futerman. 2001). There are also proteins that are constantly 
moving, potentially accessing many different membrane compartments during their 
lifetime, such as the GPI-anchored folate receptors (Wang et al. 1997). In some cases, 
protein ligands for GPI proteins shift the receptor proteins from lipid rafts/caveolae to 
other compartments, where they may become tethered by a resident protein (Stahl and 
Mueller 1995; Conese et al. 1995; Gliemann et al. 1994; Andreasen et al. 1994). A 
relatively fast lateral mobility combined with a natural attraction for liquid-ordered 
phase lipids allows GPI proteins to shuttle information among different membrane 
compartments. Typically, the raft inclusion or exclusion of proteins is determined by 
whether or not they are found in membrane fragments extracted using Triton X-100, 
the ‘detergent resistence’ defenition of a raft. By these means, the partitioning of 
proteins in and out of rafts can be tightly regulated.  
 
1.2.3.2. Lipids in lipid rafts/caveolae 
 
Glycosphingolipids, sphingomylin and cholesterol, which form the lipid core of lipid 
rafts/caveolae, govern the phase properties of the lipids in these domains. Cholesterol 
is enriched 3- to 5-fold in the detergent-resistant fraction compared to total 
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membranes, and represents one-third to one-half of the total raft membrane lipid 
(Brawn et al. 1992; Pike et al. 2002; Prinetti et al. 2002). Cholesterol is thought to 
serve as a spacer between the hydrocarbon chains of the sphingolipids and to function 
as dynamic glue that keeps the raft assembly together (Simons and Toomre 2000). 
Cholesterol compartmentalizes between the raft and the non-raft phase, having a 
higher affinity for raft sphingolipids than to unsaturated phospholipids. Removal of 
raft cholesterol leads to dissociation of most proteins from rafts and renders them 
nonfunctional. One example is that perturbing the lipid-ordered phase with 
cholesterol-sequestering drugs such as filipin disperses GPI proteins in the plane of 
the membrane (Rothberg et al. 1990; Smart et al. 1996a). Protein-protein and protein-
lipid interactions within lipid rafts/caveolae are the major forces that determine how 
long the molecules would remain at this site (Zhang et al. 1991; Fiedler et al.1994). 
The phase properties of the core lipids therefore play major roles in generating the 
complex molecular environment found in lipid rafts/caveolae. 
 
Sphingomyelin is similarly enriched and represents 10–15% of total membrane lipid 
in rafts (Brawn et al 1992; Pike et al. 2002; Prinetti et al. 2002). An additional 10–
20% of raft lipid comprises glycosphingolipids, such as cerebrosides and gangliosides 
(Brawn et al. 1992; Prinetti et al. 2002). Glycerophospholipids, including the major 
membrane phospholipids, phosphatidylcholine and phosphatidylethanolamine, 
comprise less than 30% raft lipids compared to approximate 60% of lipids in total 
membranes (Brawn et al. 1992; Pike et al. 2002). Inner-leaflet lipids, such as 
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phosphatidylethanolamine and anionic phospholipids, are particularly depleted (Pike 
2003). Thus Triton X-100 resistant lipid rafts are distinct from bulky plasma 
membrane because they are enriched in cholesterol and sphingolipids, but are 










Fig 1. 4. A.  Schematic structure of a lipid raft. Lipid raft (purple) is specialized 
membrane domain containing high concentrations of cholesterol, sphingomyelin, and 
gangliosides. It is also enriched in phospholipids that contain saturated fatty acyl chains 
(straight lines in lipid tails). This composition results in lateral phase separation and the 
generation of a liquid-ordered domain. Bulk plasma membrane (orange) contains less 
cholesterol, sphingomyelin, gangliosides, and more phospholipids with unsaturated acyl 
chains. As a result, it is more fluid than lipid raft. A variety of proteins partition into lipid raft: 
glycosylphosphatidylinositol (GPI) -anchored proteins; transmembrane proteins; glycocylated 
modification of proteins and lipids. The invaginated caveola, a subclass of lipid raft that 

























Fig 1. 4. B. Schematic representation of the lipid and protein organization of a 
caveola. Sphingolipid- and cholesterol-rich domain is shown in purple and nonraft lipid 
domains are shown in orange. Caveolae contain a coat of oligomeric caveolin molecules 
inserted into the cytoplasmic leaflet of the membrane. Some proteins, including certain 
GPCR (shown as heptahelical structures with associated G protein), partition to caveolar 
domains due to either acylation, binding to caveolin or formation of a sphingolipid 'shell' 
around the protein or by a combination of these or yet unknown mechanisms. There are also 
GPI-linked enzymes, receptors (blue)  and palmitolated, Src-like kinases (orange) present in 
the caveolae. Also shown are undefined cytoskeletal interacting proteins (purple, grass green 


















1.2.4. Caveolins and their roles in signaling transduction 
 
1.2.4.1 The properties of caveolins 
 
Caveolin is the first marker protein and also the principle protein of caveolae 
(Rothberg et al. 1992). In the absence of caveolin, no morphologically identifiable 
caveolae could be observed (Razani and Lisanti 2001).  Multiple members of the 
caveolin gene family have been identified. These include caveolin-1 isoforms -1 (24 
kDa 178 amino acids) and -1 (21 kDa, 147 amino acids); caveolin-2 (20 kDa, 149 
amino acids), and caveolin-3 (17.2kDa, 151 amino acids) (Way and Parton 1996; 
Tang et al. 1996; Scherer et al. 1996; Glenney 1992; Kurzchalia et al. 1992). Among 
them, caveolin-1 was the first discovered and has been most extensively characterized. 
Caveolin-1  and -1  isoforms have in common a hydrophobic stretch of amino acids, 
the scaffolding domain, and the acylated C-terminal region. An N-terminal 31 amino 
acids sequence is unique to the  isoform. The two isoforms were shown to have an 
overlapping but slightly different distribution in mammalian cells (Scherer et al. 
1995). No detailed understanding of their functional diversity is available. More 
recently, three isoforms of caveolin-2 (2, 2, 2) have been described, however, 
caveolin-2, and -2 have not been characterized (Razani et al. 2002; van Derus et al. 
2003). Caveolin-1 and -2 are found in most cells, whereas caveolin-3 is muscle-
specific (most abundantly expressed in skeletal and heart muscle cells). 
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Caveolins are integral membrane proteins and adapt a hairpin-loop conformation in 
the lipid bilayer. There are three major domains in the structure of caveolins. The 
scaffolding domain (SCF) (19-21 amino acids in length) is essential for both caveilin 
oligomerization and the interaction with other proteins (Li et al. 1996a). The 
membrane-spanning domain (MS) forms a hairpin-like loop within the membrane, 
thereby exposing both the amino- and carboxyl-termini to the cytoplasmic surface, 
with no part of the polypeptide chain directly exposed to the extracellular 
environment (Parton 1996). The caveolin signature motif (CSF) is a conserved 
sequence (FEDVIAEP) found in all of the caveolins (Razani et al. 2002). Besides the 
above domains, another feature of caveolin-1 and -3 (but not caveolin-2) is the 
palmitoylation on three Cys residues at the C-terminal region. The palmitoylation is 
not necessary for caveolin targeting to caveolae (Dietzen et al. 1995, Bender et al. 
2002) but serves to stabilize the caveolin oligomers (Monier et al. 1996). Furthermore, 
palmitoylation of caveolin has been proposed to have a role in increasing its 
membrane association mediated by a 33-amino-acid hydrophobic domain (Parat and 





















      
 
Fig 1.5. Schematic diagram of the domain structure of caveolins. There are three 
major domains in the caveolins’ structure. The scaffolding domain (SCF) is essential for both 
caveolin oligomerization and the interaction with other proteins. The membrane-spanning 
domain (MS) forms a hairpin-like loop within the membrane. Caveolin signature motif (CSM) 
is the conserved sequence for all of the caveolins. Caveolins are parmitoylated on three 
cysteine residues. Such modifications are likely to stabilize the oligomers and increase its 
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1.2.4.2. The cellular functions of caveolins 
 
Caveolin-1 forms oligomers in the membrane, interacting directly with cholesterol, 
which stabilizes caveolin-1 oligomers (Monier et al. 1996; Murata et al. 1995; Li et al. 
1996a). High cholesterol levels in cells cause an increase in caveolin-1 mRNA levels 
(Fielding et al. 1997). On the other hand, sequestration of membrane cholesterol with 
drugs such as filipin (Rothberg et al. 1992), or depletion of intracellular cholesterol 
(Chang et al. 1992), causes the caveolae to disassemble and subsequently disappear. 
Since there is a threshold level of plasma membrane cholesterol below which 
caveolae cannot be formed (Hailstones et al. 1998), targeting caveolin-1 and caveolae 
can be achieved by several methods. These include modulating cholesterol-
production and caveolar lipid composition using cholesterol sequestration drugs such 
as filipin, nystatin, and amphotericin, or cholesterol depletion by -cyclodextrin, 
saponin, digitonin, and streptolysin, , or inhibition of cellular cholesterol-biosynthesis 
by statins (e.g. lovastatin). Direct perturbation of caveolin-1 and caveolae functions 
by caveolin-1 targeting small interfering RNA (siRNA) is also used in many current 
studies. Besides, caveolin-1 appears to be part of an intracellular lipid transport 
system capable of moving sterols between ER and caveolae, and this transport is 
related to the unique lipidic composition of the caveolar membrane (Murata et al. 
1995; Smart et al. 1996b). Furthermore, over-expression of caveolin-1 could lead to 
de novo formation of caveolae (Fra et al. 1995a). These observations suggest that 
caveolin-1 is an indispensable protein for both the structure and function of caveolae.  
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Apart from the fact that caveolins have lipid transportation and structural function 
within caveolae, various signaling molecules found in caveolae interact with 
caveolins, suggesting that caveolins may also participate in transmembrane signaling. 
These molecules include receptor tyrosine kinases and their downstream targets (e.g. 
epidermal growth factor receptor, c-Neu, platelet-derived growth factor receptor, 
insulin receptor, nerve growth factor receptor, neurotrophin receptor, H-Ras, Raf-1, 
and ERK), non-receptor protein tyrosine kinases (e.g. Src, Fyn, Yes, Bmx, Btk, and 
Fak), receptor serine/threonine kinases (e.g. transforming growth factor -type I 
receptor), G-protein-coupled receptors and their downstream signaling molecules (e.g. 
adenylyl cyclase, protein kinase A, 2-adrenoceptors), steroid hormone receptors 
(androgen and estrogen receptors), and enzymes of nitric oxide (NO) signaling 
(endothelial and neuronal NO synthase) (Krajewska and Maslowska 2004). 
Immunoprecipitates of caveolin-1 from cells exposed to insulin (Mastick et al. 1995) 
or platelet-derived growth factor (PDGF) (Liu et al. 1996) contain different sets of 
tyrosine-phosphorylated proteins. Anti-caveolin IgG precipitates can also contain 
eNOS (Feron et al. 1996), Ras (Wu et al. 1997; Li et al. 1997), p75 NTR (Bilderback et 
al. 1997), bradykinin receptors (de Weerd et al. 1997), and endothelin receptors 
(Chun et al. 1994). Immunoprecipitates of alpha integrin (Wary et al. 1996), and 
dystrophin (Song et al. 1996), contain caveolin-1, whereas caveolin-1 binds G (Li et 
al. 1995), Ras and Src (Li et al. 1996b) in vitro. GM1 ganglioside binds caveolin-1 
after it is inserted into cells (Fra et al. 1995b). The above receptors and major 
downstream components in their signaling chains are just a few examples which 
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suggest that caveolins fulfill a role in the modulation of cellular signaling cascades. 
The compartmentalization of various signaling molecules in caveolae and their direct 
and functional interaction with caveolins via the ‘scaffold’ domain provides a 
paradigm by which these membrane microdomains are involved in regulating signal 
transduction pathways.  
 
Caveolins are also implicated in many cellular processes, including transcytosis, 
vesicular migration, proliferation, apoptosis as well as endocytosis. On the basis of 
their endocytotic function, they may therefore also be used for drug delivery of new 
targeted therapeutic agents (Carver et al. 2003; Carver and Schnitzer 2003). In 
contrast to clathrin-dependent endocytosis, the caveolae-associated internalization 
pathway avoids lysosomes, and this bypassing of the acidic and disruptive 
compartment may be a major advantage in drug delivery. 
 
Notably, the association with caveolins seems, in most cases, to be inhibitory and 
serve to maintain the signaling molecules in an inactive or repressed state (Razani et 
al.  2002). For example, interaction of caveolins with TrkA and p75 NTR negatively 
regulated neurotrophin signaling in neuronal and glial cells (Bilderback et al. 1999). 
One possible explanation for this could be that the binding to caveolins serves to 
aggregate the components of a signaling system in a spatially-defined cell 
circumstances and to prevent inappropriate activation. Once the environment is 
suitable and the right ligand is available, signaling is then initiated with the molecules 
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dissociating from caveolins. Some evidence for such a mechanistic notion has been 
gained in investigation on PDGF and EGF receptors activation (Liu et al. 1996, 1997; 
Yamamoto et al. 1999; Couet et al. 1997; Mineo et al. 1999). Recent studies show 
that caveolin-1 can also function as a multi-drug resistance promoter and tumor-
promoter, dependent on the tumor type (Cohen et al. 2004;Williams and Lisanti 2005). 
Thus, the function of caveolin-1 and caveolae continues to be a fertile ground for new 
discoveries, as well as interesting controversies. 
 
1.3. Signaling transduction from lipid rafts/caveolae  
 
1.3.1. Different signaling transduction pathways from lipid rafts/ 
caveolae 
 
Lipid rafts/caveolae have gained much attention as important sites for signal 
transduction. This may be the most important role of rafts at the cell surface in a 
variety of cell types. Lipid rafts/caveolae containing a given set of proteins can 
change their size and composition in response to intra- or extra-cellular stimuli. The 
identification of signaling proteins in lipid rafts/caveolae has led to the hypothesis 
that these sphingomyelin- and cholesterol-enriched microdomains form a more stable 
lipid matrix, which can in turn act as an ordered support for receptor-mediated 
signaling events. The majority of receptors form complex aggregations of effector 
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molecules, which favors specific protein-protein interactions, thus resulting in the 
activation of signaling cascades.  
 
Numerous studies support the view above. For example, immunoprecipitation of 
several GPI proteins co-precipitates protein tyrosine kinases (PTKs) which are 
reliable markers for lipid raft/caveolae (Stefanov´a et al. 1991). Immunoblotting, 
enzymatic activity studies, and immunocytochemistry analyses all indicate that lipid 
raft /caveolae are major locations for PTKs. Their activity has also been localized to 
lipid rafts/caveolae (Liu et al. 1997). A major substrate for PTKs is, in fact, caveolin-
1 (Glenney 1989; Glenney 1986; Glenney and Zokas 1989), in which a peptide 
sequence (amino acids 82–101) that interacts with c-Src, possibly modulates PTK 
activity (Li et al. 1996b). In the case of tyrosine kinase signaling, adaptors, scaffolds 
and enzymes are recruited to the cytoplasmic side of the plasma membrane as a result 
of ligand activation (Hunter 2000). Both PDGF (Liu et al. 1996) and EGF (Mineo et 
al. 1996) stimulate the recruitment of multiple signal-transducing molecules to lipid 
rafts/caveolae, and are functionally connected to effectors in lipid rafts/caveolae. Also 
they stimulate the migration of the respective receptors out of caveolae. Several 
studies suggest that caveolin-1 has a role in recruiting G proteins to lipid 
rafts/caveolae as well as in modulating their activity (Scherer et al. 1996; Song et al. 
1996; Li et al. 1996a; Li et al. 1995). In addition, a model of excitation-contraction 
coupling mediated by lipid rafts/caveolae suggested that calcium storage and entry 
sites were located at lipid rafts/caveoale (Popescu 1974). Lipid rafts/caveolae play an 
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immediate role in the biogenesis of the T-tubule system (Parton et al. 1997). Indeed, 
Ca2+ ATPase (Schnitzer et al. 1995; Fujimoto 1993), inositol 1, 4, 5, -trisphosphate 
(IP3) receptors (Schnitzer et al. 1995; Fujimoto et al. 1992), and calmodulin (Shaul et 
al. 1996), key molecular components of calcium transport, have all been found to be 
localized to caveolae. These findings suggest a role for ER-caveolae interactions 
during calcium signaling and that lipid rafts/caveolae compartmentation at the surface 
is important for signaling. Numerous biochemical methods (Shaul et al. 1996; Liu et 
al. 1996; Garcia-Cardena et al. 1996a; Michel and Michel 1997; Sase and Michel 
1997) show that the majority of cell surface eNOS is also located in caveolae. This 
finding suggests that lipid rafts/caveolae are the site of NO production. In another 
example, GPI 5'-nucleotidase targeted to caveolae may convert extracellular 5'-AMP 
to adenosine, where it locally activates receptors (Strohmeier et al. 1997).  
 
Last but not least, some of the lipids and lipid-anchored proteins incorporated into 
rafts in the Golgi apparatus are important sources of signaling intermediates. 
Substrates for enzymes that release ceramide (Bilderback et al. 1997; Liu and 
Anderson 1995), IP3 (Hope and Pike 1996; Pike and Casey 1996), and 
inositolphosphoglycans (IPG) (Clemente et al. 1995; Stralfors 1997) are produced in 
rafts after a specific stimuli. These responses appear to be specific because neither 
ceramide nor IP3 is generated in non-rafts fractions, and the IPG released on the 
extracellular side of the membrane is internalized, presumably by rafts. All these 
three molecules elicit characteristic cellular responses, which must be a general 
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mechanism whereby lipids sorted to lipid rafts/caveolae become the source of critical 
signaling intermediates. 
 
With so many different signaling molecules in one location, lipid rafts/caveolae are 
the logical places to look for signal integration. For instance, GPI proteins can 
activate PTKs and generate a Ca2+ influx (van den Berg et al. 1995; Morgan et al. 
1993). PTKs phosphorylate eNOS, thereby inhibiting the enzyme and promoting its 
interaction with caveolin-1 (Garcia-Cardena et al. 1996b). However, the released Ca2+ 
will bind calmodulin, which activates eNOS. Any NO produced will stimulate the 
MAP kinase pathway through Ras, (Lander et al. 1996), in synergy with PTKs (Liu et 
al. 1997). All the above components are present in endothelial cell lipid rafts/caveolae, 
allowing cross talk between pathways to occur at one site on the plasma membrane. 
 
Furthermore, the ability of lipid rafts/caveolae to sequester molecules provides an 
opportunity for locally produced or imported molecules to modulate these signaling 
events. It has been proposed that one of the functions of the lipid rafts/caveolae is that 
they form concentration platforms for individual receptors, activated by ligand 
binding. If receptor activation takes place in a lipid rafts/caveolae, the signaling 
complex is protected from non-raft enzymes such as membrane phosphatases that 
otherwise could affect the signaling process. Rafts/caveolae recruit proteins to a new 
micro-environment, where their phosphorylation states can be modified by local 
kinases and phosphatases, thus resulting in further downstream signaling. In general
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rafts/caveolae represent spatial concentration of specific sets of proteins such that the  
efficiency and specificity of signal transduction are enhanced by facilitating 
interactions between proteins and by preventing non-specific cross-talk between 
pathways (Moffett et al. 2000). However, how these raft receptor complexes form 
while maximizing spatial requirements by selectively localizing various components 
from a densely packed cytosolic milieu to satisfy the temporal requirements of cell 
signaling, is still poorly understood.  
 
1.3.2. Models for signaling initiation through lipid rafts/caveolae   
 
Researchers have tested the presence and importance of lipid rafts/caveolae in cellular 
signaling based on two models which was proposed to generalize the initial signaling 
processes (Simons and Toomre 2000) in lipid rafts/caveolae. Signaling initiation 
occurs either in single raft or clustered rafts. In single raft this can occur by protein 
activation either within the raft, or by altering the partitioning dynamics of the 
proteins. The proteins could be phosphorylated in rafts after dimerization or 
oligomerization. The second model considers the case of having several rafts in the 
membrane, which differ in protein compositions. Individual raft clusters together to 
connect raft proteins and interacting proteins into a signaling complex. Clustering 
could occur either extracellularly, within the membrane, or in the cytosol. It could 
also occur through GPI-anchored proteins either as a primary or co-stimulatory 
response. A network of interactions between adaptors, scaffolds and anchoring 
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proteins would be built up to organize the signal complex in space and time through 
formation of a raft cluster. The formation of clustered rafts would not only result in 
the signaling complex being insulated from the surrounding liquid-disordered matrix, 
but also amplify the signal through concentration of signaling molecules, as well as 
exclusion of unwanted modulators. The models of signaling initiated by 
rafts/caveolae are as illustrated in Fig 1.6. 
 
The interactions that drive raft assembly are dynamic and reversible. Raft clusters can 
be disassembled by negative modulators and/or by removal of raft components from 
the cell surface. The coalescence of individual raft to form raft clusters has been 
observed repeatedly when, for example, raft components were cross-linked with 
antibodies (Harder 1998; Janes et al. 1999). In addition, these two models are not 
mutually exclusive. For instance, extracellular signals could both increase a protein's 
raft affinity therefore drawing more of the protein into the raft where it can be 






















                                  .Adapted  with permission from Nature reviews/Molecular cell biology 1,31-9(Oct.2000)  
Fig 1.6. Schematic diagram for the model of lipid rafts/caveolae 
signaling.   Signaling occurs in either single raft (A or B) or clustered rafts (C). Following 
dimerization (or oligomerization) the protein becomes phosphorylated (purple sphere) in rafts. 
In single raft, this can occur (A) by activation within the raft, or (B) by altering the 
partitioning dynamics of the protein. In clusters of rafts (C), single raft would be coalesced by 
clustering so that they would contain a new mixture of proteins such as crosslinkers and 
enzymes. Raft clustering could occur either extracellularly, within the membrane, in the 















































The GPCRs family with seven transmembrane -helical domains constitute a large 
group of membrane receptors known to modulate a wide range of biological 
responses, including cell growth, differentiation, migration, and inflammatory 
processes. Their malfunction may lead to a range of pathologies, including 
psychiatric and neurological disorders. Despite their importance, the mechanisms that 
regulate their function and signaling remain incompletely understood. Recently, it has 
become evident that some of the GPCRs, such as angiotensin1 (AT1) receptor, are 
not homogeneously distributed in the plasma membrane, but instead localizes to lipid 
rafts/caveolae (Wyse et al. 2003). Human GPCRs have recently been classified into 
five different groups named GRAFS (an acronym for the groups: glutamate, 
rhodopsin, adhesion, frizzled/taste2, and secretin (Fredriksson et al. 2003). PAC1R, 
as discussed earlier, belongs to the secretin subfamily.  GPCRs signal through 
receptors couple to heterotrimeric G proteins. Agonist binding at the receptor leads to 
exchange of G-protein-bound GDP for GTP. The activated heterotrimer dissociates 
into its component  subunit and the  dimer, both of which have independent 
capacities to signal downstream through the activation or inhibition of a myriad of 
effectors. Hydrolysis of GTP to GDP leads to signal termination and re-association of 
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the heterotrimer. Signal termination is modulated by regulators of G-protein-signaling 
(RGS) proteins which enhance the weak intrinsic GTPase activity of the G subunit. 
 
Under basal conditions, some GPCRs, such as gonadotrophin-releasing hormone 
(GnRH) receptors are almost exclusively located in rafts (more than 90%) (Navratil et 
al. 2003). Some others, such as oxytocin receptor (OTR), are present in much smaller 
proportions (only 10%) (Gimpl and Fahrenholz 2000; Guzzi et al.2002). Each GPCR 
seems to possess a specific pattern of trafficking to, and association with 
rafts/caveolae. Some receptors, such as the somatostatin (Sst2) receptor, move into 
lipid rafts/caveolae upon agonist binding (Krisch et al. 1998; Mentlein et al. 2001). 
Some receptor moves into lipid rafts after agonist binding in order to activate specific 
signaling events, but eventually moves out, as in the case of the AT1 receptor 
(Ishizaka et al. 1998; Wyse et al. 2003). There are also some other receptors that 
initially reside in lipid rafts but leave after agonist binding, such as the 2-AR 
(Schwencke et al. 1999; Rybin et al. 2000). These different paradigms reflect the 
different roles played by lipid rafts/caveolae in regulating the signaling and 
trafficking of any particular GPCR, and are dependent on cell-specific factors. The 
precise mechanism of how these receptors specifically shuttling inside/outside rafts 





1.4.2. The importance of lipid rafts/caveolae for GPCRs signaling 
 
There is growing evidence suggesting that lipid rafts/caveolae actively participate in 
the regulation of intracellular signal transduction by GPCRs as well as the trafficking 
of a number of GPCRs. Lipid rafts/caveolae are important for GPCRs signaling 
because heterotrimeric G proteins, RGS proteins, as well as GPCRs themselves, have 
been proposed to be targeted to lipid rafts/caveolae. The targeting of GPCRs 
signaling molecules and the creation of signaling complex in the lipid rafts/caveolae 
may be dependent on the lipid composition such as fatty acid of lipid rafts/caveolae 
surrounding the GPCRs and the signaling molecules, which can modulate the 
targeting of these proteins. For example, G subunits are fatty-acylated with amide-
linked myristate, thioester-linked palmitate, or both (Wedegaertner et al. 1995), which 
is proposed to be responsible for the targeting of G subunits to lipid rafts/caveolae. 
The regulator RGS proteins also undergo palmitoylation by an acyl transferase 
present in the rafts, which is linked to the increase in GTPase activity (GAP) of RGS 
(Hiol et al. 2003). In addition, GPCRs can also be palmitoylated at specific cysteine 
residues, which is necessary to target receptors to specific subdomains in the lipid 
bilayer (Milligan et al. 1995).  
 
The plasma membrane muscarinic acetylcholine receptor, for example, is 
redistributed to lipid rafts/caveolae upon addition of agonists but not antagonists 
(Raposo et al. 1987). G-protein-coupled bradykinin B2 receptor was also reported to 
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induce an upregulation of cellular responses mediated by localization of epidermal 
growth factor receptor (EGFR) to the rafts. Depletion of cholesterol by methyl--
cyclodextrin disrupted the raft localization of EGFR and Src, as well as bradykinin-
induced signaling. This suggests that lipid rafts/caveolae are essential participants in 
the regulation of receptor-mediated signal transduction and the crosstalk between 
different kinds of receptors, presumably via organizing signaling complexes in 
membrane microdomains (Hur et al. 2004). However, there is much that remains 
unknown in terms of the dynamic relationship of GPCRs with lipid rafts/caveolae, as 
well as the regulation mechanisms of both on the signaling transducing process. 
 
 
1.5. Functions of lipid rafts/caveolae in different biological 
processes  
 
1.5.1. Lipid rafts/caveolae and immune cell signaling  
 
 
Much of the information gained about rafts/caveolae was from studies of the immune 
cell: T lymphocyte, in which rafts are critical for the formation and function of the 
immunological synapse during initial activation through the T cell antigen receptor 
(TCR). Some research groups (Marmor and Julius 2001; Goebel et al. 2002; Vereb et 
al. 2000; Rakesh et al. 2004) have identified lipid rafts/caveolae as an important 
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component of the interleukin (IL)-2 signal transduction system in T cells. The role of 
rafts in T cell signaling is not limited to signal transduction in the context of initial 
activation through the TCR (Leitinger and Hogg 2001; Mañes et al. 2001; 
Subramaniam et al. 2002). Magee et al. (2002) proposed a mechanism whereby TCR 
engagement promotes aggregation of lipid rafts/caveolae, which facilitates 
colocalization of some signaling proteins while excluding others, thereby potentiating 
protein tyrosine phosphorylation and downstream signaling. Draber and Draberova 
(2002) have also suggested that the IgE receptor (FcepsilonRI), which is not 
associated with lipid rafts/caveolae in resting mast cells, induces a weak association 
with rafts upon aggregation and subsequent activation events. Recent evidence 
indicates that spatial organization of the immune receptors and components of their 
signaling cascades are not limited to T cells. Crucial aspects of subcellular 
localization of signaling molecules in regulation of B cell signaling was also pointed 
out and discussed (Hassan et al. 2004). Rafts lipid-, protein-controlled interactions 
and cell biological processes acted synergistically to generate functional domains that 
mediate B cell activity (Thomas and Karin 2004).  
 
Numerous experiments have provided substantial evidence that raft integrity is crucial 
for the initiation and maintenance of intracellular signals in lymphocytes. It was 
found that when rafts were depleted in T lymphocytes, the TCRs lost their ability to 
relay signals upon antigen attachment ( Matko and Szollosi 2002). Similarly, 
destroying lipid rafts by depleting cholesterol in B cells inhibited signaling through B 
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cell receptors (BCRs)  when they encountered an antigen, and no antibodies were 
produced (Petrie et al. 2000). It has also been shown that in the absence of rituxan (an 
anti-CD20 antibody), CD20 exhibits a low affinity to lipid rafts. However, binding of 
rituxan significantly increases the affinity of CD20 for lipid rafts, and that disturbing 
the raft integrity by cholesterol extraction results in dissociation of CD20 from lipid 
rafts followed by complete inhibition of rituxan-induced calcium entry and apoptosis 
(Janas et al. 2005). All of above suggest an essential role for intact lipid rafts/caveolae 
for cellular signaling and functioning in the immune-system.  
 
In addition to the immune cells, the function of lipid rafts/caveolae in signaling 
processes was also investigated in some other cell types. For example, in brain 
oligodendrocytes, regulation of integrin and growth factor interactions by lipid 
rafts/caveolae microdomains, through separation or colocalization of integrin and 
growth factor receptors, generates a signaling environment within the rafts for the 
activation of survival-promoting PI3K/Akt activity (Baron  et al. 2003). More 
recently, a role for lipid rafts/caveolae in signal transduction mechanisms capable of 
promoting the neuroendocrine differentiation phenotype in LNCaP PCa (aggressive 






1.5.2. Lipid rafts/caveolae and signaling in neuronal cells 
 
Investigations were also focused on the mechanisms of lipid rafts/caveolae in 
neuronal cell signaling. In 1999, Huang et al. found that many of the intermediates in 
the signaling cascade activated by Trk receptors which contributed to cell survival 
were present in lipid rafts/caveolae in PC12 cells, and that neurotrophin NGF binding 
to p75NTR and TrkA occurred mainly in lipid rafts/caveolae (Huang et al. 1999). 
Recently, it was reported that in differentiating PC12 cells, the protein tyrosine kinase 
Pyk2 and multifunctional adaptor protein Cbl, which were implicated in the 
regulation of the cytoskeleton in several cell types, formed a signaling complex that 
translocates to lipid rafts/caveolae and were enriched in growth cones of 
differentiating PC12 cells following growth factor stimulation (Haglund  et al. 2004). 
These results indicated that the recruitment of Pyk2/Cbl complexes to lipid 
rafts/caveolae participated in growth factor-induced regulation of the actin 
cytoskeleton in growing neurites.  
 
As a matter of fact, the roles of lipid rafts/caveolae on different neurotrophic factor-
induced signaling pathways have gained increasing attention. Ephrins and Eph 
receptors, the glial cell line-derived neurotrophic factor (GDNF) family receptors (c-
Ret and GFR), epidermal growth factor receptors (EGFR), neuregulin receptors 
(ErbB2-4), fibroblast growth factor receptors (FGFR) were known groups of 
receptors playing critical roles in neuronal cell survival, proliferation and 
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differentiation during neuronal development (Wu et al. 1997; Airaksinen and Saarma 
2002; Furuchi and Anderson 1998; Trachtenberg and Thompson 1997; Kramer et al. 
1996; Gritt et al. 1996). Upon activation, Ephrins, Eph receptors, and neuregulin 
receptors (ErbB2-4) were reported to localize to the lipid rafts/caveolae 
microdomains and many signaling events triggered by them appeared to be critically 
dependent on this localization (Wu et al. 1997; Bruckner et al. 1999; Frenzel et al. 
2001). Similarly, GDNF receptors’ signaling had been shown to depend on the 
integrity of lipid rafts/caveolae because cholesterol depletion with methyl--
cyclodextrin reduced GDNF-dependent activation of MAPK and Akt kinases (Tansey 
et al. 2000). On the other hand, EGFR concentrated in plasma membrane caveolae 
under resting conditions, but moved out of caveolae following EGF stimulation 
(Furuchi and Anderson 1998; Mineo et al.1999). In addition, several rapid signaling 
events induced by EGF binding, including tyrosine kinase activation, recruitment of 
adaptor proteins, phospholipase C-mediated hydrolysis of phosphatidylinositol 4, 5-
bisphosphate, and activation of Ras/MAPK, appeared to occur within caveolae, 
suggesting that EGFR signaling was initiated and organized in these microdomains 
(Mineo et al. 1999). On the other hand, FGFR does not appear to be present in lipid 
rafts/caveolae. However, many proteins involved in FGFR signaling resided within 
these lipid domains (Kouhara et al. 1997). For example, stimulation of human 
neuroblastoma cells with FGF2 was shown to result in tyrosine phosphorylation of 
several proteins, including the two Src family kinases Fyn and Lyn, as well as Src 
family substrate anexin II within lipid rafts/caveolae (Davy et al. 2000).  
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The rapid growth in lipid rafts/caveolae research has brought with it a changing view 
of these enigmatic membrane domains. Lipid rafts/caveolae constitute a membrane 
system equal in complexity to any cellular compartment or organelle. Although the 
role of lipid rafts/caveolae in regulating some transduction pathways is now well 
established, such as the assembly of the various components of the immune receptor 
signaling cascade (Dykstra et al. 2001; Sedwick and Altman 2002; Werlen and 
Palmer 2002), detail understanding the role of rafts/caveolae in the functional 
regulation of other signaling components is still lacking. Lipid rafts/caveolae are 
potentially capable of regulating different receptors including GPCRs in different 
ways depending on the cell’s metabolic state, differentiation and stage of growth. As 
a result, it is difficult to make any generalizations or to elucidate the exact role played 
by rafts/caveolae in different physiological and pathological conditions.  
 
Although a broad range of receptors has been investigated on these microdomains 
during these decades; many important aspects of the role of lipid raft/caveolae in 
neurotrophic factor signaling remain unanswered. In particular, understanding of the 
roles that lipid rafts/caveolae may play on PACAP-induced neuronal differentiation 
pathways is largely poor. Furthermore, in specific neurodegenerative diseases such as 
Alzheimer’s disease, these microdomains may be defective, making it important to 
learn more about their normal biology. From another perspective, lipid rafts/caveolae 
are important research tools. They clearly contain a variety of signal-transducing 
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molecules that interact in characteristic patterns after cell stimulation. The ease of 
lipid rafts/caveolae isolation makes it possible to study how the natural organization 
of these molecules imparts cell function at the molecular level. The physiological 
significance of lipid rafts/caveolae in cell signaling is not confined to the cell surface, 
but is also relevant in several other important processes, such as pathogen entry, 
receptor internalization, and protein nuclear translocation (Schroeder et al. 2001; Lai 
2003).  
 
Previous studies have established that lipid rafts/caveolae are presented in PC12 cells, 
and they are involved in the propagation of a PACAP-induced signal (Huang et al. 
1999; Deutsch and Sun 1992; Hernandez et al. 1995; Lazarovici et al. 1998). In 
addition, PACAP receptor type I, PAC1R, is expressed and positively coupled to 
AC6, the type 6 adenylate cyclase isoform found in PC12 cells (Detsch and Sun 1992; 
Spengler et al. 1993; Oshikawa et al. 2003; Ravni et al. 2006). PC12 cells should 
therefore serve as an excellent cellular model to study the role of membrane 
microdomains scaffolded by caveolins, such as those found in neurons (Galbiati et al. 







1.6. Objectives of this study 
 
In this study, the main objectives are to unravel the molecular mechanisms of 
signaling pathways that control the differentiation of neuronal-like PC12 cell upon 
PACAP stimulation. Since lipid rafts/caveolae have been reported to play very active 
roles in a variety of biological responses including regulation of the receptors and 
signaling molecules gathering in NGF-mediated pathways in PC12 cells, they could 
also be potentially involved in PACAP-stimulated differentiation signaling in this cell 
line. Therefore, this study aims to gain insight on the putative role of lipid 
rafts/caveolae and their components, i.e. cholesterol, glycosphingolipids and caveolin, 
as well as the integrity of lipid rafts/caveolae in PC12 cell neurite outgrowth 
following PACAP treatment. To achieve these objectives, I used ganglioside GM1 
and NB-DNJ treatments to modulate the levels of plasma membrane 
glycosphingolipids level and cholesterol-methy--cyclodextrin complex as exogenous 
supplementation to increase the level of cholesterol in lipid rafts/caveolae. On the 
other hand, raft-disrupting agent U18666a was applied to inhibit intracellular 
cholesterol trafficking, while filipin, nystatin and methy--cyclodextrin were used to 
chelate or deplete cholesterol in the plasma membrane. A gene silencing siRNA 
approach was used to inhibit the expression level of caveolin-1 Through these 
methods, the structure of lipid rafts/caveolae microdomains could be perturbed or 
disrupted and the importance of lipid rafts/caveolae in PACAP signaling can thus be 
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investigated.This study also aims to identify the precise signaling components and 
pathways initiated by PACAP, leading to neurite extension in PC12 cells. 
 
Briefly, this study sought to determine: 
1). the function of lipid rafts/caveolae in PACAP-stimulated neurite extension process 
in PC12 cells. 
2). the signaling cascades activated upon PACAP agonist binding as well as the 
molecular mechanisms of the process that lead to neurite generation induced by 
PACAP in PC12 cells. 
 3). the underlying molecular mechanisms of how lipid rafts/caveolae modulate 
PACAP signaling in PC12 cells. 
 
This project may shed light on the fundamental role of plasma membrane lipid 
rafts/caveolae, especially their core lipids compositions (ie. glycosphingolipids and 
cholesterol) and their integrity, in neuritogenesis upon agonist PACAP stimulation. 
Also, it may characterize the molecular mechanisms of PACAP-induced signaling 
transduction pathways mediated by these membrane microdomains, leading to better 
understanding of the underlying principles of neuritogenesis process. These, in turn, 
could result in effective prevention and therapeutic intervention of neurodegenerative 


















PC12 cell line and horse serum were purchased from American Type Culture 
Collection (ATCC) (Manassas, VA, USA). Cytochalasin D, pituitary adenylate 
cyclase activating polypeptide-38 (PACAP), direct cAMP enzyme immunoassay kit, 
RP-adenosine 3’,5’-cyclic monophosphorothioate, lithium, methyl--cyclodextrin, 
filipin, nystatin, mouse monoclonal anti--actin antibody, crystalline 
tetramethylrhodamine isothiocyanate (TRITC)-conjugated rabbit anti-goat antibody, 
poly-d-lysine hydrobromide, dimethyl sulfoxide (DMSO), N, N, N’, N’- tetramethyl-
ethylenediamine (TEMED), trypsin-EDTA, paraformaldehyde (PFA), 
phenylmethanesulfonyl fluoride (PMSF), sucrose, sodium dodecyl sulfate (SDS) and 
valproate were obtained from Sigma (St Louis, MO, USA). Adenosine 4’, 5’-cyclic 
monophosphate, N6, O2-dibutyryl (db-cAMP), chelerythrine, FPT inhibitor II, glycine, 
H89, N - butyldeoxynojirimycin (NB-DNJ), 7S nerve growth factor (NGF) (mouse 
submaxillary glands), PD98059, 8-(4-chlorophenylthio)-2’-O-methyl-adenosine 3’, 
5’-cyclic monophosphate (8-OM-cAMP), Triton X-100, U18886A and U73122 were 
obtained from Calbiochem (Darmstadt, Germany). Opti-MEM® I reduced serum 
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medium was obtained from Invitrogen Corporation (Grand Island, NY, USA). 
MESACUP® Protein kinase assay system was purchased from UPSTATE (Lake 
Placid, NY, USA). Collagen, type I rat tail was obtained from BD Biosciences 
(Franklin Lakes, NJ, USA). Fetal bovine serum, lipofectaminTM 2000 cationic lipid 
reagent, RPMI 1640 and Tris glycine SDS running buffer were obtained from 
Invitrogen life technology (Renfrew, Strathclyde, PA4 9RF, UK). Acrylamide/bis 
solution, ammonium persulfate, the HRP-conjugated secondary antibodies, the 
protein assay kit and precision plus proteinTM standards were purchased from Bio-
Rad Laboratories (Hercules, CA, USA). EZ-DetectTM Rap1 Activation Kit, EZ-
DetectTM Ras Activation Kit, Super-Signal® West Femto Maximum Sensitivity 
Substrate, Super-Signal® West Pico Chemiluminescent Substrate and CL-X PosureTM 
film were obtained from Pierce (Rockford, IL, USA). The FluorSaveTM reagent was 
purchased from Calbiochem, EMD Biosciences, Inc. (San Diego, CA, USA). The 
mouse monoclonal transferrin receptor antibody was obtained from ZYMED (S. San 
Francisco, CA, USA). Rabbit polyclonal caveolin-1 antibody, rabbit polyclonal IgG 
ERK1/2 antibody, goat polyclonal IgG PACAP receptor antibody and protein G plus 
agarose were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Phospho-p44/42 ERK1/2 (Thr-202/ Tyr-204) antibody, CREB antibody, phospho-
CREB antibody, Elk antibody, phospho-Elk antibody, phospho-GSK3 (Ser-9) 
antibody, GSK3 antibody, Rap1 antibody, LY294002 and wortmannin were 
obtained from Cell Signaling Technology (Beverly, MA, USA). Alexa Fluor® 488 
and Alexa Fluor® 594 cholera toxin subunit B conjugates, goat anti-rabbit Alexa 
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Fluor® 488, Hoechst 33342, jasplakinolide and propodium iodide were obtained from 
Molecular Probes (Eugene, OR, USA). The Complete EDTA-free protease inhibitor 
cocktail tablet was obtained from Roche Diagnostics (Basel, Switzerland). GM1 
Ganglioside was purchased from Avanti Polar Lipids (Alabaster, Al, USA). Re-Blot 
Plus Strong Solution (10 ×) and Re-Blot Plus Mild Solution (10 ×) were obtained 
from Chemicon International (Temecula, CA, USA). Absolute methanol and sodium 
chloride were obtained from Merck (Darmstadt, Germany). Tris (base) and 
chloroform were obtained from J. T. Baker, Mallinckrodt Baker, Inc. (Phillipsburg, 
NJ, USA). Bio TraceTM PVDF (polyvinglidene difluoride) transfer membrane was 
obtained from Pall Corporation (East Hills, NY, USA). Carbon dioxide (CO2) was 
obtained from Singapore Oxygen Air Liquid Pte. Ltd. (Singapore). Hydrochloric acid 
was obtained from Spectrum Chemical Mfg. Corp. (Gaedena, CA, USA). 
 
 




The instruments and general consumables used in this work include biological safety 
cabinet class II (Gelman Science Inc., Ann Arbor, MI, USA), CO2 incubator (Heraeus 
Kulzer Australia Pty Ltd., Chatswood, Australia), eppendorf centrifuge 5810R (B. 
BRAUN, Melsungen, Germany), TL-100 ultracentrifuge, XL-100 ultracentrifuge, pH 
meter, SW60 Ti polyallomer microfuge® tube, SW60 Ti rotor and DU®640B 
spectrometer (Beckman Coulter, Inc., Fullerton, CA, USA), Olympus IX71 
fluorescence microscope and Olympus laser scanning confocal microscope (LSM510 
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and FV 500) (Olympus Technologies Singapore Pte Ltd, Singapore), cyan cytometer 
(Dakocytomation, Glostrup, Denmark), microplate reader spectraMax 190 (Molecular 
devices, Sunnyvale, CA, USA), orbital shaker 100 (ARMALAB, Bethesda, MD, 
USA), Rocker II (Boekel Scientific, Philadelphia, PA, USA), oven and sonicator 
(Heat Systems, XL 2020, Farmingdale, NY, USA), water bath (Memmert, Schwabach, 
Germany), PowerPac basic power supply 100, mini-gel casting chamber, gel running 
and transferring system (Bio-Rad Laboratories, Hercules, CA, USA), vortex machine 
(VWR Scientific, West Chester, PA, USA), ultrasonic water bath (ITS Science and 
Medical, Singapore), eppendorf tubes (Axygen, Union City, CA, USA), MAXTM 50 
ml/ 15 ml polypropylene conical tube, 1 ml / 2 ml / 5 ml / 10 ml / 50 ml nonpyrogenic 
serological pipette, 22G (0.7 × 38 mm) PrecisionGlide  needle, sterile MillexTM 
syringe driven filter unit (Millipore Corporation, Bedford, MA,USA), 10 ml and 20 
ml syringe (Becton Dickinson Company, Franklin Lakes, NJ, USA), Cryo Tube™ 
vials, 6 well-, 12 well-, 24 well-, 48 well- and 96 well- plate and Easy Flask 75 V/C, 
25 V/C (NUNC, Apogent Company, Roskilde, Denmark).  
 




The transplantable rat pheochromocytoma-derived PC12 cell line was obtained from 
the American Type Culture Collection (ATCC). It was established from a rat adrenal 
gland cell. The cells respond reversibly to NGF by induction of a neuronal phenotype 
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(Greene et al. 1976). PC12 cell adheres poorly to plastic and tends to grow in small 
clusters. Cell adhesion is improved by using collagen-coated surfaces. 
 
Working cultures were maintained in culture flasks in RPMI 1640 complete medium 
and incubated in an incubator under a humidified atmosphere containing 5% CO2 at 
37 ºC. The medium was changed every 2-3 days and cells were subcultured when at 
about 80% confluency.  
 
A new flask was initiated by the following procedures: 
1).The complete RPMI 1640 medium was warmed up to 37 ºC before use.  
2).The cells were removed from the liquid nitrogen tank and incubated into 37 ºC 
water bath immediately with gentle shaking. Upon being thawed out, the cells were 
rapidly transferred into the flask which was prewarmed in the 37 ºC incubator. 
Another 15 ml RPMI 1640 complete medium was added into the flask. The flask was 
then placed in an incubator at 37 ºC under a humidified atmosphere containing 5% 
CO2 overnight to allow the cells to attach. 
3).The medium in the flask was replaced by fresh RPMI 1640 complete medium on 
the next day after the cells were settled down on the surface of the flask. 
4).The cells were passaged after 2-3 days or the cells’ confluence reaches 80-90%.   
 
Cells were passaged according to the following procedures: 
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1).The cells were gently and thoroughly washed with 1 × phosphate-buffered saline 
(PBS) twice. 
2).Two ml of trypsin-EDTA was added to a 75-cm2 flask for 5 min. The flask was 
gently shaked or beaten to dislodge the cells. 
3).The action of trypsin-EDTA was stopped by adding 10 ml RPMI 1640 complete 
medium.  
4).The cells were resuspended in a new tube and dispersed gently using a 22G 
PrecisionGlide needle for 10 strokes to dissociate cell clumps. 
5).An appropriate amount of the cells were transferred to a new flask or a new plate 
and appropriate amount of fresh RPMI 1640 complete medium was subsequently 
added into the flask or plate. 
 
Cells were frozen down according to the following procedures: 
Fresh RPMI 1640 complete medium was replaced to cells one day before freezing. 
Subconfluent cells (70-80%) were trypsinized and centrifuged at 500 g for 5 min at 
room temperature. The cell pellet was resuspended in 2 ml frozen medium and 
aliquoted into two NUNC Cryo TubeTM vials. The vials were kept at 4 ºC for 20-30 
min, followed by -20 ºC for 2 h and then -80 ºC overnight. The vials were transferred 











To determine the neurite length per cell after different treatments, subconfluent PC12 
cells were subcultured and seeded at a density of 0.7-0.8 × 103 cells per well in 96-
well plates (NUNC) precoated with 50 µg/ml type I collagen. For GM1, cholesterol-
methyl--cyclodextrin, U18666a compound and NB-DNJ treatments, PC12 cells were 
pretreated with the above for 24 h before changing to a “serum-starved” RPMI 1640 
medium containing 1% horse serum and indicated concentrations of PACAP (or 100 
ng/ml NGF) in the presence of the above chemicals. Alternatively, 24 h after seeding, 
the culture medium was changed to PACAP containing medium in the absence 
(control) or presence of 8-cpt-cAMP (1 mM), cytochalasinD (1 µg/ml) or 
jasplakinolide (0.1 µM or 25 nM). Culture was maintained for up to 96 h. For filipin 
(1 or 10 µg/ml), nystatin (50 µg/ml), methy--cyclodextrin (1%), H89 (20 µM), 
FPTII (0.05 mM), RP-cAMP (0.5 or 1 mM), chelerythrine (10 µM), U73122 (10 µM), 
PMA (0.1 or 1 µM), PD98059 (100 µM), LY294002 (5 or 10 µM), wortmannin (2.5, 
5 or 10 µM), lithium (10 mM), valproate (1 mM) treatments, PC12 cells were 
incubated with the above chemicals in the RPMI 1640 complete medium for 1 h at 37 
°C in the CO2 incubator. The medium was then removed and changed to fresh serum-
starved medium containing PACAP. For gene silencing with siRNA, PC12 cells were 
transiently transfected with caveolin-1 siRNA, Rap1 siRNA or control siRNA as 
described in the “Gene silencing” section below, and the medium was changed to 
fresh RPMI 1640 medium containing PACAP on the following day.  
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For other biochemical analysis, PC12 cells were seeded into precoated 6-well plate at 
a cell density of about 6 × 105 cells/well, or 12-well plate at about 3 × 105 cells/well, 
or 24-well plate at 1~2 × 105 cells/well. 24 h after seeding, the cells were treated with 
different chemicals as described above. The cells were then washed extensively with 
PBS before stimulation with PACAP for the desired period of time as indicated.  
 
2.4. Cholesterol-mehtyl--cyclodextrin complex preparation 
 
The complex was synthesized as described by Klein et al. (1995) and Emily et al. 
(2003) with slight modification. Briefly, 
1).7.5 mg of free-cholesterol was dissolved in 300 µl of methanol/ chloroform (2: 1 
v/v) mixture.  
2).0.25 g methyl--cyclodextrin was dissolved in 5.5 ml of PBS.  
3).This methyl--cyclodextrin solution was heated to 80 °C with stirring.  
4).The initially precipitating steroid (cholesterol in methanol/chloroform solution) 
was added in small aliquots to the heated methyl--cyclodextrin solution for at least 
30 min until complete dissolution. 
5).This well melted solution was then aliquot into eppendorf tubes and freeze-dried 
for at least 24 h to generate the solid cholesterol-methyl--cyclodextrin complex.  




2.5. Neurite length quantification 
 
1).For neurite length quantification, differently treated PC12 cells were cultured in a 
humidified 5% CO2 incubator at 37 °C for as long as 96 h as described.  
2).Phase contrast images were acquired using a 20 × objective of an Olympus IX 71 
microscope with 1 × adaptor lens of Olympus DP 70 camera at different time points 
of incubation, i.e.: 24 h, 48 h, 72 h and 96 h respectively.  
3).The phase contrast images obtained were changed into 8 bits/channel grayscale 
pictures using the DP Manager software (Olympus Technologies Singapore Pte Ltd, 
Singapore) before neurite length quantification.  
4).Neurite length was quantified using an interactive semiautomatic neurite tracing 
technique (“Neuron J”) designed and validated by Meijering et al (2004). This 
technique was implemented in the Java programming language (Sun Microsystems 
Inc., Santa Clara, CA) in the form of a plugin for ImageJ (National Institutes of 
Health, Bethesda, MD), the computer-platform independent public domain image 
analysis program inspired by NIH-Image. The line of each particular neurite can be 
traced by this “Neuron J” tool precisely. Neurite length was defined as the distance 
between the cell body and the farthest tip of the neurite. When a neurite reached the 
margin of the visual field, this was regarded as the end of this neurite. Neurites 
entering the visual field from outside without origin from a cell body within the visual 
field were not measured. Since parameters such as percent neurite-bearing cells and 
mean length of the longest neurite were found proportional to the average neurite 
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length/cell, only the latter was documented in the figures of this thesis for the sake of 
explicitness. The total length of neurites was measured and then divided by the 
number of cells counted to obtain average neurite length/cell. 
5). Images of approximately 1000 cells were acquired under each experimental 
condition.  Data were presented as mean ± SD of at least three independent 
experiments. 
 
2.6. Protein kinase activity assay 
 
To determine the protein kinase A and C activity, the MESACUP® Protein Kinase 
Assay System (Lake Placid, NY, USA) based on an ELISA method and by making 
use of a synthetic peptide (RFARKG [pS] LRQKNV) and a monoclonal antibody 
2B9 that recognizes the phosphorylated form of the peptide was employed. The 
peptide was immobilized on the microwell plates and can be phosphorylated by PKA 
or PKC present in the samples and then recognized by the biotinylated 2B9 antibody, 
which can be subsequently detected with streptavidin conjugated peroxidase. The 
color intensity is measured at 490 nm spectrophotometrically using a microplate 
reader, DU®640B spectrophotometer (Beckman Coulter, Inc., Fullerton, CA, USA).  
 
Protein kinase activity assay was conducted as follows: 
1).The reagents which were needed in this assay were prepared as described. 
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a).ATP (0.1 M): 60 mg ATP was dissolved in 0.8 ml H2O, pH 7.0 and volume was 
adjusted to 1 ml with H2O.  The solution was stored at -20 ºC and diluted to 1 mM 
immediately prior to use. 
b).Wash solution: 1 part wash concentrate was diluted with 9 part of distilled H2O 
just prior to assay.  
c).Substrate solution: one tablet of substrate A was dissolved with 12 ml of substrate 
B just prior to color development. The solution was kept in the dark and used as soon 
as possible. 
d).cAMP (10 mM): 4 mg cAMP was dissolved in 0.8 ml H2O and the volume was 
adjusted to 1 ml with H2O. The solution was stored at -20 ºC and diluted to 20 µM 
immediately prior to use. 
e).PKA: 0.5 µg of the catalytic subunit of PKA was added to 1 ml of 1 mg/ml bovine 
serum albumin, 50 mM 2-mercaptoethanol, 50% (w/v) sucrose and 2 mM EGTA. The 
solution was aliquoted and stored at -70 ºC. The PKA solution was diluted to 0.01-
0.05 µg/ml just prior to use. 
f).Diluted sample preparation buffer: 50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 10 mM 
EGTA, 50 mM 2-mercaptoethanol, 1 mM PMSF, 10 mM benzamidine. 
g).EGTA (200 mM): 7.6 g EGTA was dissolved in 0.8 ml H2O and pH was adjusted 
to 7.0. The volume was topped up to 100 ml with H2O. The solution was diluted to 20 
mM with H2O just prior to assay. 
h).Cell lysate: The subconfluent cells were washed a few times with ice-cold PBS 
(pH 7.4) and were scraped with rubber scraper. The cells were centrifuged at 500 g 
 62 
for 5 min. and the pellet fraction was resuspended in 1 ml cold diluted sample 
preparation buffer. The suspension was sonicated on ice for 30-60 seconds using 15 
seconds pulses on and off and then centrifuged at 100,000 g for 1 h at 4 ºC. The 
cytosolic fraction was saved and used for the protein kinase activity assay. 
2).The component mixtures were prepared as describe below: 
a).For PKA activity assay, 25 mM Tris-HCl, pH 7.0, 3 mM MgCl2, 0.1 mM ATP, 2 
µM cAMP, 0.5 mM EDTA, 1 mM EGTA, 5 mM 2-mercaptoethanol were mixed 
thoroughly. For PKC activity assay, the 2 µM cAMP in the PKA components was 
changed to 2 mM CaCl2 and 38 µg/ml PS.  The components were mixed thoroughly. 
b).108 µl of the above component mixture was added to each well of polystyrene 
plate and preincubated in a water-bath (23-27 ºC) for 5 min. 
3).12 µl of sample was added to each well and mixed thoroughly. 
4).100 µl of reaction mixture was added to each peptide-coated well. 
5).The plate was incubated in a water-bath (23-27 ºC) for 5-20 min followed by 
adding 100 µl of stop solution to each well. 
6).The solution was removed and the well was washed 5 times with wash solution 
carefully. 
7).100 µl of biotinylated antibody 2B9 was added to each well and the plates 
incubated in a water-bath (23-27 ºC) for 60 min. 
8).The wells were washed again and the wash steps were repeated for 5 times and 100 
µl of peroxidase-conjugated streptavidin was added to each well and incubated in 
water-bath (23-27 ºC) for 60 min. 
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9).The well was washed and the wash steps were repeated for 5 times and 100 µl of 
substrate solution was added to each well. 
10).The solution was incubated in water-bath (23-27 ºC) for 3-5 min. 
11).100 µl of stop solution was added to each well and the optical density of each 
well was read at 490 nm on the DU® 640B spectrophotometer (Beckman Coulter, Inc., 
Fullerton, CA, USA). The experiments were performed at least in triplicate. 
 
2.7. Flow cytometry 
 
1). Sample preparation: 
a).To quantify the fluorescence intensity of ganglioside GM1 in the plasma 
membrane by flow cytometry, PC12 cells were incubated with complete RPMI 1640 
medium in the absence (control) or presence of 45 µM NB-DNJ or 100 µM GM1 or 
both in 25-cm2 flasks for two days.  
b).The cells then were washed carefully with ice-cold PBS containing 0.1% bovine 
serum albumin (BSA; fraction V) and 0.02 M sodium azide (Buffer A) a few times 
and transferred into eppendorf tubes.  
c).The number of the cell was counted by a hemocytometer.  The final concentration 
of the cell was around 1× 106 cells/ml.  
d).The cells were then centrifuged at 500 g for 5 min and washed gently and 
thoroughly with ice-cold Buffer A for a few times.  
e).The supernatant was aspirated. 
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2). Cell staining: 
a).To stain the cells, the pellet fraction of the cells were resuspended in 50 µl 
PBS/BSA/azide (Buffer A) in the presence of 0.1 mg/ml CTxB-Alexa 488 and were 
incubated on ice for 30 min in the dark. 
b).The cells were then gently washed once with 500 µl buffer A. 
c).The cells were resuspended with 1 ml of buffer A containing 2 µg/ml propodium 
iodide for 15 min on ice.  
d).The stained cells in solution were immediately transferred to glass tubes for further 
analysis. 
3). Analysis: 
a).The transferred cells were then sorted and counted using a Cyan cytometer 
(Dakocytomation, Glostrup, Denmark). 
b).The data generated were analyzed with the Summit software from Dakocytomation 



















PC12 cells were seeded in 24-well plate which contains a coverslip in each well. The 
coverslips were double-coated with 1 mg/ml poly-d-lysine and 100 µg/ml collagen 
type I.
 
24 h after seeding, PC12 cells were treated with or without (control) U18666a and 
cholesterol-methyl--cyclodextrin for another 24 h.  
1).The Cells were washed gently and thoroughly with ice-cold PBS and then fixed 
with 4% paraformaldehyde (PFA) for 1 h at room temperature. 
2).The fixed cells were incubated with 50 µg/ml filipin solution in PBS for 30 min at 
room temperature. 
3).The stained cells were washed with PBS for three times, 5 min each time without 
shaking.  
4).The stained cells on the coverslips were transferred onto glass slide by immersing 
into anti-fade mounting solution FluorsaveTM Reagent and kept in the dark to be air 
dried.  
5).Digital images were immediately acquired using an inverted microscope (Olympus 




 2.8.2. CTxB staining  
 
 
To measure the expression level of GM1 in the plasma membrane by fluorescence or 
confocal microscopy, PC12 cells were treated as previously described.  
1).After 48 h’s incubation, the medium was removed and the cells were gently 
washed with ice-cold PBS for several times.  
2).PC12 cells were then fixed with 4% PFA for 1 h at 4 °C followed by three times of 
washing with PBS.  
3).After fixation, the cells were stained with 2 µg/ml CTxB-Alexa 594 (diluted in ice-
cold RPMI 1640 medium) for 30 min at 4 °C in the dark and followed by several 
times of washing with PBS.  
4).The stained cells on the coverslips were transferred onto glass slide by immersing 
into FluorsaveTM Reagent and kept in the dark for the sample to be dry before being 
viewed with an inverted microscope (Olympus IX 71) or an Olympus laser scanning 
confocal microscope system (LSM 510).  
5).Mean fluorescence density was quantified using Image-Pro Plus software (version 







2.8.3. Immunocytochemistry and colocalization staining 
 
To examine whether of PAC1R receptor and lipid raft/caveolae are colocalized, PC12 
cells were stained with both PAC1R receptor antibody and lipid raft/caveolae marker 
GM1 with fluorescence-conjugated CTxB. 
1).The cells were seeded into 24-well plate containing double-coated coverslips at the 
cell density of 2 × 105 cell/ml and cultured for 24 h before GM1 and NB-DNJ were 
treated as described previously.  
2).The cells were then rinsed with ice-cold PBS a few times and were fixed with 4% 
PFA for 1 h at room temperature. 
3).After a few times rinse with PBS, the cells were preincubated with 10% goat serum 
in PBS overnight at 4 ºC to block the nonspecific binding. 
4).The primary antibody (anti-PAC1R) was diluted with 10% goat serum at the ratio 
of 1:100 and the cells were incubated with this primary antibody overnight at 4 ºC.  
5).The coverslips were washed with PBS for three times (5 min each at room 
temperature). 
6).The rabbit anti-goat TRITC secondary antibody was diluted in the blocking buffer 
at the ratio of 1:160. The cells were incubated with the secondary antibody for 2 h at 
room temperature in the dark. 
7).The cells were then washed with PBS three times (5 min each at room 
temperature).  
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8).Double staining was carried out with 2 µg/ml CTxB-Alexa 488 (diluted in ice-cold 
RPMI 1640 medium) for 30 min at 4 °C in the dark and followed by several times of 
washing with PBS.  
9).The cells on the coverslips were then mounted before being viewed with the 
confocal microscope or fluorescence microscope as described previously. 
 
To examine the translocation of PACAP-induced phospho-p44/42 ERK1/2 in cell 
nucleus after perturbation of lipid rafts/caveolae via caveolin-1 siRNA, PC12 cells 
were immuno-stained with both phospho-p44/42 ERK1/2 and Hoechst 33342 (direct 
DNA staining as an indicator of nucleus). 
1).Differently treated cells were washed for a few times with PBS and were fixed 
with 4% PFA for 1 h at room temperature. 
2). Fixed cells were permeabilized with 0.1% triton X-100 in 1% goat serum (diluted 
in   PBS). 
3).After a few times rinse with PBS, the cells were preincubated with 10% goat serum 
in PBS overnight at 4 ºC to block the nonspecific binding. 
4).The primary antibody (phospho-p44/42 ERK1/2) was diluted with 10% goat serum 
at the ratio of 1:100 and the cells were incubated with this primary antibody overnight 
at 4 ºC.  
5).The coverslips were washed as describe above. 
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6).The goat anti-rabbit Alexa Fluor® 488 secondary antibody was diluted in the 
blocking buffer at the ratio of 1:500. The cells were incubated with the secondary 
antibody for 2 h at room temperature in the dark. 
7).The cells were then washed for three times as described.  
8).Double staining was carried out with 1 µg/ml Hoechst 33342 (diluted in PBS) for 
15 min at room temperature in the dark and followed by several times of washing 
with PBS.  
9).The cells on the coverslips were mounted and viewed with fluorescence 
microscope as described previously. 
 




This was performed as described by Wang et al. (2004) with some modifications.  
 
1).Differently treated PC12 cells were harvested and washed with ice-cold PBS and 
resuspended in hypotonic homogenization buffer (10 mM KCl, 1.5 mM MgCl2, 1 mM 
Na-EDTA, 1 mM Na-EGTA, 1 mM dithiothreitol, 10 mM Tris-HCl, pH 7.4 with 
protease inhibitor cocktail).  
2).The cells were transferred into 1.5 ml eppendorf tubes and chilled on ice for 20-30 
min.  
3).The cells were then homogenized carefully with 20 strokes in a Dounce 
homogenizer.  
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4).The homogenates were centrifuged at 150 g for 5 min at 4 °C to remove unbroken 
cells, and followed by 2000 g for 5 min at 4 °C to obtain the pellet of nuclei.  
5).The pellet fraction (nuclear fraction) was washed twice with the isotonic 
homogenization buffer (250 mM sucrose in hypotonic homogenization buffer) and 
dissolved in the lysis buffer with freshly added protease inhibitor.  
6).The fractions were then subjected to SDS-PAGE and Western blot analysis for 
CREB, phospho-CREB, Elk and phospho-Elk, ERK1/2 and phospho- p44/42 ERR1/2. 
 
   2.10. The detergent-soluble and -insoluble sample preparation 
 
This was performed as described by Nyasae et al. (2003) with slight modification.  
1).Basically, after different treatments as previously described, PC12 cells were 
thoroughly washed with ice-cold PBS a few times. 
2). The cells were then extracted in 0.3 ml lysis buffer (50 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM PMSF and protease inhibitor 
cocktail (Roche)) for 30 min on ice.  
3).The samples were homogenized by sonication for 1 min with 15 seconds on-and-
off pulses on ice and centrifuged at 100,000 g for 1 h at 4 °C.  
4).The resultant pellet fractions were solublized in 0.2 ml solublization buffer (1% 
SDS, 50 mM Tris-HCl, 5 mM EDTA, pH 8.8) and briefly sonicated for 1 min with 
alternate 15 seconds of pulsings on and off. The samples were diluted to 1 ml (final 
volume) with the lysis buffer. 
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5).The supernatant fractions were also adjusted  to 1 ml (final volume) with the lysis 
buffer, ensuring that both the supernatant (or detergent-soluble) fraction and the 
resuspended pellet (or detergent-insoluble) fraction would contain the same 
concentration of buffer components. 
6).Identical aliquots of the detergent-soluble and -insoluble fractions from the same 
sample were taken for immunoprecipitation and immunoblot analysis as described 
below. 
 
2.11. SDS-PAGE and Western blotting 
 
Samples for SDS-PAGE and Western blotting were prepared according to the 
following procedure: 
1).Differently treated cells were lysed in the lysis buffer with freshly added protease 
inhibitors on ice. 
2).The postnuclear supernatants of cell lysates from each treatment were collected 
after centrifugation at 13,000 g for 5 min.  
3).One volume of 5 × loading buffer was added into four volumes of postnuclear 
supernatant and the samples were vortexed thoroughly and boiled at 100 °C for 5 min 
followed by spun at 13,000 g for 2 min.  
4).The supernatant of each sample with equal amount of proteins was subjected to 
electrophoresis using 10 to 15% polyacrylamide gels (Bio-Rad Laboratories).  
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SDS-PAGE and Western blotting was performed as below: 
1).The resolving gel solution was mixed well and allowed to degas before ammonium 
persulfate (APS) and N, N, N’, N’-tetramethyl-ethylenediamine (TEMED) were 
added.  
2). APS and TEMED were added into the resolving gel solution and mixed quickly. 
The mixture was poured into a mini-gel casting chamber. A depth of 2 cm from the 
top was left empty.  
3).The resolving gel was overlaid with water immediately to separate the resolving 
gel buffer from air and allowed to stay for 30-60 min.  
4).When the resolving gel had solidified, water was removed.  
5).APS and TEMED were added into the stacking gel solution (4%) quickly and the 
mixture was poured on top of the resolving gel. 
6). A comb was inserted into the stacking gel immediately.  
7).The stacking gel solution was allowed to stay for 30-60 min to solidify.  
8).After the stacking gel solidified, the comb was removed. 
9).Equal amount of samples and precision protein standard were loaded into each 
well.  
10).The gel was then electrophoresised at constant voltage (40V) while the samples 
were in the stacking gel. 
11).The voltage was adjusted to run at constant voltage (100V) when the dye entered 
the resolving gel.  
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12).The electrophoresis was terminated when the dye front reaches the bottom of the 
resolving gel.  
13).The resolving gel was isolated from gel casting chamber and soaked in the 
precooled transfer buffer for about 10 min. 
14).The gel sandwich was stacked in the order of sponge, filter paper, gel, membrane, 
filter paper and sponge.  
15).The proteins were transferred from gel onto PVDF membrane at a constant 
voltage of 100V for 60 min at 4 °C.  
16).After transferring the protein to the PVDF, the membrane was washed with 1 × 
TBS and  then blocked in blocking buffer (5% skimmed milk) overnight at 4 °C or for 
1 h at room temperature with shaking. 
17).The blots were probed overnight at 4 °C or for 1 h at room temperature with 
different primary antibodies at indicated dilution with the blocking buffer: anti-
PAC1R was diluted to 1:500, anti-Ras was diluted to 1:200, anti-caveolin-1 was 
diluted to 1:100, anti-ERK1/2  was diluted to 1:3000, anti-phospho-p44/42 ERK1/2, 
anti-Elk, anti-phospho-Elk, anti-CREB, anti-phospho-CREB, anti-GSK3, anti-
phospho-GSK3, anti-Rap1, anti-caveolin-1 and anti-transferrin receptor was diluted 
to 1:1000 and anti--actin was diluted to 1:2000. 
18).The membrane was then washed with TBST buffer four times to remove the 
excess primary antibody and then incubated with corresponding secondary antibody 
conjugated to horseradish peroxidase (Bio-Rad Lab) for 1 h at room temperature. 
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19).The membrane was then thoroughly washed with TBST buffer four times to 
remove the excess secondary antibody.  
20).The membranes were then submerged in a mixture of equal volume of super 
signal west pico chemiluminescent substrate and enhancer or in a mixture of equal 
volume of west femto substrate and enhancer with appropriated dilution with H2O 
(Pierce Biotechnology, Inc.).  
21).The membrane was removed from the mixture and placed against the film in the 
cassette.  
22).The film was developed using a Kodak X-ray film processor after appropriate 
exposure.  
23).After visualization on film, densitometry of the bands generated was quantified 
by using Gene Tools software generated on the Chemi-16 Gel DOC machine 




The immunoprecipitation procedure was performed as following: 
1).PC12 cells were gently and thoroughly washed with ice-cold PBS for several times.  
2).The cells were lysed in the lysis buffer which contains the freshly added protease 
inhibitor and were chilled on ice for 30 min with occasional vortex. 
3).The lysate was centrifuged at 13,000 g for 5 min at 4 ºC.  
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4).The supernatant fractions were collected and were precleared by adding Protein G 
Plus-Agarose beads (50% slurry). The mixture was incubated at 4 °C for 10 min on 
an orbital shaker. 
5).Protein G beads were removed by centrifugation at 13,000 g for 10 min at 4 °C.  
6).The protein concentration of the cell supernatant fractions was determined.  
7).Samples with identical amount of total protein were used for immnoprecipitation 
and the volume of each sample was adjusted to the same with the lysis buffer. For the 
detergent-soluble and -insoluble fractions of each sample, whose preparation methods 
were introduced above, identical aliquots of the membrane fractions were applied for 
the immunoprecipitation. 
8).The same amount of primary antibody (PAC1R) was added to each sample and the 
mixture was incubated overnight with gentle rolling on a roller at 4 °C.  
9).The antibody was then captured by adding protein G Plus-Agarose beads slurry on 
the next day and incubated for at least 4 h at 4 °C with gentle rolling.  
10).The beads were collected by pulse centrifugation at 14, 000 g for 10-30 seconds 
and washed a few times with ice-cold PBS.  
11).The supernatants were discarded.  
12).The beads were resuspended with 60 µl-100 µl of 2 × Lameali buffer (loading 
buffer) and heated at 100 °C for 5 min. The samples were centrifuged and kept at -20 




2.13. Gene silencing of caveolin-1 and Rap1 using siRNA  
 
PC12 cells were plated at 50-70% confluence in complete RPMI 1640 cell culture 
medium in collagen-coated plates and incubated for 24 h. Cells were then transiently 
transfected in Opti-MEM® I medium (Invitrogen) with Lipofectamine2000 reagent 
(Invitrogen) and siRNA for caveolin-1 (GeneBank accession number: NM 031556): 
sense strand CCA GAA GGG ACA CAC AGU UdTdT (5'-3'), and anti-sense strand 
AAC UGU GUG UCC CUU CUG GdTdT (5'-3'), targeting rat caveolin 221 
nucleotides downstream from the start codon, or siRNA for double-stranded RNA 
oligoribonucleotide sense strand GGC ACC AAC CAU GAA AUC AdTdT (5'-3'), 
and anti-sense strand UGA UUU CAU GGU UGG UGC CdTdT (5'-3'), which 
corresponds to the positions 553 to 571 of rat Rap1 (GeneBank accession number: 
XM-233509),  or a scrambled sequence without known homology to mammalian 
genes as a negative control: sense strand  UUC UCC GAA CGU GUC ACG UdTdT 
(5'-3') and anti-sense strand ACG UGA CAC GUU CGG AGA AdTdT (5'-3'). After 
24 h, the Opti-MEM® I reduced serum medium was replaced by RPMI 1640 complete 
culture medium. Suppression of caveolin-1 or Rap1 expression by RNAi was carried 
out by Western blotting analysis 48 h after transfection.  
 
Silencing with siRNA was carried out as follows: 
1). One day before transfection, PC12 cells were seeded into 6-well or 96-well plate 
(for neurite quantification assay) according to the following procedures. Cells with 
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80-90% confluence in culture flask were washed twice with PBS gently. The adherent 
cells were then detached by trypsinization. The cell suspension was diluted with a 5-
fold volume of fresh RPMI 1640 complete medium without antibiotics and 
transferred to a falcon centrifuge tube. Cells were dispersed by using a 22G needle 
with 10 gentle strokes. Cells were then seeded into 6-well plate at the cell density of 6 
×105 cells/well or into 96-well plate at the cell density of 5 × 104 cells/well so that 
overnight growth resulted in 70-80% confluence at the time of transfection.  
2).24 h after seeding, 1000 µl (6-well plate) or 100 µl (96-well plate) fresh RPMI 
1640 complete medium without antibiotics was added into each well before siRNA 
transfection. 
3).The siRNA and LipofectamineTM2000 complexes were freshly prepared for each 
transfection. 
(i). 4.5 µl (6-well plate) or 0.45 µl (96-well plate) of caveolin-1 siRNA (20 µM), 
Rap1 siRNA (20 µM) or negative control siRNA (20 µM) was diluted in 250 µl (6-
well plate) or 25 µl (96-well plate) Opti-MEM® I reduced serum medium for each 
treatment condition. The samples were mixed gently, followed by incubation for 5 
min at room temperature. 
(ii).At the same time, LipofectamineTM2000 was gently mixed before use. For each 
treatment, 9 µl (6-well plate) or 0.9 µl (96-well plate) of LipofectamineTM2000 was 
diluted in 500 µl (6-well plate) or 50 µl (96-well plate) Opti-MEM® I medium 
respectively with gentle mix, followed by incubation for 5 min at room temperature. 
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(iii).After 5 min of incubation, the diluted siRNA was combined with the diluted 
LipofectamineTM2000 at a ratio of 1:1. The combination was mixed gently and 
incubated for 20 min at room temperature to allow the formation of the siRNA and 
LipofectamineTM2000 complexes. 
4). 500 µl (6-well plate) or 50 µl (96-well plate) of the siRNA or negative control 
siRNA (for control) and LipofectamineTM2000 complexes was added to each well 
which containing 1000 µl (6-well plate) or 100 µl (96-well plate)  freshly added 
RPMI 1640 complete medium without antibiotics, so that the total volume was 1500 
µl (6-well plate) or 150 µl (96-well plate) respectively and the final concentrations of 
siRNA and negative control siRNA were 60 nM. The medium was gently mixed by 
rocking the plates back and forth. Opti-MEM® I medium was replaced 24 h after 
transfection with fresh complete medium. 
5).48 h after siRNA transfection, analysis on caveolin-1 and Rap1 knockdown 
efficiency was conducted by Western blotting with caveolin-1 and Rap1 antibodies. 
-Actin signals were used as an internal control. The expression level of each protein 
was determined by densitometry and normalized by comparing with that of -actin. 
The results were confirmed by at least three independent experiments. 
 
2.14. Protein determination  
 
Samples for protein determination were prepared according to the following 
procedure: 
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1).Culture medium was removed and the ice-cold PBS buffer was used to wash the 
cells.  
2).The cells were lysed and the lysate was collected into eppendorf tubes and chilled 
on ice for 30 min.  
3).Then cell lysate was spun at 13,000 g for 10 min at 4 °C to remove the unbroken 
cells and nucleus.  
4).The postnuclear supernatant was used to determine the protein concentration. 
  
Protein concentration was measured using the RC-DC protein assay kit II from Bio-
Rad according to the manufacturer’s instructions. A standard curve (0-2 mg BSA/ml) 
was conducted every time the assay was performed.  
1).A total of 25 µl of standard BSA and the samples were added into clean and dry 
eppendorf tubes.  
2).125 µl of RC reagent I was added into each tube which was vortexed and incubated 
for 1 min at room temperature.  
3).125 µl of RC reagent II was added into each tube and the tubes were vortexed  and 
centrifuged at 13,000 g for 10 min at room temperature.  
4).The result supernatant was discarded by inverting the tubes on clean and absorbent 
paper. 
5).Liquid was dried completely from the tubes by air. 
6).5 µl of DC reagent S was added to each 250 µl of DC reagent A. This solution was 
referred to reagent A’ and 127 µl of reagent A’ (prepared freshly) was added to each 
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tube and the tubes were vortexed and incubated at room temperature for 5 min or 
until the precipitate was completely dissolved.  
7).After the contents were briefly vortexed, 1 ml of DC reagent B was then added to 
each tube. The tube was vortexed immediately and incubated at room temperature for 
15 min.  
8).The liquid was transferred into cuvettes and the absorbance of each standard and 
sample was read at 750 nm on DU®640B spectrophotometer (Beckman Coulter, Inc., 
Fullerton, CA, USA).   
 
2.15. cAMP enzyme immunoassay  
 
To prepare the sample for the enzyme immunoassay, PC12 cells were subcultured 
and seeded into 12-well NUNC plate and different treatments were performed as 
described previously.  
 
The sample preparation was performed according to the following procedure: 
1).After treatments, the cells were gently and thoroughly washed with ice-cold  PBS a 
few times to remove the media.  
2).The cells were then incubated with 0.1 M HCl for 10 to 20 min until the cells were 
entirely lysed to stop endogenous phosphodiesterase activity.  
3).The cells were scraped carefully into ependorf tubes and centrifuged at 650 g for 5 
min at room temperature. 
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4).The supernatant was directly used in the assay. The protein concentration of the 
supernatant of each sample was determined and the same amount of protein of each 
sample was applied for the assay.  
5).The volume of each sample was top up to 200 µl with 0.1 M HCl. The sample was 
ready for the cAMP immunoassay. 
 
A competitive ELISA method was used in this cAMP immunoassay and the 
procedure follows the manufacture’s instruction ((Direct cAMP Enzyme 
Immunoassay Kit from Sigma). A polyclonal antibody to cAMP was used to bind, in 
a competitive manner, cAMP in the sample or an alkaline phosphatase molecule 
conjugated with cAMP. Samples or standards, alkaline phosphatase conjugate and 
antibody were simultaneously incubated at room temperature in a secondary 
antibody-coated microwell plate for 2 h with constant shaking on an orbital shaker. 
The reagents in excess were then washed away and substrate was added and the 
mixture was incubated at room temperature without shaking for 1 h. The enzyme 
reaction was then stopped and the yellow color generated was spectrophotometrically 
measure with a microplate reader at 405 nm. The intensity of the bound yellow color 
was inversely proportional to the concentration of cAMP in either standards or 
samples. The measured optical density was used to calculate the concentration of 
cAMP as described below. 
 
The cAMP enzyme immunoassay was performed according the following procedure: 
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1).The 2000 pmol/ml cAMP standard solution was warmed to room temperature.  
Series dilution to the following concentrations: 20, 5, 1.25, 0.312 and 0.078 pmol/ml 
respectively was prepared as the standards.  
2).To increase the sensitivity of the assay, the samples and standards were acetylated 
by adding in acetylating reagent (1 part of acetic anhydride with 2 parts of 
triethylamine). Ten µl acetylating reagent was added for each 200 µl of standard or 
sample. 50 µl of acetylating reagent was added to the Zero Standard/NSB (none 
specific binding). The acetylating reagent was added directly to the samples or 
standards and the mixtures were vortexed for 2 seconds. 
3).50 µl of the Neutralizing Reagent was added into each well, except the TA (total 
activity) and Blank wells. 
4).150 µl of the 0.1 M HCl was pipetted into the NSB and 100 µl of the 0.1 M HCl 
was pipetted into the B0 (0 pmol/ml standard) wells. 
5).100 µl of the standards and samples was added into the appropriate wells. 
6).50 µl of cAMP conjugate was added into each well except the TA and Blank wells. 
7).50 µl of cAMP antibody was added into each well, except the Blank, TA and NSB 
wells. 
8).The reaction plate covered by the plate sealer provided was incubated at room 
temperature for 2 h on a plate shake at 250 rpm.  
9).The contents of the wells were removed and the well was washed three times by 
adding 200 µl of wash solution to every well. After the final wash, the wells were 
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emptied thoroughly and the plate was firmly tapped to remove any remaining 
washing buffer. 
10).5 µl of the cAMP conjugate was added to the TA well. 
11).200 µl of the p-NPP substrate solution was added to every well and the mixture 
was incubated at room temperature for 1 h without shaking. 
12).50 µl of stop solution was added to every well to stop the reaction and the optical 
density of the sample was read immediately at 405 nm on a plate reader. 
13).The results can be calculated as follows: 
Average Net Optical Density = Average bound OD- Average NSB OD 
Percentage bound= Net OD/ Net B0 OD 
A logit-log paper was used to plot percent bound (B/B0) versus concentration of 
cAMP for the standards. A straight line through the standard points was approximated 
accordingly. The concentration of cAMP in the unknown samples can be determined 
by interpolation. 
 
2.16. Sucrose density gradient centrifugation 
 
The cell extract for the continuous sucrose gradient was prepared as following: 
The cell extract was washed with ice-cold PBS buffer a few times and scraped into 
the homogenization buffer (250 mM sucrose, 3 mM imidazole, 1 mM EDTA, with 
freshly added protease inhibitor pH 7.4) at 4 ºC. The extract was sequentially 
disrupted by homogenization with a Dounce homogenizer (20 gentle strokes). The 
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homogenate was then centrifuged at 2700 rpm for 10 min at 4 ºC.  The supernatants 
were applied to the continuous sucrose gradient. 
To make the 10–40% continuous sucrose gradient, 10% and 40% sucrose in 
homogenization buffer was allowed to diffuse into continuous gradients. The volume 
of the 40% and 10% sucrose solutions to be added was marked according to the 
standard marker which was provided on the tube rack by Beckman. The 40% and 
10% sucrose solutions were then layered into Beckman SW61Ti polyallomer 
microfuge tubes subsequently and diffusion was allowed to proceed.  
 
The procedure was carried out as following: 
1) The lighter sucrose, 10% solution was layered in a centrifuge tube which should be 
placed straight in a tube rack. 
2).A denser sucrose solution (40%) was carefully overlaid to the lighter sucrose 
solution. The interface would be formed at this point. 
3).The tube was closed with a silicon rubber stopper. 
4).The tube rack on its side was gently laid down, and allowed to diffuse for 4 h. 
5).The tube racket was slowly put to the upright position. The gradients were formed 
and ready to use. 
6).The prepared samples were then layered onto the top of the sucrose solution.  
7).Equilibrium centrifugation was carried out on the 10-40% continuous sucrose 
gradient.  
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8).Samples were then centrifuged in a SW61 Ti rotor in XL-100 ultracentrifuge 
(Beckman Coulter, Palo Alto, CA) at 30,000 rpm for 16 h at 4 ºC. 
9).After centrifugation, ten fractions were carefully collected from top to bottom of 
the tubes and aliquots were subjected to SDS-PAGE and Western blotting with Rap1 
and TfR antibodies. 
 
2.17. Ras and Rap1 activation assay 
 
Differently treated cells as described previously were collected and used for Ras and 
Rap1 activation assay.  
To evaluate Ras activation, a GST-fusion protein containing RBD of Raf1 was used 
to specifically pull-down active Ras. GST-Raf1-RBD was incubated with cell lysate 
in the presence of a SwellGel® Immobilized Glutathione Disc. In Rap1 activation 
assay, the GST-RalGDS-RBD fusion protein was incubated with cell lysate and a 
Swell Gel® Immobilized Glutathione Disc. The pulled-down active Ras and Rap1 
were detected by Western blot analysis using anti-Ras antibody and anti-Rap1 
antibody respectively. 
 
The procedures were carried out following manufacturer’s instruction: 
1).The medium was removed and the cells were rinsed by ice-cold TBS. 
2).0.4-0.6 ml Lysis/Binding/Wash buffer per 6-well plate was added to lyse the cells. 
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3).The cells were scraped and transferred to a new microcentrifuge tube and 
incubated on ice for 5 min. 
4).The cells were then centrifuged at 16,000 g at 4 ºC for 15 min. 
5).The supernatant was transferred to a new tube. 
6).The protein concentration was determined before performing the activation assay. 
7).The SwellGel® Immobilized Glutathione Disc was placed into a spin column with 
a collection tube. 
8).80 µg of GST-Raf1-RBD was added to the disc containing spin cup for Ras 
activation assay, while 20 µg of GST-RalGDS-RBD was added to the spin cup for 
Rap1 activation assay. 
9).Equal amount of cell lysate (up to 750 µl) for different treatments was immediately 
transferred to the spin cup and the sample was vortexed. 
10).The cap of the collection tube was sealed with Parafilm® laboratory film to 
prevent the leakage from the cap and the sample was vortexed. 
11).The reaction mixture was incubated at 4 ºC for 1 h with gentle rocking. 
12).The film was removed and the spin cup was transferred to a new collection tube. 
13).The resin was washed by adding 400 µl of Lysis/Binding/Wash buffer to the resin. 
The buffer was reverted for three times and the sample was centrifuged at 7200 g for 
10-30 seconds. The buffer was decanted. 
14).The above washing step was repeated for two more times. 
15).The spin cup was transferred to a new collection tube. 
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16).60 µl sample buffer was prepared for each pull-down reaction by mixing 1 part -
mercaptoethanol to 20 parts 2×SDS sample buffer. 
17).The above sample buffer containing -mercaptoethanol was added to the resin. 
The cap was wrapped with laboratory film and boiled at 100 ºC for 5 min. 
18).The tube was centrifuged at 7200 g for 2 min. Samples were stored at -20 ºC until 
use.  
 
2.18. Statistical analysis 
 
Statistical analyses were performed using the SPSS statistical package (version 11.0, 
SAS Institute, Chicago, IL, USA). Data were presented as mean ± SD. For statistical 
analysis, one-way ANOVA followed by Turkey’s post-hoc tests was applied. p<0.05 
was considered statistically significant. In the figures and figure legends, p<0.05 was 

















CHAPTER 3. LIPID RAFTS/CAVEOLAE IN PACAP-




As alluded to in Chapter I, lipid rafts/caveolae are plasma membrane microdomains 
enriched with both glycosphingolipids and cholesterol (Brown and London 1998a). 
Cholesterol regulates both the flexibility and mechanical stability of the membrane 
bilayer and plays a critical role in assembling membrane microdomains. It is thought 
to function as a spacer between the sphingolipid hydrocarbon chains and to serve as a 
glue to maintain the raft assembly (Simons and Toomre 2000). Removal of raft 
cholesterol leads to disruption of the integrity of lipid rafts/caveolae and dissociation 
of most proteins from the membrane microdomains (Simons and Ehehalt 2002). The 
most effective way of disrupting caveolae function therefore involves the use of 
sterol-binding drugs that sequester cholesterol. In fact, depletion, redistribution, or 
removal of this lipid results in the flattening and disassembly of caveolae and 
unclustering of receptors (Schnitzer et al. 1994; Rothberg et al. 1990; 1992). Such 
sterol-binding drugs include nystatin, filipin and methyl--cyclodextrin (CD) (Orlandi 
and Fishman 1998; Schnitzer et al. 1994; Rothberg et al. 1992; Neufeld et al. 1996). 
Cholesterol-depleting reagents, such as saponin has also been used to destabilize 
DRM structures, rendering them sensitive to detergents such as Triton X-100 
(Wassler et al. 1987; Montixi et al. 1998). On the other hand, cholesterol intracellular 
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trafficking inhibitors, such as U18666a (Bierkamper and Cenedella 1978), which 
impairs transport of cholesterol to the plasma membrane (Liscum and Colliiins 1991; 
Sexton et al. 1983), are also effective in depleting rafts cholesterol.  
 
In addition to cholesterol, glycosphingolipids, which contain long and largely 
saturated acyl chains pack tightly in the plasma membrane and are a key component 
of lipid rafts/caveolae organization (Brown and London 1998b; Ahmed et al. 1997; 
Schroeder et al.1998). It is believed that these carbohydrate-containing lipids could 
also affect the integrity and stability of rafts/caveolae (Simons et al. 1999; Mitsuda et 
al. 2002; Liu et al. 2004). Hence, the integrity of the lipid rafts/caveolae is expected 
to be compromised by alteration of the cellular glycosphingolipid level. This can be 
achieved by several approaches, such as by administration of exogenous gangliosides 
(Farooqui et al. 1997; Simons et al. 1999; Crespo et al. 2002), overexpression of a 
glycosphingolipid synthase gene (Mitsuda et al. 2002; Nishio et al. 2004) or by 
inhibitors of glycosphingolipid biosynthesis (Platt et al. 1994a; b; Nagafuku et al. 
2003). In this study, the ganglioside level was modulated by exposure of the cells to 
exogenous GM1 or treatment with NB-DNJ, a potent inhibitor of glucosylceramide 






3.2. Results and discussion 
 
3.2.1. PACAP-induced neurite outgrowth in PC12 cells is attenuated by 
perturbation of the integrity of membrane lipid rafts/caveolae 
 
3.2.1.1. Inhibition to the biosynthesis or intracellular transport of the 
major lipid components of lipid rafts/caveolae, glycosphingolipids and 
cholesterol, inhibits PACAP-induced neurite outgrowth in PC12 cells 
 
PACAP-stimulated PC12 cells were treated with NB-DNJ or U18666a at different 
concentrations for 24 h before phase contrast micrographs of the cells were taken for 
the following 4 days at indicated time points (i.e. 24 h, 48 h, 72 h and 96 h). The 
average neurite length per cell was quantified as described in Materials and Methods, 
and the relative change under various conditions was shown in Fig 3.2.1.1.A. Both 
NB-DNJ and U18666a inhibited PACAP-induced neurite outgrowth in a dose-
dependent manner. The maximum inhibitory effect of NB-DNJ on the neurite length 
reached approximately 80% of that induced by PACAP alone. On the other hand, 
although the inhibitory effect of U18666a at the indicated concentrations (70 nm, 500 
nm,1 µM) was not as strong as that of NB-DNJ at the concentrations applied (45 µM, 
90 µM, 180 µM), the maximum repressive effect of U18666a on neurite length also 
reached 70% of that induced by PACAP alone. These results demonstrate that 
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reduction of the plasma membrane glycosphingolipid or cholesterol level by NB-DNJ 
or U18666a attenuated PACAP-induced neurite outgrowth in PC12 cells. It appears 











































Fig 3.2.1.1.A. The inhibitory effects of NB-DNJ and U18666a on the neurite 
outgrowth induced by PACAP in PC12 cells. PC12 cells were pretreated with 
exogenous NB-DNJ at various concentrations (45, 90 or 180 µM) or U18666a at 
different concentrations (70, 500 nM, or 1 µM) for 24 h. The average neurite 
length/cell was measured at time points of 24 h, 48 h, 72 h and 96 h after PACAP 
(100 nM) was added. The relative change was expressed as a percentage of the mean 
neurite length/cell for the cells treated with PACAP alone (100%) as described in 
Materials and Methods. The results are shown as means ± SD for at least three 
independent experiments. * p< 0.05,  ** p< 0.01 and *** p< 0.005  versus the 
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Fig 3.2.1.1.B. The inhibitory effects of NB-DNJ and U18666a on the neurite 
outgrowth induced by NGF in PC12 cells. PC12 cells were pretreated with 
exogenous NB-DNJ at various concentrations (45, 90 or 180 µM) or U18666a at 
different concentrations (70, 500 nM, or 1 µM) for 24 h. The average neurite 
length/cell was measured at time points of 24 h, 48 h, 72 h and 96 h as indicated after 
NGF (100 ng/ml) was added. The relative change was expressed as a percentage of 
the mean neurite length/cell for the cells treated with NGF alone (100%). The results 







cells were treated for 48 h to 72 h. A similar inhibitory effect by NB-DNJ and 
U18666a on neurite outgrowth was also seen in NGF-induced PC12 cells (Fig 
3.2.1.1.B). Therefore, decrease in the two major lipid components of lipid 
rafts/caveolae, glycosphingolipids and cholesterol, could attenuate neurite outgrowth 
of PC12 cells induced by both NGF and PACAP, suggesting that lipid rafts/caveolae 
microdomains might be essential for neurite outgrowth of PC12 cells. 
 
3.2.1.2. Drugs targeting at cholesterol in the plasma membrane retards 
PACAP-induced neurite outgrowth in PC12 cells 
 
To further address the importance of membrane rafts/caveolae in PACAP-induced 
cell differentiation, the effects of cholesterol-chelators nystatin, filipin and methyl--
cyclodextrin (CD) on neurite outgrowth of PC12 cells were investigated.  In the 
control experiments, the mean neurite length per cell reached 28.3 ± 3.3 µm after 
PC12 cells were cultured for 24 h in the presence of PACAP. Pretreatments with 
nystatin (50 µg/ml), filipin (10 µg/ml) or CD (1%) for 1 h retarded the PACAP-
induced neurite outgrowth by approximately 50% (Fig 3.2.1.2). The inhibitory effects 
of these drugs were attenuated slightly 48 h after the cells in culture, but the 
difference in the mean neurite length per cell between the drug-treated and the control 
cells was still significant (about 30% retardation). This attenuated inhibitory effect of 
the cholesterol chelators on neurite outgrowth after 48 h’s treatment could be due to 












































Fig 3.2.1.2. Effect of cholesterol sequestering agents: nystatin, filipin or 
cyclodextrin (CD) on PACAP-induced neurite outgrowth in PC12 cells. PC12 
cells were pretreated with nystatin (50 µg/ml), filipin (10 µg/ml) or methyl--
cyclodextrin (CD) (1%) for 1 h. The mean neurite length/cell was measured at 24 h 
and 48 h in the presence of PACAP (100 nM), and the relative change was expressed 
as a percentage of the mean neurite length/cell for cells treated with PACAP alone 
(100%), as described in Materials and Methods. The results are shown as mean ± SD 
for at least three independent experiments. * p< 0.05 and  ** p< 0.01 versus the 
samples treated with PACAP alone for the same period of time. The results are shown 
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lipids to these microdomain after prolonged incubation time (i.e. 48 h).  The results 
obtained here provided compelling evidence that perturbation of the integrity of c 
cholesterol and glycosphingolipid-sensitive microdomains, such as lipid 
rafts/caveolae, affected the neurite outgrowth in PC12 cells, supporting the 
importance of lipid rafts/caveolae in neuritogenesis process in PC12 cells. 
 
 
3.2.1.3. Caveolin-1 siRNA attenuates PACAP-induced neurite outgrowth 
in PC12 cells 
 
To ascertain that caveolae function specifically as a signaling platform for this 
process, the expression of caveolin-1, the major structural protein of caveolae, was 
silenced by caveolin-1 siRNA. As shown in Fig 3.2.1.3.A, PC12 cells transfected 
with caveolin-1 siRNA showed a marked reduction (70%) in the expression level of 
caveolin-1 protein compared to untreated cells, or cells transfected with a control 
siRNA of random sequence. As a result, neurite outgrowth was also inhibited by 
approximately 80% in the caveolin-1 siRNA-transfected cells compared to untreated 
cells and cells transfected with the control siRNA (Fig 3.2.1.3.B). These results 
suggest that caveolae were most likely the primary membrane microdomains involved 
in PACAP signaling leading to neurite outgrowth of PC12 cells, and that perturbation 
to caveolar integrity would retard this process. Consistent with these results, another 
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Fig 3.2.1.3. A. Effects of caveolin-1 siRNA on caveolin-1 expression in PC12 cells. 
Caveolin-1 expression in PC12 cells transfected with caveolin-1 siRNA or control 
siRNA for 48 h in the presence or absence of PACAP (100 nM) was detected and 
quantitated by Western blot analysis of the whole cell lysates. The blots were 
representatives of at least three independent experiments performed. -Actin was 
used as the internal control. In the quantitative analysis, the mean expression levels of 
caveolin-1 (normalized against actin levels) in untreated PC12 cells was set as 100%. 
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Fig 3.2.1.3. B. Effects of the disruption of the integrity of lipid rafts/caveolae on 
the PACAP-induced neurite outgrowth in PC12 cells. 24 h after seeding, PC12 
cells were transfected with or without control siRNA or caveolin-1 siRNA. The 
transfection medium was replenished with fresh RPMI1640 medium containing 1% 
horse serum and PACAP 24 h after transfection. Phase contrast micrographs were 
taken at the time points of 24 h and 48 h after PACAP was added and neurite 
length/cell was quantified as described. The relative change was expressed as a 
percentage of the mean neurite length/cell for the cells treated with PACAP alone 












structures and alters their detergent-sensitive (Wassler et al. 1987; Montixi et al. 
1998), also eliminated the PACAP-induced neurite outgrowth (data not shown), 
further confirming that the integrity of lipid rafts/caveolae was critical for this neurite 
extension process. 
 
3.2.2. PACAP-induced neurite outgrowth inhibited by U18666a can be 
restored by exogenous cholesterol 
 
To further investigate the function of raft lipids/caveolae cholesterol in neurite 
extension process of PC12 cells, cholesterol-methyl--cyclodextrin complex, which 
was used as an exogenous source of cholesterol, was applied to the PC12-stimulated 
cells with or without U18666a (Fig 3.2.2). Obviously, PACAP-induced neurite 
extension was potently enhanced by the added cholesterol complex (Fig 3.2.2). In the 
presence of PACAP, the neurite length per cell in cholesterol-treated cells was 
approximately two-fold longer than that in cells treated with PACAP alone (Fig 3.2.2), 
whilst in the absence of PACAP, the cholesterol complex on its own did not elicit 
neurite generation (data not shown). In addition, this cholesterol complex restored the 
U18666a-inhibited neurite extension to at least the level of cells treated with PACAP 
alone. Although the stimulatory effect of cholesterol in NGF-induced neurite 
outgrowth in PC12 cells was not as potent as that in PACAP-induced cells, the 
overall pattern of the effect of cholesterol on neurite extension was similar in both 
NGF- and PACAP-treated cells (data not shown). These data, together with the 
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previous results shown in Figs 3.2.1.1 and 3.2.1.2, suggest that modulating plasma 
membrane cholesterol levels affected neurite extension stimulated by both PACAP 
and NGF in PC12 cells. This is consistent with the notion that neurite extension was 







































Fig 3.2.2. The dose-dependent effect of cholesterol on PACAP-induced neurite 
outgrowth and its effects on the U18666a-inhibited neurite outgrowth in PC12 
cells. PC12 cells were cultured with 10 µg/ml cholesterol-CD (Cholesterol) or 1 µM 
U18666a or a combination of both in the fresh culture medium for 24 h. The average 
neurite length/cell was measured at time points of 24 h, 48 h, 72 h and 96 h after 
PACAP was added. The relative change was expressed as a percentage of the mean 
neurite length/cell for the cells treated with PACAP alone (100%). The results are 
shown as means ± SD for at least three independent experiments. 
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3.2.3. The neurite outgrowth inhibited by NB-DNJ can be restored by 
exogenous GM1 
       
Our previous data show that inhibition to the biosynthesis of the lipid rafts/caveolae 
component glycosphingolipids by NB-DNJ retarded PC12 cells differentiation 
induced by PACAP (Fig 3.2.1.1), which indicate that sufficient level of 
glycosphingolipids was an essential cellular requirement for PC12 differentiation. To 
further verify this, PC12 cells were treated with NB-DNJ, or GM1, or both at 
different concentrations in the presence of PACAP. The phase contrast micrographs 
were taken for the following 4 days at indicated time points. Exogenous GM1, 
although on its own did not evoke neurite generation in the absence of PACAP (data 
not shown), potently promoted PACAP-induced neurite extension at different 
concentrations (except at a very high dose of 200 µM) (Fig 3.2.3). Interestingly, cell 
differentiation inhibited by NB-DNJ could be restored in the presence of GM1 in a 
concentration-dependent manner. Lower concentration of GM1 (1 µM) appeared to 
enhance neurite outgrowth more potently than higher GM1 concentrations (10, 100 
µM) at early hours of treatment. However, only higher GM1 concentrations (10 or 
100 µM) appeared to be able to sustain the neuite outgrowth. These results 
demonstrate that the effects of GM1 on neurite outgrowth in PACAP-treated PC12 
cells were concentration-dependent. In addition, there appears to be an optimal range 






























































   
Fig 3.2.3. The dose-dependent effect of GM1 on the PACAP-induced neurite outgrowth and the restoration effects 
of GM1 on the NB-DNJ-inhibited neurite outgrowth in PC12 cells. PC12 cells pretreated with GM1 at various 
concentrations (1, 10, 100, 200 µM) or NB-DNJ (45, 180 µM) or combination of both for 24 h. Neurite length/cell was 
measured at time points of 24 h, 48 h, 72 h and 96 h after PACAP was added. The relative change was expressed as a 
percentage of the mean neurite length/cell for the cells treated with PACAP alone (100%). The results are shown as means 
± SD for at least three independent experiments. 
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be enhanced, as overloading the cells with GM1 might result in retardation of neurite 
extension. The latter could be at least partly due to GM1-caused decrease in 
membrane fluidity (Nishio et al. 2004). Taken together, the results obtained above 
indicate that the inhibitory effects on the neurite outgrowth caused by depletion of 
lipid components of membrane rafts could therefore be reversed by exogenous 
supplement of these elements. 
 
3.2.4. Disruption of the integrity of the lipid rafts/caveolae by caveolin-1 
siRNA abolishes the enhancing effect of GM1 or cholesterol on the 
PACAP-induced neurite outgrowth 
 
Previous data from this study show that disruption of the integrity of lipid 
rafts/caveolae by knock-down of the major structure protein of caveolae, caveolin-1, 
significantly reduced the PACAP-induced neurite outgrowth (Fig 3.2.1.3.B). To 
examine the effect of glycosphingolipid GM1 and cholesterol on the neurite extension 
inhibited by caveolin-1 siRNA treatment, the caveolin-1 knock-down cells were 
concurrently incubated with GM1 or cholesterol. In contrast to those results obtained 
in cells treated with NB-DNJ or the cholesterol-sequestering agents, caveolin-1 
siRNA blocked completely the enhancing effect of both GM1 and cholesterol on 
PACAP-induced neurite outgrowth (Fig 3.2.4). In other words, the neurite extension 
inhibited by knocking down caveolin-1 expression, which might in turn disrupt the 















































Fig 3.2.4. Effects of glycosphingolipids and cholesterol on the PACAP-induced 
neurite outgrowth in PC12 cells where the integrity of lipid rafts/caveolae were 
disrupted. PC12 cells were transfected with control siRNA or caveolin-1 siRNA in 
the presence or absence of GM1 (100 µM) or cholesterol (10 µg/ml) for 24 h. Phase 
contrast micrographs were taken at the time points of 24 h and 48 h after PACAP was 
added and neurite length/cell was quantified as described. The results are shown as 








results suggest that the presence of architectural and functional intact rafts/caveolae 
was critical for neurite extension. 
 
 3.2.5. Cholesterol level at the plasma membrane surface alters 
following treatment with exogenous cholesterol-methyl--cyclodextrin 
and cholesterol-depletion drugs 
 
In the studies described above, we had assumed that plasma membrane cholesterol 
was depleted or replenished by the respective treatments. To verify whether 
cholesterol level was indeed altered at the plasma membrane surface following 
cholesterol-methyl--cyclodextrin or U18666a treatment, PC12 cells were treated 
with either of the above drugs for 24 h before performing filipin staining, a 
fluorescent polyene antibiotic widely used for the detection and quantitation of 
cholesterol in biomembranes. Fluorescence micrographs (Fig 3.2.5) show that 
addition of cholesterol-methyl--cyclodextrin complex clearly increased the 
membrane fluorescence intensity comparing to that observed from the untreated cells 
(Fig 3.2.5). On the other hand, fluorescence intensity on the plasma membrane was 
decreased in U18666a-treated cells, accompanied by an increase in intracellular 
accumulation of filipin staining as revealed by the appearance of spotty structures in 
the cytoplasmic fraction indicated by arrow bars (Fig 3.2.5). This would be expected 
since U18666a is an inhibitor of intracellular cholesterol trafficking (Liscum and 
Colliiins 1991; Sexton et al. 1983) and is widely used to mimic the Niemann Pick 
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Type C (NPC) disease cellular phenotype (Mohammadi et al. 2001; Pol et al. 2001; 
Runz et al. 2002; Liscum and Faust 1989; Hall et al. 2003), which is characterized by 
accumulation of intracellular cholesterol in lysosomes (Davies et al. 2000) resulting 
from defectiveness in cholesterol transportation to the plasma membrane (Wojtanik 
and Liscum 2003; Chang et al. 2005). These results therefore confirm that 
cholesterol-methyl--cyclodextrin and U18666a can either increase or decrease the 
plasma membrane cholesterol level respectively. Cholesterol enrichment in the 
cellular membrane surface boosted the PACAP-induced PC12 cells neurite extension 
and the effect was persistent within the time period of observation (Fig 3.2.2), whilst 
membrane cholesterol depletion restrained PACAP-induced neuritogenesis (Fig 
3.2.1.1). These data were further confirmed by treatment with well-established 
cholesterol-sequestering drugs (Fig 3.2.1.2), such as filipin and nystatin, which 
sequester cholesterol within the lipid bilayer by inserting into plasma membrane 
(Simons and Toomre 2000), and methyl--cyclodextrin, which extracts cholesterol 
from plasma membrane (Klein et al., 1995; Schuck et al. 2003) and removes 
morphologically recognizable invaginated caveolae (Harder et al. 1997; Rodal et al. 
1999). In addition, when supplemented with cholesterol after membrane cholesterol-
depletion, neurite extension was resumed (Fig 3.2.2). These results show that plasma 
membrane cholesterol could be modulated in vitro. Clearly, alteration of plasma 
membrane cholesterol affected the extent of PACAP-induced neurite outgrowth in 
PC12 cells. Since cholesterol is one of the major components of the lipid 
rafts/caveolae, these data provide additional evidence that these plasma membrane 
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microdomains are very likely involved in the PACAP signaling pathways in PC12 
cells. 
 
3.2.6. GM1 level at the plasma membrane surface changes following 
treatment with exogenous GM1 and NB-DNJ 
 
 
To ascertain that GM1 expression level was indeed altered at the plasma membrane 
surface following treatment with exogenous GM1 and NB-DNJ, PC12 cells were 
either treated with 45 µM NB-DNJ or exposed to 100 µM ganglioside GM1 or both 
for 24 h before staining with Cholera toxin B (CTxB)-Alexa 594, which specifically 
binds to the lipid rafts/caveolae-associated glycosphingolipids GM1. Both 
fluorescence micrographs (Fig 3.2.6.A) and flow cytometry profile (Fig 3.2.6.B) 
show marked changes in the cellular level of GM1 after the respective treatments. 
The addition of NB-DNJ clearly reduced the membrane CTxB-Alexa 594-conjugated 
fluorescence level to approximately 50% of that of the control cells, while GM1-
treated cells had a dramatically increased intensity (Fig 3.2.6.C). When cells were 
treated with GM1 and NB-DNJ simultaneously, their effects were neutralized (Fig 
3.2.6.C). The pattern of fluorescence intensity changes was consistent when observed 
with either fluorescene microscopy or flow cytometry. The results further confirm 
that GM1 and NB-DNJ either increased or decreased the plasma membrane 
glycosphingolipid GM1 levels effectively. Clearly, GM1 enrichment at the plasma 












                      
                      
 
Fig 3.2.5. Relative expression levels of cholesterol in PC12 cells treated with 
exogeneous cholesterol-CD complex or U18666a. Fluorescence and corresponding 
phase contrast micrographs of control PC12 cells and those treated with cholesterol-
CD (10 µg/ml, 24 h) or U18666a (1 µM, 24 h). a and a’, cholesterol-CD treated PC12 
cells; b and b’, untreated PC12 cells; c and c’, U18666a-treated PC12 cells. 50 µg/ml 
filipin was used to stain the cholesterol. The arrows in figure a indicate the increased 
cholesterol staining intensity comparing to the control cells. The arrows in figure c 
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effect was sustainable within the time period of observation (Fig 3.2.4.A). GM1 
depletion, on the other hand, suppressed the PACAP-induced neuritogenesis (Fig 
3.2.1.1). Evidently, GM1 alone had no effects on neuritogenesis of PC12 cells in the 
absence of PACAP (data not shown). Hence, alteration of plasma membrane 
glycosphingolipid levels influenced neurite outgrowth induced by PACAP in PC12 
cells. Since the glycosphingolipids on the plasma membrane are dominantly found in 
the lipid rafts/caveolae microdomains, these results further implicate a role for lipid 
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Fig 3.2.6. A. Relative expression levels of gangliosides GM1 in PC12 cells treated 
with exogeneous GM1 or NB-DNJ. Fluorescence and corresponding phase contrast 
micrographs of control PC12 cells and those treated with GM1 (100 µM, 24 h) or 
NB-DNJ (45 µM, 24 h) or both. a and a’, untreated PC12 cells; b and b’, NB-DNJ- 
treated cells; c and c’, NB-DNJ and GM1-treated cells; d and d’, GM1-treated cells. 
CTxB-Alexa 594 was used to stain cell surface GM1. The scale bar represents 10 µm. 
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Fig 3.2.6. B. Relative expression levels of glycosphingolipid in PC12 cells treated 
with exogeneous GM1 or NB-DNJ.  PC12 cells were treated as described in Fig 
3.2.6.A, and stained with CTxB-Alexa 488 on ice for 30 min. The expression levels 
of cell surface GM1 was detected by flow cytometry. The profiles represent the 
untreated cells (in red), NB-DNJ-treated cells (in black), NB-DNJ and GM1-treated 












































































Fig 3.2.6. C. Quantitative analysis of CtxB fluorescence was based on Fig 3.2.6.B 
















CHAPTER 4. LIPID RAFTS/CAVEOLAE-MEDIATED 
PACAP SIGNALING PATHWAYS AND UNDERLYING 








PACAP binds to PACAP-specific G-protein-coupled receptor family member to 
promote both neuronal differentiation and survival. In PC12 cells, addition of PACAP 
induces neurite outgrowth (as shown in Chapter 3) and inhibits cell proliferation 
(Deutsch and Sun, 1992; Hernandez et al. 1995; Lazarovici et al. 1998). In fact, 
PACAP-preferring receptor type I, PAC1R is the only endogenous G-protein-coupled 
receptor that could stimulate neurite outgrowth in PC12 cells (Tristan et al. 2003).   In 
addition, PAC1R is expressed and positively coupled to adenylate cyclase (AC) 6, the 
type 6 isoform of adenylate cyclase found in PC12 cells (Deutsch and Sun 1992; 
Spengler et al. 1993; Oshikawa et al. 2003; Ravni et al. 2006). However, details of the 
molecular events leading to the coupling of ligand-bound PACAP receptors to 
downstream effectors are still unclear. In addition, the subsequent events leading to 
the eventual induction of neuritogenesis are also vague. The work described in this 
chapter focuses on the mechanistic role for the lipid rafts/caveolae in the regulation of 




4.2. Results and discussion 
 
4.2.1. The expression level of PACAP receptor type I (PAC1R) is not 
adversely affected by perturbation of lipid rafts/caveolae 
 
Since perturbation of caveolae altered PACAP-induced neurite outgrowth, the 
question was asked whether this was due to changes in the expression level of 
PACAP receptor type I: PAC1R.  Exposure of PC12 cells to PACAP resulted in a 
marginal but statistically significant increase in PAC1R expression (Fig 4.2.1). 
However, treatments with nystatin, filipin, NB-DNJ or GM1, which would cause 
inhibition or promotion of PACAP-induced neurite outgrowth in PC12 cells, did not 
change the expression level of PAC1R any further compared to cells treated with 
PACAP alone. Moreover, PAC1R expression level was not affected by caveolin-1 
siRNA. These data suggest that, although perturbation of caveolae might retard 
neurite outgrowth, it did not affect expression of PAC1R in PC12 cells. 
 
4.2.2. PACAP induces partition of PAC1R into lipid rafts/caveolae 
microdomains and enhances its interaction with adenylate cyclase (AC) 
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Fig 4.2.1. Expression of PAC1R in PC12 cells. Unstimulated or PACAP-stimulated 
PC12 cells were pretreated with various reagents as described in Materials and 
Methods. The whole cell lysates were used for immunobloting using anti-PAC1R 
antibody. The blots are representatives of at least three independent experiments 
performed. -Actin was used as a loading control. In the quantitative analysis, the 
mean expression level of PAC1R in untreated PC12 cells was set as 100%. Values are 
mean ± SD of at least three independent experiments. *p<0.05 versus the 
unstimulated samples under identical treatment conditions. 
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To elucidate the molecular events following PACAP stimulation, the detergent 
solubility of PAC1R in unstimulated and PACAP-stimulated PC12 cells was 
investigated. As shown in Fig 4.2.2.A, the Triton X-100-insoluble fraction (P) was 
caveolin-1-enriched and free from the non-caveolar marker, transferrin receptor (TfR). 
Following PACAP stimulation, approximately 52 ± 4% of the total PAC1R were 
found in the detergent-insoluble fraction, a substantial increase compared to that 
found in unstimulated PC12 cells (37 ± 2%) (Figs 4.2.2.B and C). More PAC1R was 
translocated into caveolin-1-enriched detergent-insoluble fraction in GM1-loaded 
cells (75 ± 6%). In contrast, depletion of glycosphingolipids by NB-DNJ decreased 
the detergent insolubility of PAC1R to the level seen in unstimulated cells (39 ± 6%). 
Furthermore, treatments with filipin, nystatin and caveolin-1 siRNA, which were all 
expected to disrupt the structure of caveolae, prevented the translocation of PAC1R 
into the detergent-insoluble membrane microdomains (Figs 4.2.2.B and C). In 
addition, treatment of the cells with each of the above reagents in the absence of 
PACAP stimulation did not alter the distribution of PAC1R between the detergent-
soluble and -insoluble fractions (data not shown), suggesting that PACAP stimulation 
is essential for the translocation of PAC1R to the detergent-insoluble membrane 
fraction. 
 
The next question is whether altered membrane distribution of PAC1R facilitates its 
interaction with adenylnyl cyclase (AC), the target enzyme located in caveolae of 
various types of cells, including PC12 (Schwencke et al. 1999; Rybin et al. 2000; 
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Fig 4.2.2. Translocation of PAC1R into caveolin-enriched detergent-insoluble 
fractions following PACAP stimulation. (A) PC12 cells were extracted with 1% 
Triton X-100 at 4 oC for 30 min and the soluble (S) and pelleted (P) fractions were 
separated by centrifugation. Presence of TfR and caveolin-1 in separate fractions was 
detected by Western blot with anti-TfR and anti-caveolin-1 antibodies, respectively. 
The blots are representatives of three independent experiments performed. (B) 
Identical aliquots of the detergent-insoluble and -soluble fractions obtained from 
PC12 cells treated under various conditions were processed by resuspending the 
pelleted fractions in the solubilization buffer and correcting the soluble fractions for 
the solubilization buffer components as described under “Materials and Methods”. 
Immunoprecipitation was conducted with an anti-PAC1R antibody. The same 
antibody was used for the subsequent immunoblotting analysis. (C) Quantitative 
analysis on the relative change of the ratio of detergent-insoluble to total PAC1R for 
each of the treatment conditions. The results are shown as means ± SD for at least 
three independent experiments. *p<0.05 and ***p<0.005 versus the sample treated 
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Ostrom et al. 2000a; 2001; Oshikawa et al. 2003; Insel et al. 2005). 
Immunoprecipitation was performed with an anti-PAC1R antibody and the 
immunoprecipitate was probed with an anti-AC5/6 antibody (Fig 4.2.2.D). The level 
of AC associated with PAC1R in the PACAP-stimulated cells was approximately 4-
fold higher than that in the untreated cells, suggesting much stronger interactions 
between PAC1R and AC, the effector enzyme that catalyzes the conversion of ATP to 
cAMP. 
 
4.2.3. PACAP alters the distribution pattern of PAC1R in cell 
membranes 
 
To further analyze whether the altered detergent solubility of PAC1R following 
PACAP stimulation was accompanied by changes in membrane distribution pattern of 
the receptor, immunostaining was performed for PAC1R and the staining pattern was 
visualized by confocal microscopy (Fig 4.2.3, middle column). PAC1R in the 
unstimulated cells showed a rather uniform plasma membrane distribution, whereas 
the receptors in the PACAP-stimulated PC12 cells showed a patchy distribution, 
indicating PACAP-induced accumulation of PAC1R in certain micro-regions of the 
plasma membrane. Addition of exogenous GM1 did not change the pattern of PAC1R 
distribution in the stimulated cells. However, depletion of GM1 by treatment of the 
cells with NB-DNJ caused dispersion of the patched PAC1R molecules. On the other 
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Fig 4.2.2. D. Increased affinity between PAC1R and AC after PACAP 
stimulation. Whole cell lysates obtained from untreated cells or cells stimulated with 
PACAP (100 nM, 5 min) were used for immunoprecipitation with an anti-PAC1R 
antibody, then for immunobloting using anti-AC5/6 antibody. β-Actin was used as a 
loading control. In the quantitative analysis, the mean level of AC in untreated PC12 
cells was set as 100%. Values are mean ± SD of at least three independent 
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Fig 4.2.3. Effect of PACAP stimulation on PAC1R distribution in cell 
membranes. PC12 cells were cultured on glass coverslips and some of them were 
pretreated with GM1 (100 µM, 24 h) or NB-DNJ (45 µM, 24 h), respectively, 
followed by stimulation with PACAP (100 nM, 5 min), as indicated, before being 
fixed and stained with anti-PAC1R antibody and cultured in the presence of a 
TRITC-conjugated secondary antibody (red). The cells were then stained with CTxB-
Alexa 488 (green). Note that the regions with a red-green overlap leads to yellow in 
the merged image (right column). The micrographs shown are representative of three 
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addition of PACAP, which showed a patched distribution in both the unstimulated 
control and the PACAP-stimulated cells (Fig 4.2.3, left column). Evidently, the level 
of colocalization between PAC1R and GM1, a lipid marker for the detergent-
insoluble microdomains of cell membranes, was increased following PACAP 
stimulation, particularly in GM1-loaded cells (Fig 4.2.3, right column), in agreement 
with the results obtained by immunoprecipitation studies (Fig 4.2.2.B). Moreover, the 
distribution pattern of PAC1R was not affected by treatments with exogenous GM1 
or NB-DNJ in the absence of PACAP (data not shown). 
 
4.2.4. cAMP is involved in PACAP signaling and perturbation of 
caveolae affects intracellular cAMP synthesis 
 
 4.2.4.1. The effect of perturbation of caveolae on cAMP generation in 
PC12 cells 
 
PAC1R is known to exert its major effect by coupling to AC, leading to the 
generation of cAMP. A prominent question to be asked is whether the cAMP 
synthesis stimulating ability of PAC1R was related to its translocation into caveolae. 
Fig 4.2.4.A shows that intracellular cAMP level was increased significantly by 
PACAP stimulation. When partition of PAC1R into caveolae was promoted by 
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Fig 4.2.4. A. Effects of perturbation of caveolae on PACAP-stimulated cAMP 
generation and the critical role of cAMP signaling in neurite outgrowth of PC12 
cells. Effects of various pretreatments (see “Materials and Methods” for details) on 
cAMP generation following PACAP stimulation (100 nM, 5 min). The results are 
shown as means ± SD for at least three independent experiments. *p<0.05, **p<0.01 
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absence of PACAP, cAMP level was not increased by GM1 alone (Fig 4.2.4.A). In 
contrast, treatments which prevented PAC1R from translocating into the detergent-
insoluble membrane microdomains resulted in a reduction in cAMP generation. 
Taken together, it appears that translocation of PAC1R into caveolae enhanced its 
coupling to AC and thus positively contributed to the regulation of intracellular 
cAMP production. 
 
4.2.4.2. The involvement of cAMP in lipid rafts/caveolae-mediated PACAP 
signaling in PC12 cells 
 
To test whether the cAMP pathway was directly involved in PACAP-induced neurite 
outgrowth of PC12 cells, cAMP signaling was specifically blocked by adding, prior 
to PACAP stimulation, RP-Adenosine 3’, 5’-cyclic monophosphorothioate (RP-
cAMP), a competitive membrane permeable cAMP antagonist, to PC12 cells. Fig 
4.2.4.B shows that RP-cAMP significantly inhibited PACAP-induced neurite 
outgrowth at both concentrations used (0.5 mM and 1 mM). In addition, the 
enhancing effect of GM1 on the neurite extension was attenuated by RP-cAMP (Fig 
4.2.4.B), reflecting the involvement of cAMP in rafts-mediated neurite elongation 
process elicited by PACAP. 
 
On the other hand, adenosine 3’, 5’-cyclic monophosphate, N6, O2-dibutyryl (db-
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Fig 4.2.4. B. The inhibitory effect of RP-cAMP on the PACAP-induced neurite 
outgrowth and its effect on the function of glycosphingolipid in PACAP-induced 
neurite outgrowth. The mean neurite length/cell was measured at 24 h and 48 h in 
the presence of PACAP (100 nM), or a mixture of PACAP (100 nM) with RP-cAMP 
(0.5 mM or 1 mM) or a mixture of  PACAP (100 nM), RP-cAMP (0.5 mM) and GM1 
(100 µM) respectively, and the relative change was expressed as a percentage of the 
mean neurite length/cell for the cells treated with PACAP alone (100%), as described 



















































Fig 4.2.4. C. Effects of GM1 and the caveolar disruptors on PACAP analog, db-
cAMP, caused neurite outgrowth of PC12 cells. The mean neurite length/cell was 
measured at 24 h and 48 h in the presence of PACAP (100 nM) or db-cAMP (1 mM). 
In some experiments, the cells were pretreated with NB-DNJ (45 µM) or GM1 (100 
µM) or filipin (10 µg/ml) or nystatin (50 µg/ml). The relative change in neurite length 
was expressed as a percentage of the mean neurite length/cell for the cells treated 
with PACAP alone (100%), as described in Materials and Methods. The results are 









of PACAP, and this effect was even stronger than that by PACAP itself (Fig 4.2.4.C). 
These results and those of others (Gunning et al. 1981; Hernandez et al. 1995) suggest 
that cAMP signaling was necessary to induce neurite outgrowth in PC12 cells. Unlike 
PACAP, db-cAMP-induced neurite outgrowth in PC12 cells appeared not to be 
affected by perturbation of caveolae, as demonstrated by addition of exogenous GM1 
and other caveolar disruptors (Fig 4.2.4.C).  However, the effect of GM1 on PACAP-
induced neurite extension was significantly attenuated by perturbation of caveolae 
(Fig 3.2.5.A), indicating that the amount of cAMP produced in caveolae, but not other 
possible secondary sources, was responsible for the effect of GM1. Therefore, these 
observations demonstrate that rafts/caveolae microdomains regulated the PACAP 
signaling through cAMP in PC12 cells. 
 
4.2.5. ERK kinase1/2 (MEK1/2) is regulated by PACAP in PC12 cells 
 
It has been reported that NGF-induced neuronal differentiation in PC12 cells is 
associated with extended activation of ERK (Qui and Green 1992), which has been 
shown to be necessary for neurite outgrowth (Fukuda et al. 1995). The molecular 
mechanisms involved in transducing signals from PACAP receptors to downstream 
targets such as ERK, however, are less defined than those for NGF. Here, PACAP-
stimulated ERK phosphorylation and the regulation of its activation were investigated. 
The level of activated ERK was assessed using an anti-phospho-ERK antibody that 
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detects the dual Threonine (Thr)-202 / Tyrosine (Tyr)-204 phosphorylated forms of 
the kinase. 
 
4.2.5.1. The sustained activation of ERK1/2 induced by PACAP 
 
As expected, PACAP induced an increase in the levels of phosphorylation of ERK1/2 
at Thr-202 and Tyr-204 (Fig 4.2.5.1.A). ERK1/2 phosphorylation reached a 
maximum level upon 5 min-stimulation with PACAP and gradually faded away but 
remained above the basal level (untreated cell) for a few hours (Fig 4.2.5.1.A). 
Compared to the phosphorylation level of ERK1/2 at 5 min post-stimulation with 
PACAP, it decreased by approximately 20% after incubation for 15 min and 50% for 
30 min-incubation (Fig 4.2.5.1.C). On the other hand, NGF-induced ERK1/2 
phosphorylation remained at a similar level after 15 min of stimulation compared to 
that of 5 min-incubation. It declined slightly (approximately 10%) after incubation for 
30 min and remained approximately 70% of that observed at 5 min after stimulation 
for 60 min (Fig 4.2.5.1.C). The dynamic profile of the PACAP-evoked ERK1/2 
phosphorylation was therefore similar to that for NGF (Fig 4.2.5.1.B). However, the 
effect of NGF on ERK1/2 activation was more pronounced and sustained. These 
observations were consistent with the more robust effect of NGF than that of PACAP 
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Fig 4.2.5.1. The phosphorylation level of ERK1/2 upon PACAP and NGF 
stimulation in PC12 cells.  PC12 cells were incubated with or without (control) 
PACAP (A) or NGF (B) for the indicated time periods (5 min, 15 min, 30 min, 1 h or 
2 h). The above treated cells were then harvested and subjected to SDS-PAGE and 
Western blotting using a phosphospecific ERK1/2 (pERK1/2) antibody. Equal 
loading was verified by probing the blots with an anti-ERK1/2 (ERK1/2) antibody. 
The data are representative of three independent experiments. (C). Quantitative 
analysis of the relative change of the level of phosphorylated ERK1/2 for each of the 
incubation time period with or without (control) the PACAP or NGF versus that of 
the cells treated for 5 min (100%) was obtained by densitometry determination. 
Values are mean ± SD of at least three independent experiments. 
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4.2.5.2. The essential role of MEK1/2 activation for PACAP-induced 
activation of ERK1/2 and for the function of glycosphingolipid on the 
neurite extension 
 
                                
To further confirm that the ERK1/2 phosphorylation was regulated upon PACAP 
stimulation and to examine the pertinent mechanism, the ERK kinase1/2 (MEK1/2)-
specific inhibitor, PD98059, was used to treat the PC12 cells. PD98059 dramatically 
inhibited PACAP-induced phosphorylation of ERK1/2 from the early stage (5 min) of 
PACAP stimulation and this inhibitory effect was found to be sustainable (Fig 
4.2.5.2.A). Moreover, morphological investigation of PC12 cells in response to 
PACAP treatment in the presence of PD98059 up to 48 h revealed that PD98059 
abolished the ability of PACAP to induce neurite outgrowth in PC12 cells (Fig 
4.2.5.2.B. middle column). In addition, PD98059 also obliterated the neurite growth 
stimulatory effect of glycoshingolipid GM1 (Fig 4.2.5.2.B, right column), suggesting 
that MEK1/2 is an essential downstream effector molecule in the process of lipid 
rafts/caveolae-modulated PC12 cells differentiation elicited by PACAP. 
 
4.2.5.3. The effect of perturbation of lipid rafts/caveolae on ERK1/2 
activation 
 
Our experimental data showed that enrichment of the plasma membrane with either 
cholesterol or glycosphingolipid enhanced the PACAP-induced phosphorylation of  
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                                              5 min                        30 min 
 
             PACAP               -            +                     +              +              + 
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Fig 4.2.5.2. A. The inhibitory effect of PD98059 on the PACAP-induced 
phosphorylation of ERK1/2. PC12 cells were incubated with or without PD98059 
(100 µM) for 1 h before incubated with PACAP for 5 min or 30 min. The samples 
were subjected to Western blotting using a phosphospecific ERK1/2 (pERK1/2) 
antibody. Equal loading was verified by probing the blot with an anti-ERK1/2 
(ERK1/2) antibody.  
 
B. 
                              PACAP              PACAP+PD98059  PACAP+PD98059+GM1 
             24 h   
                      48 h 
 
Fig 4.2.5.2. B. The effect of specific ERK inhibitor PD98059 on the function of 
glycosphingolipid and the PACAP-induced neurite outgrowth in PC12 cells. 
PC12 cells were cultured with RPMI1640 medium containing 1% horse serum and 
100 nM PACAP in the absence or presence of either PD98059 alone or both 
PD98059 and 100 µM GM1. Phase contrast micrographs were taken after 24 h and 48 
h after PACAP stimulation. The scale bar represents 10 µm. 
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ERK1/2, whilst depletion of either one of the rafts component attenuated the level of 
ERK1/2 phosphorylation (Fig 4.2.5.3 upper panel). These data were consistent with 
the finding that blocking ERK1/2 phosphorylation by MEK1/2 inhibitor abolished the 
morphological response of PC12 cells to PACAP (Fig 4.2.5.2.B, right column). Both 
suggest the critical role of ERK1/2 phosphorylation in PACAP-induced neurite 
outgrowth of PC12 cells. Taken together, these data demonstrate that perturbation of 
the lipid rafts/caveolae would inhibit PACAP-stimulated activation of ERK1/2 
signaling cascade as well as subsequent neurite extension, while enhancements to 
ERK1/2 phosphorylation would promote the differentiation of PC12 cells (Figs 3.2.3 
and 3.2.4). 
 
4.2.5.4. The involvement of cAMP in the PACAP-stimulated activation of 
ERK1/2  
                                                                                                         
To further investigate whether PACAP-induced ERK1/2 phosphorylation was 
regulated by cAMP, RP-cAMP, a specific antagonist of cAMP, was used to treat the 
cells (Fig 4.2.5.4.A). The activation of ERK1/2 was decreased by RP-cAMP (Figs 
4.2.5.4.A and B), which inhibited the PACAP-induced neurite outgrowth as well (Fig 
4.2.4.B). These data suggest that ERK1/2 phosphorylation was a downstream event of 
cAMP synthesis in PACAP-generated neurite extension pathway. On top of this, the 
stimulatory effect of GM1 and prohibitive effect of NB-DNJ on PACAP-induced 
ERK1/2 phosphorylation was simultaneously restrained in the presence of RP-cAMP 
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(Fig 4.2.5.4). These results indicate that plasma membrane rafts modulated PACAP-
elicited ERK1/2 activation via cAMP, and that ERK1/2 was the effector protein 
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Fig 4.2.5.3. The effect of cholesterol and glycosphingolipids on PACAP-induced 
phosphorylation of ERK1/2. PC12 cells were treated with GM1, NB-DNJ, 
cholesterol-mCD or U18666a, respectively, for 24 h before incubated with or 
without (control) PACAP for 5 min or 30 min, respectively. The cell lysates were 
subjected to SDS-PAGE and Western blotting analysis using a phosphospecific 
ERK1/2 (pERK1/2) antibody. Equal loading was verified by probing the blots with an 
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Fig 4.2.5.4. The inhibitory effect of RP-cAMP on the PACAP-induced 
phosphorylation of ERK1/2. (A). PC12 cells were treated with or without (control 
group) RP-cAMP. Both groups of cells were treated with GM1 or NB-DNJ for 24 h 
before incubation with or without (control) PACAP for 5 min. The samples were 
harvested and subjected to Western blotting using a phosphospecific ERK1/2 
(pERK1/2) antibody. Equal loading was verified by probing the blot with an anti-
ERK1/2 (ERK1/2) antibody. The data are representative of three independent 
experiments. (B). Quantitative analysis of the relative change of the level of 
phosphorylated ERK1/2 for each of the treatment with or without RP-cAMP versus 
that of the cells incubated with PACAP alone (100%) was determined by 



































4.2.6. PACAP signaling and the function of glycosphingolipid on 
PACAP-induced neuritogenesis are independent of protein kinase A 
activity 
 
The most elaborately studied cAMP effector protein in mammalian cells was, until 
recently, the cAMP dependent protein kinase A (PKA), whose mechanisms of 
activation and structure have been investigated in detail. To determine whether the 
PACAP-stimulated neurite extension was attributed to activation of PKA, two 
pharmacological blockers of PKA, H89 and protein kinase inhibitor (PKI), were 
applied to treat the PC12 cells. H89 is a classical and potent PKA inhibitor, while PKI 
is a cell permeable selective PKA inhibitor which contains a pseudo-substrate 
sequence for PKA and inhibits PKA enzymatic activity by binding to free C subunits 
(Scott et al. 1985). Interestingly, neither of these inhibitors tested affected PACAP-
induced neurite outgrowth in PC12 cells (Fig 4.2.6.A). In addition, the PACAP-
stimulated ERK1/2 activation level was not influenced by the inhibition of PKA 
either at early stage (5 min), or the prolonged incubation (30 min) with PACAP (Fig 
4.2.6.B). These data suggest that PKA might not be involved in PACAP-stimulated 
neurite extension. To further confirm this and test the specificity and efficiency of 
these pharmacological blockers, PKA activity was measured directly. As expected, 
the induction of PACAP did not affect the PKA activity statistically (Fig 4.2.6.C), 
which was consistent with the finding that inhibition of PKA did not influence 








































Fig 4.2.6. A. The effect of PKA on the PACAP-induced neurite outgrowth. PC12 
cells were pretreated with different concentrations of cell permeable protein kinase 
inhibitor (PKI) (1, 10, 100 µM) or PKA inhibitor H89 (10, 20 µM) for 1 h before 
incubated with PACAP-containing medium. Neurite quantification analysis was 
measured at the indicated time points (24 h and 48 h). The relative change was 
expressed as a percentage of the mean neurite length/cell of the cells treated with 
PACAP alone (100%), as described in Materials and Methods. Values are mean ± SD 
of at least three independent experiments. 
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Fig 4.2.6. B. The effect of PKA on the PACAP-induced ERK1/2 activation. PC12 
cells were pretreated with PKI (10 µM) or H89 (20 µM) for 1 h before incubated with 
or without PACAP containing medium for 5 min or 30 min. The samples were 
harvested and subjected to Western blotting using a phosphospecific ERK1/2 
(pERK1/2) antibody. Equal loading was verified by probing the blots with an anti-
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Fig 4.2.6. PKA activity assay. (C) PC12 cells were treated with NB-DNJ or GM1 or 
both for 24 h, or (D) treated with H89 (20 µM) or PKI (10 µM) for 1 h before 
harvesting for PKA activity assay, as described in the Materials and Methods. Values 




inhibited the PKA activity effectively (Fig 4.2.6.D). These results suggest that PKA 
activation was not necessary for PACAP-induced differentiation of PC12 cells. On 
top of this, the function of glycosphingolipid, the major component of membrane 
rafts/caveolae, either upregulated by GM1 or downregulated by NB-DNJ, on 
PACAP-induced neurite outgrowth was not affected by inhibition of PKA as well 
(Fig 4.2.6.E). On the other hand, PKA activity was not influenced by modulations of 
the membrane glycosphingolipid level with GM1 and NB-DNJ in PACAP signaling 
(Fig 4.2.6.C). Taken together, these results demonstrate that PKA activity was 
unlikely to be involved in the PACAP-stimulated neurite extension of PC12 cells, nor 
a signaling intermediate in rafts/caveolae-mediated PACAP signaling pathways. 
 
4.2.7. The guanine nucleotide exchange factor (EPAC) is activated in 
the downstream of cAMP formation 
 
It has long been questionable whether PKA is the only mediator of cAMP action 
(Dremier et al. 1997; Cass et al. 1999), until the discovery of Exchange Protein 
directly activated by cAMP (EPAC), a guanine nucleotide exchange factor for Rap1 
(de Rooij et al. 1998; Kawasaki et al. 1998). EPAC is activated by cAMP through a 
cAMP-binding regulatory domain (Enserink et al. 2002). EPAC therefore provides an 
alternative path leading from PACAP-cAMP to MEK1/2 and ERK1/2 activation, 










































Fig 4.2.6. E. The effect of PKA on the PACAP-induced neurite outgrowth and 
the influence of membrane glycosphingolipid. PC12 cells were pretreated with or 
without GM1 or NB-DNJ for 24 h before incubated with H89 for 1 h. The medium 
was then changed to PACAP containing medium. The cells were cultured for another 
72 h. The phase contrast photos were taken at the indicated time points (24 h, 48 h 
and 72 h). Neurite quantification analysis was carried out as described. The relative 
change was expressed as a percentage of the mean neurite length/cell of the cells 
treated with PACAP alone (100%), as described in Materials and Methods. Values 









4.2.7.1. The effect of EPAC on neurite outgrowth in the absence or 
presence of PACAP and its effects on the function of membrane 
glycosphingolipid in PACAP signaling 
 
The potential role of EPAC in PACAP-induced neurite outgrowth was tested next. 
The EPAC-selective activator, 8-cpt-2’-o-methyl-cAMP (8-OM-cAMP), an analog of 
cAMP that does not activate PKA (Christensen et al. 2003), provides a unique tool to 
activate EPAC without affecting other parallel signaling cascades. Fig 4.2.7.A shows 
that no stimulation of neurite outgrowth above background level was observed upon 
the addition of 8-OM-cAMP alone (Fig 4.2.7.A, column 1 and 2). Concurrent 
incubation with NB-DNJ (Fig 4.2.7.A, column 3) or GM1 (Fig 4.2.7.A, column 4) 
had no effect on neurite extension either. However, in the presence of PACAP, 8-
OM-cAMP facilitated PACAP-induced neurite outgrowth and the average neurite 
length/cell was approximately 1.8-fold of that induced by PACAP alone during the 
first 24 h incubation (Fig 4.2.7.B). In addition, the inhibitory effect of NB-DNJ on 
PACAP-induced neurite elongation was rescued by the addition of 8-OM-cAMP (Fig 
4.2.7.B). Taken together, these preliminary results indicate that EPAC was likely to 
be involved in the pathways of PACAP-stimulated neurite extension and its activity 
was affected by the integrity of lipid rafts/caveolae. However, EPAC activation on its 
own was insufficient to induce neurite extension, indicating that other pathway(s) 
activated by PACAP might collaborate with EPAC to induce neurite extension in 
PC12 cells.       
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4.2.7.2. The effect of EPAC on PACAP-stimulated activation of ERK1/2  
 
To further establish the significance of EPAC in PACAP-stimulated activation of 
ERK1/2, the level of activated ERK1/2 was assessed in the presence or absence of 
PACAP (Fig 4.2.7.C). Treatment of PC12 cells with the EPAC activator 8-OM-
cAMP alone did not increase the basal phosphorylation level of ERK1/2, which was 
consistent with the results of others (Enserink et al. 2002). On the other hand, in the 
presence of PACAP, EPAC activator robustly augmented MEK1/2-dependent 
ERK1/2 phosphorylation to a level approximately 4-fold higher than that induced by 
PACAP alone (Fig 4.2.7.C). This finding, coupled with the effects of EPAC activator 
on PACAP-elicited neuritogenesis (Fig 4.2.7.B), implicates a PACAP signaling 
cascade that EPAC could be involved in. 
 
4.2.8. Both Rap1 and Ras are responsible for PACAP-induced and 
MEK1/2 -dependent ERK1/2 activation in PC12 cells 
 
Ras and Rap1 are small GTP-binding G proteins of the Ras superfamily and govern a 
wide variety of cellular functions, including cell growth and differentiation (Ehrhardt 
et al. 2002; Quilliam et al. 2002). Guanine exchange factor (GEF) functions to 
promote the conversion of small G protein from a GDP-bound inactive form to a 
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Fig 4.2.7. A. The effect of EPAC activator 8-OM-cAMP on the neurite outgrowth 
of PC12 cells in the absence of PACAP and the influence of membrane 
glycosphingolipid level in this process. PC12 cells were treated without (control) or 
with 8-(4-chlorophenylthio)-2’O-methyl-3’, 5’-cyclic monophosphate (8-OM-cAMP) 
(1 mM) or a mixture of 8-OM-cAMP and NB-DNJ (45 µM) or GM1 (100 µM). Phase 
contrast micrographs were taken at 24 h and 48 h after treatment with 8-OM-cAMP. 
The scale bar represents 10 µm. 
 

















































Fig 4.2.7. B. The effect of EPAC activator 8-OM-cAMP on the neurite outgrowth 
of PC12 cells in the presence of PACAP and the influence of membrane 
glycosphingolipid level in this process.  PC12 cells were treated with or without 8-
OM-cAMP (1 mM) in the presence or absence of NB-DNJ. The neurite length/cell 
was measured 24 h and 48 h after addition of PACAP. The relative change was 
expressed as a percentage of the mean neurite length/cell of the cells treated with 
PACAP alone (100%), as described in Materials and Methods. Values are mean ± SD 
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Fig 4.2.7. C.  The effect of EPAC activator 8-OM-cAMP on PACAP-stimulated 
ERK1/2 activation. PC12 cells were pretreated with or without 8-OM-cAMP (1 mM) 
for 24 h before stimulation with PACAP for 5 min. The cells were then harvested and 
subjected to Western blotting using phosphospecific ERK1/2 (pERK1/2) antibody. 
Equal loading was verified by probing the blots with an anti-ERK1/2 (ERK1/2) 




     + 





promote the conversion from the active form to inactive form. Both Ras and Rap1 are 
targeted to membranes via their CAAX prenylation motifs (Ehrhardt et al. 2002; 
Hancock 2003), and their subcellular localization is also kinetically regulated 
(Maridonneau-Parini and de Gunzburg 1992). Rap1 and Ras have approximately 50% 
amino acid homology and share many binding partners, including ral guanine 
nucleotide dissociation stimulator (ral-GDS), phosphoinositol-3-kinase (PI3K), B-Raf 
and Raf-1 (Stork 2003). 
 
4.2.8.1. PACAP-elicited sustained Rap1 activation and the critical role of 
Rap1 in the subsequent MEK1/2 -dependent ERK1/2 activation 
                                                                                                                                                                 
Since EPAC is a Rap1 guanine nucleotide exchange factor that mediates Rap1 
activation by direct binding to cAMP, Rap1 activation upon PACAP stimulation was 
examined. Fig 4.2.8.1.A shows that the activation, or GTP-loading, of Rap1 occurred 
very rapidly in the presence of PACAP and this activated form might sustain for a 
few hours. To establish that Rap1 is responsible for the PACAP-elicited activation of 
ERK1/2, a siRNA-based approach was used to reduce Rap1 protein levels. The 
efficacy of the inhibitory effect of Rap1 siRNA was evaluated concurrently with 
ERK1/2 activation assay. PC12 cells transfected with Rap1 siRNA led to a marked 
decrease ( 70%) in Rap1 expression compared to untransfected control cells (Fig 
4.2.8.1.B, middle lower panel). Rap1-specific siRNA reduced the 
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Fig 4.2.8.1. A. The Rap1 activation upon PACAP stimulation. PC12 cells were 
treated with PACAP for the indicated time periods and harvested. Rap1 activation 
assay was performed by Rap1 activation assay kit from Pierce and detected by anti-
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Fig 4.2.8.1. The effect of Rap1 on ERK1/2 activation. B. PC12 cells were 
transfected with or withoutwa Rap1 siRNA and then incubated with PACAP for the 
indicated time periods before harvested. The samples were subjected to Western 
blotting using Rap1 and phosphospecific ERK1/2 (pERK1/2) antibodies. Total 
ERK1/2 was shown by probing the blots with an anti-ERK1/2 (ERK1/2) antibody and 
equal loading was verified by probing the blots with an anti--actin antibody. The 
data are representative of three independent experiments. C. The relative decrease of 
pERK1/2 in Rap1 siRNA-treated cells versus that in the control PC12 cells at 
indicated time points was evaluated from the quantitative analysis of the Western 
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treatment in PC12 cells (Fig 4.2.8.1.B and C), whereas the total level of ERK1/2 in 
the cells was unaffected (Fig 4.2.8.1.B). This inhibitory effect could sustain for at 
least 2 h (Fig 4.2.8.1.B). Moreover, neurite length quantification shows that in Rap1-
depleted cells, neurite extension was inhibited by approximately 50% comparing to 
the control siRNA-treated cells under similar experimental conditions (Fig 4.2.8.1.D). 
Taken together, these data suggest that, subsequent to EPAC activation, Rap1 played 
an important role in PACAP-elicited ERK1/2 phosphorylation, and was at least 
partially responsible for the PACAP-induced neurite elongation. On top of this, the 
glycosphingolipid GM1 could compensate the inhibitory effect of Rap1 siRNA on 
neuritogenesis, suggesting that the effect of rafts/caveolae on PACAP-induced neurite 
outgrowth might be somehow associated with Rap1 activation and this will be 
examined further in the next section. 
 
4.2.8.2. The effect of perturbation of lipid rafts/caveolae on the activation 
of Rap1 and on the re-distribution of Rap1 between detergent-soluble and 
-insoluble membrane fractions 
 
To further confirm that rap1 activation was associated with the function of lipid 
rafts/caveolae, caveolar disruptors were applied to the cell cultures. When plasma 
membrane was enriched with cholesterol or glycosphingolipid, the level of GTP-
loaded Rap1 was increased (Fig 4.2.8.2.A). By contrast, depletion glycosphingolipid 












































Fig 4.2.8.1. D. The effect of inhibition of Rap1 on the PACAP-induced neurite 
outgrowth and the influence of membrane glycosphingolipid level in this process. 
PC12 cells were transfected with control siRNA or Rap1 siRNA in the presence or 
absence of GM1 for 24 h. The neurite length/cell was measured at the indicated time 
points (24 h and 48 h, respectively) following PACAP stimulation. The relative 
change of the mean neurite length/cell was expressed as a percentage of that for the 
cells treated with PACAP alone (100%), as described in Materials and Methods. 








treatments with filipin, nystatin, methyl--cyclodextrin, and caveolin-1 siRNA, which 
were expected to disrupt the structure of lipid rafts/caveolae, all reduced Rap1 
activation (Fig 4.2.8.2.A). 
 
It has been reported that Rap1 becomes membrane-attached upon growth factor 
stimulation (Bivona et al. 2004; Li et al. 2005), and its subcellular localization is 
dynamically regulated (Maridonneau-Parini and de Gunzburg 1992). Therefore, it 
was of interest to check whether the distribution of Rap1 in the cell membranes was 
altered upon PACAP stimulation and upon perturbation of the lipid rafts/caveolae. As 
shown in Fig 4.2.8.2.B, cell lysate separated by a 10-40% continuous sucrose gradient 
was probed with anti-Rap1 antibody and anti-transferrin receptor (TfR) antibody. In 
untreated cells, the majority of Rap1 proteins were found in the first three light 
fractions which were free from the non-caveolar marker, TfR. There were some Rap1 
found in the non-caveolar fractions (fractions 4-6) (Fig 4.2.8.2.B). Upon stimulation 
with PACAP, Rap1 in the non-caveolar fractions was largely diminished and a 
majority has moved to the caveolar fractions (fractions 1-3). In the presence of GM1, 
the extent of distribution of Rap1 to the caveolar fractions increased, leaving little 
Rap1 remained in the non-caveolar fractions. On the other hand, reduction of the 
plasma membrane glycosphingolipid by NB-DNJ dispersed the distribution of Rap1 
to non-rafts fractions. In addition, when the cells were treated with other caveolar 
disruptors such as nystain, filipin, CD or caveolin-1 siRNA, Rap1 was also diverted 
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Fig 4.2.8.2. A. The effect of perturbation to the lipid rafts/caveolae on the 
activation of Rap1. PC12 cells were treated with GM1, cholesterol or the lipid 
rafts/caveolar disruptors before stimulated with PACAP for 5 min. The cells were 
harvested and performed Rap1 activation assay using the EZ-detect Rap1 activation 
assay kit from Pierce. In brief, activated GTP-loaded Rap1 protein was pulled down 
by GST affinity-precipitation using Rap1 binding domain GST-RalGDS-RBD and 
immunodetected with a Rap1 antibody. The GDP-bounded Rap1 protein was shown 












































    1      2    3     4     5     6      7      8      9     10                                      Fraction number                1      2      3      4     5    6    7     8     9     10 
                    Control         
                                     PACAP           
               PACAP+Filipin              
             PACAP+Nystatin                                                                    
                                                       PACAP+CD         
                          PACAP+NB-DNJ         
                     PACAP+GM1                                            
                              PACAP+Control siRNA                                          
      PACAP+Caveolin-1 siRNA              
   
       Rap1  TfR 
 
Fig 4.2.8.2. B. The effect of perturbation of lipid rafts/caveolae on the distribution of Rap1 in the membrane fractions. PC12 cells were 
treated with the above caveolae disruptors before PACAP stimulation for 5 min except the control. The cells were harvested and subjected to 
continuous sucrose gradient (10%-40%) separation as described in Materials and Methods. The fractions, whose density was in an ascending 






4.2.2.B). Taken together, these data demonstrate that upon stimulation with PACAP, 
Rap1 shifted to the caveolar fraction of the plasma membrane where signaling 
molecules were gathered, which was likely to facilitate the signaling cascade. 
Treatment of the cells with glycosphingolipid and cholesterol, which might stabilize 
and maintain the lipid rafts/caveolae microdomains, strengthened this translocation, 
and enhanced the assembly of the signaling molecules in the rafts platform leading to 
magnified signaling cascade. Contrastingly, perturbation the lipid rafts/caveolae 
dispersed Rap1 to the non-caveolar fractions, and therefore disrupting PACAP 
signaling. 
 
4.2.8.3. PACAP-elicited transient Ras activation and the effect of 
modulation of plasma membrane glycosphingolipid level on its activation 
 
Although EPAC activation enhanced PACAP-stimulated ERK1/2 phosphorylation 
(Fig 4.2.7.C) and subsequently promoted neurite extension of PC12 cells induced by 
PACAP (Fig 4.2.7.B), activation of EPAC itself did not induce neuritogenesis (Fig 
4.2.7.A). Activating the EPAC-Rap1 signaling cascade was therefore not sufficient 
for neurite extension, and there must exist other pathway(s) which was (were) 
necessary for integrating the signals to generate the biological outcome. It has been 
reported that NGF required both Rap1- and Ras-dependent B-Raf activation to induce 
neurite extension (Lazarovici et al. 1998). Whether this happens in PACAP signaling 




To address the above, Ras activation upon PACAP stimulation was further 
investigated in PC12 cells. Ras was rapidly activated upon PACAP addition (Fig 
4.2.8.3.A), with a maximum level of activation occurring in the early phase of 
stimulation. However, PACAP-elicited Ras GTP-loading was transient and much 
weaker than that observed with NGF (Fig 4.2.8.3.A), which was consistent with the 
more dramatic neurite extension in NGF- than in PACAP-stimulated PC12 cells.  
These data indicate that Ras might have been involved in PACAP signaling.  
 
Ras farnesylation is an absolute requirement for Ras membrane anchorage and 
transforming activity (Hancock et al. 1989; Casey et al. 1989; Gibbs 1991; Kato et al. 
1995). Consistent with this notion, the potent Ras farnesyltransferase inhibitor FPTII 
significantly inhibited both PACAP-induced neurite extension (Fig 4.2.8.3.B) and 
ERK1/2 phosphorylation (Fig 4.2.8.3.C). Similar data from others (Busca et al. 2000) 
show that activation of ERK by cAMP was blocked by a dominant-negative Ras in 
melanocytes. These results further confirm that Ras had played a role in mediating 
PACAP signaling in PC12 cells, although it might not be directly activated by cAMP 
(Busca et al. 2000). In addition, modulating the rafts glycosphingolipid level by either 
GM1 or NB-DNJ affected the Ras GTP-loading elicited by PACAP (Fig 4.2.8.3.D).  
Ras activation was enhanced when plasma membrane was imbued with GM1 and was 
prohibited when membrane glycophingolipid level was decreased by NB-DNJ (Fig 
4.2.8.3.D). Similar enhancement on Ras activity by GM1 might still exist in the 
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Fig 4.2.8.3.  A.  PACAP-stimulated Ras GTP loading. PC12 were incubated with 
or without (negative control) PACAP or NGF (positive control) for indicated time 
periods. The cells were harvested and performed Ras activation assay using EZ-detect 
Ras activation assay kit from Pierece. GTP-loaded Ras was affinity-precipitated using 
Ras binding domain GST-Raf1 and immunodetected with a Ras antibody (upper 
panel). The GDP-loaded Ras protein was shown in the lower panel. 
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Fig 4.2.8.3. B.  The inhibitory effect of FPTII on PACAP-induced neurite 
outgrowth and the influence of membrane GM1 in this process. PC12 cells 
incubated with PACAP in the absence or presence of FPTII (0.1 mM) or both FPTII 
and GM1. Phase contrast micrographs were taken 24 h and 48 h after PACAP was 
added. Neurite length/cell was quantified. The relative change was expressed as a 
percentage of the mean neurite length/cell for the cells treated with PACAP alone 
(100%), as described in Materials and Methods. Values are mean ± SD of at least 
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Fig 4.2.8.3. C.  The inhibitory effect of FPTII on the ERK1/2 phosphorylation 
induced by PACAP.  PC12 cells were treated with or without FPTII (0.1 mM or 0.2 
mM) for 1 h before replacing the medium by that containing 100 nM PACAP. The 
samples were subjected to Western blotting using phosphospecific ERK1/2 (pERK1/2) 
antibody. Equal loading was verified by probing the blots with an anti-ERK1/2 
(ERK1/2) antibody. In quantitative analysis, the phosphorylated ERK1/2 level in 
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Fig 4.2.8.3. D. The effect of membrane glycosphingolipid level on the PACAP-
induced Ras activation. PC12 cells were treated with or without GM1 or NB-DNJ 
followed by incubation with PACAP for 5 min. The cells were harvested and 




















presence of FPTII because the neurite outgrowth blocked by the latter was slightly 
relieved in the presence of GM1 (Fig 4.2.8.3.B). These data demonstrate that Ras 
activation, which relied on the integrity of rafts/caveolae, was involved in PACAP 
signaling in PC12 cells. 
 
4.2.9. Phospholipase C, protein kinase C and intracellular Ca2+ 
elevation are involved in the PACAP-stimulated ERK1/2 activation and 
neuritogenesis of PC12 cells  
 
In many cases, GPCRs are positively coupled to AC or phospholipase C (PLC). As 
shown previously, the interaction between PAC1R and AC upon PACAP treatment 
was facilitated (Fig 4.2.2.C). Whether PAC1R also stimulates PLC activity was 
investigated as below. 
 
4.2.9.1. The effect of inhibition to PLC on PACAP-induced neuritogenesis 
and ERK1/2 activation as well as the influence of membrane 
glycosphingolipid  
 
First, we check the effect of the specific PLC inhibitor U73122 on the differentiation 
of PC12 cells in the presence of PACAP. Fig 4.2.9.A shows that PACAP-elicited 
neurite outgrowth was inhibited by approximately 60-70% in the presence of 1 or 10 









































Fig 4.2.9. A. The inhibitory effect of PLC inhibitor U73122 on the PACAP-
induced neurite outgrowth and the influence of exogenous GM1. PC12 cells were 
pretreated with or without different concentrations (1, 10 µM) of U73122 in the 
presence or absence of GM1 in PACAP containing medium. The phase contrast 
micrographs were taken at 24 h and 48 h after PACAP was added. The neurite 
length/cell was quantified as described. The relative change was expressed as a 
percentage of the mean neurite length/cell for the cells treated with PACAP alone 
(100%), as described in Materials and Methods. Values are mean ± SD of at least 
three independent experiments. 
 
B.      
 
                                                 5 min                   30 min 
      PACAP                   -           +             +           +                       +       
      U73122                          -                  -                                     +                      -           + 
                                 pERK1/2  
                                   ERK1/2  
 
Fig 4.2.9. B. The inhibitory effect of U73122 on the PACAP-induced ERK1/2 
activation. PC12 cells were treated with or without U73122 (1 µM) followed by 
incubation with PACAP for 5 min or 30 min respectively. The samples were 
subjected to Western blotting using a phosphospecific ERK1/2 (pERK1/2) antibody. 
Equal loading was verified by probing the blots with an anti-ERK1/2 (ERK1/2) 
antibody. The data are representative of three independent experiments. 
  
 158 
effect of U73122 could be compensated, at least partly, by increase the membrane 
GM1 concentration. In addition, inhibition of PLC reduced the PACAP-stimulated 
ERK1/2 activation significantly at both time points of observation (Fig 4.2.9.B). 
These results suggest that besides elevation of cAMP, PLC activation was also 
necessary for the PACAP-elicited activation of ERK1/2 and neuritogenesis. 
 
4.2.9.2. The role of PKC in PACAP-induced neuritogenesis and ERK1/2 
activation as well as the influence of membrane glycosphingolipid 
 
The involvement of protein kinase C (PKC) in PACAP signaling was investigated 
using the phorbol ester (PMA), a PKC activity modulator. Short-term PMA 
incubation has been reported to increase PKC levels, while long-term incubation was 
reported to downregulate PKC (Matthies et al. 1987; Singh et al 1994). In this study, 
short-term (1 h) incubation of PC12 cells with PMA alone did not result in significant 
growth of neurites (Fig 4.2.9.C and D), although such treatment is known to increase 
expression of developmentally regulated proteins (Balbi and Allen, 1994; Costello et 
al. 1990; Burry and Perrone-Bizzozero 1993; Perrone-Bizzozero et al. 1993; Reinhold 
and Neet 1989). However, PMA could enhance PACAP- (Fig 4.2.9.C) or db-cAMP- 
(a cAMP analog) (Fig 4.2.9.D) induced neurite outgrowth in PC12 cells. This 
enhancing effect of PMA was sustainable during the time period of observation (Fig 
4.2.9.C), particularly for PACAP-stimulated cells. Taken together, these results show 












































Fig 4.2.9. C. The effect of PKC activator, PMA, on PACAP-induced neurite 
outgrowth and the influence of membrane glycosphingolipids. PC12 cells were 
treated with PMA (0.1 µM) alone or pretreated with PMA for 1 h in the presence or 
absence of NB-DNJ before incubated with PACAP. The phase contrast micrographs 
were taken 24 h and 48 h after PACAP was added. The neurite quantification analysis 
was performed as described in Materials and Methods. Values are mean ± SD of at 



































































Fig 4.2.9. D. The effect of PKC activator, PMA, on the cAMP analog dbcAMP-
induced neurite outgrowth and the influence of membrane glycosphingolipids.  
PC12 cells were pretreated with or without NB-DNJ for 24 h as described in 
Materials and Methods. Differently treated cells were then incubated with various 
concentrations (0.1 or 1 µM) of PMA for 1 h before the induction of 1 mM dbcAMP. 
The phase contrast micrographs were taken at 24 h, 48 h and 72 h time points after 
dbcAMP was added and neurite quantification analysis was performed. The relative 
change was expressed as a percentage of the mean neurite length/cell for the cells 
treated with PACAP alone (100%), as described in Materials and Methods. Values 











PKC might therefore incorporate with cAMP in PACAP signaling in PC12 cells.  
 
To confirm the above, the effects of a specific PKC inhibitor, chelerythrine, which 
competes for the conserved catalytic sites of PKC (Herbert et al. 1990), and long-term 
incubation with PMA, which is known to downregulate PKC, on PACAP-induced 
neurite extension were investigated. As expected, pretreatment with chelerythrine 
inhibited PACAP-induced neurite outgrowth by 40% compared to the control (Fig 
4.2.9.E). The inhibitory effect of prolonged PMA-incubation on PACAP-induced 
neuritogenesis happened only after 48 h, nevertheless, significant (Fig 4.2.9.E). 
Consistent with this, pretreatment with chelerythrine or long-term incubation with 
PMA significantly reduced ERK1/2 activation elicited by PACAP while the total 
ERK1/2 level was unaffected (Fig 4.2.9.I). On the other hand, short-term incubation 
with PMA increased the ERK1/2 activation significantly. On top of these, PKC 
activity was increased upon PACAP activation (Fig 4.2.9.H), indicative of the direct 
involvement of PKC in PACAP signaling. Taken together, these results suggest that 
activation of PKC was necessary for PACAP to efficiently stimulate ERK1/2 
activation and subsequent neurite extension. 
 
Finally, the effects of both PKC activator PMA and inhibitor chelerythrine on 
PACAP-induced neurite outgrowth of PC12 cells could be modulated by 
glycosphingolipid level (Figs 4.2.9.C, D and F), consistent with the importance of 




4.2.9.3. The role of Ca2+ in PACAP-induced neuritogenesis and ERK1/2 
activation as well as the influence of membrane glycosphingolipid  
 
Since inositol 1, 4, 5-trisphosphate (IP3) formed by the action of PLC can activate 
Ca2+ release from intracellular Ca2+ stores, the possible involvement of intracellular 
Ca2+ was then investigated. Perturbation of intracellular Ca2+ levels by either 
prolonged or short-term exposure to thapsigargin (THG), which depletes intracellular 
Ca2+ stores, dramatically retarded the neurite outgrowth elicited by PACAP (Fig 
4.2.9.G). Apparently, prolonged exposure (24 h) to THG inhibited neurite extension 
more effectively than short-term exposure (1 h), a reflection of the time period needed 
for complete depletion of the intracellular Ca2+ store. Moreover, PACAP is known to 
stimulate transient Ca2+ influx (Osipenko et al. 2000). To analyze the involvement of 
Ca2+ influx in PACAP-stimulated neurite extension, extracellular Ca2+ was removed 
by the Ca2+ chelator ethylene glycol bis (2-aminoethyl-ether)-N, N, N’, N’-tetraacetic 
acid (EGTA). Pretreatment of cells with EGTA significantly attenuated the neurite 
extension induced by PACAP (Fig 4.2.9.F), suggesting the involvement of Ca2+ influx 
in PACAP-induced neurite extension. Moreover, both THG and EGTA inhibited the 
increase in ERK1/2 phosphorylation induced by PACAP, while total ERK1/2 level 
was unaffected (Fig 4.2.9.I). Taken together, these data suggest that PACAP might 
cause a change in intracellular Ca2+ concentration, resulting from mobilization of Ca2+ 
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from intracellular store and also Ca2+ influx, and that this rise in intracellular Ca2+ was 
likely part of PACAP signaling. 
 
In addition, retardation of PACAP-induced neurite outgrowth by THG and EGTA 
could be partially restored by GM1 (Fig 4.2.9.F and G), suggesting that the lipid 
rafts/caveolae-mediated PACAP signaling, which leads to neurite extension in PC12 
cells might be modulated, at least partly, by crosstalk with intracellular Ca2+.  
 
4.2.10. Glycogen synthase kinase 3 (GSK3) is involved in lipid 
rafts/caveolae-mediated PACAP signaling in PC12 cells 
 
Glycogen synthase kinase 3 (GSK3) is a highly conserved Ser/Thr kinase 
originally identified as a negative regulator of glycogen synthesis, but is more 
recently implicated in signaling pathways important for early CNS patterning, 
neuronal survival (Mingtao et al. 2000) as well as differentiation (Williams and 
Harwood 2000). It is one of the two isoforms of mammalian GSK3 which are 
encoded by distinct genes, namely GSK3 (51 kDa) and GSK3 (47 kDa) (Woodgett 
1990). GSK3 ( and ) is highly expressed in developing brain, where its expression 
correlates with the period of active neurite remodeling (Woodgett 1990; Takahashi et 
al. 1994; Leroy and Brion 1999). Accordingly, the role of GSK3 in regulating neurite 
morphology has been intensively studied (Eickholt et al. 2002; Sayas et al. 2002; 












































      
 
Fig 4.2.9. E. The effect of PKC activity on the PACAP-induced neurite 
outgrowth. PC12 cells were pretreated with chelerythrine (10 µM, 1 h), or PMA (0.1 
µM, 24 h) before incubated with PACAP. The phase contrast micrographs were taken 
at 24 h and 48 h after PACAP was added and neurite quantification analysis was 
performed. The relative change was expressed as a percentage of the mean neurite 
length/cell for the cells treated with PACAP alone (100%), as described in Materials 
























































Fig 4.2.9. F. The effect of glycosphingolipid on the PKC and Ca2+ treated PC12 
cells induced by PACAP. PC12 cells were pretreated with or without GM1 (100 µM, 
24 h) followed by treated with chelerythrine (10 µM, 1 h) or EGTA (5 mM, 1 h). The 
phase contrast micrographs were taken at 24 h and 48 h after PACAP was added and 
neurite quantification analysis was performed. The relative change was expressed as a 
percentage of the mean neurite length/cell for the cells treated with PACAP alone 
(100%), as described in Materials and Methods. Values are mean ± SD of at least 
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Fig 4.2.9. G. The effect of intracellular Ca2+ on the PACAP-induced neurite 
outgrowth. PC12 cells were pretreated with thapsigargin (THG) (5 µM) for either 1 h 
or 24 h in the presence or absence of exogenous GM1 before incubated with PACAP. 
The phase contrast micrographs were taken 24 h after PACAP was added and neurite 
quantification analysis was performed accordingly. Values are mean ± SD of at least 

















































Fig 4.2.9. H. PACAP-stimulated PKC activation. PC12 cells were stimulated with 
or without (control) PACAP for 5 min before harvesting for PKC activity assay as 
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Fig 4.2.9. J. The effect of PKC and Ca2+ on the PACAP-induced ERK1/2 
phosphorylation. PC12 cells were treated with thapsigargin (THG) (5 µM) or PMA 
(0.1 µM) for 1 h or 24 h, or incubated with EGTA (5 mM), PKC inhibitor 
Chelerythrine (Chele) (10 µM) for 1 h before brief incubation with PACAP for 5 min. 
The cells were harvested and subjected to Western blotting using phosphospecific 
ERK1/2 (pERK1/2) antibody. Equal loading was verified by probing the blots with 
anti- ERK1/2 (ERK1/2) antibody. 
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variants (Mukai et al. 2002; Schaffer et al. 2003).  It has constitutive inhibitory 
activity, that inactivation or activation of GSK-3 promotes or retards neurite 
outgrowth, respectively. GSK3 activity is under both positive and negative 
regulation by upstream kinases. Phosphorylation of Tyr-216 within its kinase domain 
promotes activity, whereas Ser-9 phosphorylation is inhibitory (Wang et al. 1994). 
Various kinases have been implicated in mediating serine phosphorylation and 
inactivation of GSK3, including phosphatidylinositol 3-kinase (PI3K)-regulated 
Akt/PKB, protein kinase A and protein kinase C (Cross et al. 1995; Fang et al. 2000; 
Fang et al. 2002). Lithium inhibits the activity of GSK3 by increasing its 
phosphorylation on Ser-9 (Kirshenboim et al. 2004), and sodium valproate also 
modestly increases the phosphorylation of GSK3 on Ser-9 (De Sarno et al. 2002). 
On the other hand, inhibitors of PI3K, LY294002 and wortmannin, are indirect 
activators of GSK3 as they abolished lithium-induced Ser-9 phosphorylation of 
GSK3 in both HEK 293 and PC12 cells (Kirshenboim et al. 2004). The ability of 
GSK3 to regulate neuronal architecture is thought to rely on its ability to 
phosphorylate microtubule-binding proteins, particularly the neuron-specific proteins 
tau (Hanger et al. 1992; Wagner et al. 1996), MAP1B (Trivedi et al. 2005; Goold and 
Gordon-Weeks 2004), CRMP-2 (Yoshimura et al. 2005), and the widely expressed 
adenomatous polyposis coli protein (APC) (Goold and Gordon-Weeks 2004). 
Phosphorylation of these proteins by GSK3 promotes microtubule disassembly and 
destabilization (Zhou and Snider 2005), and provided a strong rationale for 
developing selective GSK3 inhibitors for the treatment of neuropathologies (Cohen 
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and Goedert 2004). Indeed, phosphorylation of MAP1B, which maintains the 
population of unstable microtubules in growing axons and dephosphorylation of APC, 
which increases stable microtubules, have been reported during NGF-stimulated 
PC12 cell differentiation (Goold and Gordon-Weeks 2001; 2004; Zhou et al. 2004). 
However, the functions of GSK3 in differentiation induced by PACAP and the 
underlying mechanisms of regulation are still lacking. In particular, whether 
phosphorylation of GSK3 Ser-9 occurs during PACAP-induced neuritogenesis in 
PC12 cells is not known so far.  
 
4.2.10.1. The role of GSK3 in PACAP-induced neurite outgrowth and the 
influence of plasma membrane glycosphingolipid  
                   
Not surprisingly, lithium, an inhibitor of GSK3 activity, remarkably promoted 
PACAP-evoked neurite outgrowth at the concentration of 10 mM (Fig 4.2.10.A). This 
stimulatory effect was attenuated by inhibition of either the plasma membrane 
glycosphingolipid level by NB-DNJ or cholesterol level by U18666a (Fig 4.2.10.A). 
Similarly, another GSK3 activity inhibitor, valproate, enhanced the PACAP-induced 
neurite extension of PC12 cells (Fig 4.2.10.B). Again, perturbation of the plasma 
membrane rafts/caveolae by NB-DNJ or U18666a decreased the accelerative effect of 
valproate on neurite outgrowth (Fig 4.2.10.B). These data indicate that inhibition of 
GSK3 activity did increase the neurite extension elicited by PACAP. To further 












































































Fig 4.2.10. The potentiation effect of GSK3 inhibitors on the PACAP-induced 
neurite outgrowth and the influence of glycosphingolipid in this process. PC12 
cells were treated with or without NB-DNJ or U18666a for 24 h before incubated 
with or without 10 mM lithium (A) or 1 mM valproate (B) in the complete medium 
for 1 h. Phase contrast micrographs were taken at the indicated time points after 
PACAP was added and neurite quantification was performed. The relative change 
was expressed as a percentage of the mean neurite length/cell for the cells treated 
with PACAP alone (100%), as described in Materials and Methods. Values are mean 















































































Fig 4.2.10. The inhibitory effect of specific PI3K inhibitors, indirect activators of 
GSK3, on the PACAP-induced neurite outgrowth and the influence of 
glycosphingolipid in this process. PC12 cells were incubated with (D) or without (C) 
GM1 for 24 h before treated with or without various concentrations of wortmannin or 
LY294002 as indicated, in the complete medium for 1 h. Phase contrast micrographs 
were taken at 24 h and 48 h time points after PACAP was added and neurite 
quantification was performed. The relative change was expressed as a percentage of 
the mean neurite length/cell for the cells treated with PACAP alone (100%), as 







and LY294002, which are indirect activators of GSK3. Both wortmannin (2.5, 5, 10 
µM) and LY294002 (5, 10 µM) blocked PACAP-induced neurite outgrowth of PC12 
cells (Fig 4.2.10.C). The enhancing effect of GM1 on neurite extension excited by 
PACAP was also attenuated in the presence of either wortmannin or LY294002 (Fig 
4.2.10.D). Activation of GSK3 therefore reduced neurite outgrowth stimulated by 
PACAP. Taken together, these data clearly demonstrate that GSK3 was most likely 
involved in PACAP-elicited neuritogenesis of PC12 cells, which was mediated by 
plasma membrane lipid rafts/caveolae.  
 
4.2.10.2. The effect of perturbation of lipid rafts/caveolae on PACAP-
induced GSK3 phosphorylation 
 
PACAP-induced phosphorylation of GSK3 was next analyzed using an antibody 
specifically recognizing phospho-Ser-9 GSK3 (Fig 4.2.10.E). Clearly, PACAP 
significantly increased the level of GSKB3 phosphorylation on Ser-9, supporting the 
notion that GSKB3 plays a role in PACAP signaling. In addition, both GM1 and 
cholesterol-methyl--cyclodextrin, which promoted PACAP-induced neurite 
outgrowth, enhanced the phosphorylation of GSK3 on Ser-9 elicited by PACAP. On 
the other hand, NB-DNJ or U18666a, which attenuated PACAP-induced neurite 
extension, decreased the GSK3 phosphorylation. The total amount of GSK3 was 
not affected (Fig 4.2.10.E). These results confirm that GSK3 was phosphorylated 
upon PACAP stimulation and the level of inhibitory phosphorylation of GSK3 was  
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Fig 4.2.10. E. The effect of perturbation of the components of lipid rafts/caveolae 
on the PACAP-induced GSK3 phosphorylation. PC12 cells were treated with 
GM1, NB-DNJ, Cholesterol-mCD (Cholesterol) or U18666a for 24 h followed by 
incubated with PACAP for 5 min. Western blotting was performed using a 
phosphospecific GSK3 (pGSK3) antibody. Equal loading was verified by probing 
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Fig 4.2.10. F. The effect of caveolin-1 siRNA on the PACAP-induced GSK3 
phosphorylation. (a). PC12 cells were transfected with control or caveolin-1 siRNA, 
followed by incubated with or without PACAP for 5 min. The samples were 
subjected to Western blotting with a phosphospecific GSK3 (pGSK3) antibody. 
Equal loading was verified by probing the blot with an anti-GSK3 antibody. (b). 





correlative with the extent of neurite outgrowth. In addition, this phosphorylation 
appeared to be regulated in the process of PACAP signaling through lipid 
rafts/caveolae. Consistent with this notion, perturbation of lipid rafts/caveolae by 
caveolin-1 siRNA inhibited PACAP-stimulated phosphorylation of GSK3, while 
total GSK3 level was not changed (Fig 4.2.10.F). These results verify that 
phosphorylation of GSK3 by PACAP signaling was modulated by the integrity and 
proper function of lipid rafts/caveolae.  
 
4.2.10.3. The effect of PKC and Ca2+ on PACAP-induced GSK3 
phosphorylation 
 
To further determine the upstream events that regulate the activity of GSK3, PKC 
and Ca2 elevation were inhibited by pharmacological blockers and the GSK3 
phosphorylation level was examined by Western blot. Inhibition of PKC by 
chelerythrine and prolonged incubation with PMA decreased GSK3 phosphorylation 
level, while total GSK3 was not affected (Fig 4.2.10.G). These results imply that the 
activity of GSK3 was regulated by PKC. Similarly, depletion of Ca2+ store by THG 
or sequestration of the extracellular Ca2+ by EGTA reduced the GSK3 
phosphorylation level (Fig 4.2.10.G). The inhibitory effect of THG with long-term 
incubation (24 h) was more intensive than with short-term incubation (1 h) (Fig 
4.2.10.G), suggesting that the concentration of intracellular Ca2+ has an impact on the 
level of phosphorylation of GSK3. Taken together, these data indicate that PACAP-
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elicited GSK3 phosphorylation on Ser-9 might be modulated by PKC activation and 
Ca2+ mobilization. 
 
4.2.10.4. The effect of Rap1 on PACAP-induced GSK3 phosphorylation  
 
It has been shown that PKC and Ca2+, activated by PACAP, might synergize with 
cAMP elevation which in turn loaded Rap1 with GTP, thereby inducing neurite 
generation in PC12 cells.  Thus, whether the activity of GSK3 is also modulated by 
cAMP and how it was regulated were further questions to be asked. To investigate 
these, Rap1 expression was silenced by siRNA. As illustrated in Fig 4.2.10.H, PC12 
cells transfected with Rap1 siRNA showed a marked reduction (70%) in the level of 
Rap1 protein expression compared with that in control cells. As a result, the level of 
GSK3 phosphorylation, although not altered at the very early stage of PACAP 
induction (5 min), decreased significantly thereafter and the inhibitory effect of Rap1 
siRNA on the phosphorylation of GSK3 was sustainable for at least 2 h (Fig 
4.2.10.H). In addition, suppression of Rap1 also led to a marked and sustained 
reduction of ERK1/2 phosphorylation (Fig 4.2.8.1 B). These results suggest that Rap1 
activation could be an upstream event of GSK3 phosphorylation in PACAP 
signaling. Moreover, changes to GSK3 and ERK1/2 phosphorylation upon Rap1 
regulation were consistent, indicating the possible correlation between these effector 
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Fig 4.2.10. G. The effect of PKC and Ca2+ on the PACAP-induced GSK3 
phosphorylation. PC12 cells were treated with thapsigargin (THG) (5 µM) for either 
1 h or 24 h or incubated with PMA (0.1 µM), EGTA (5 mM) or Chelerythrine (Chele) 
(10 µM) for 1 h before brief incubation with PACAP for 5 min. The cells were 
harvested and subjected to Western blotting using a phosphospecific GSK3 
(pGSK3) antibody. Equal loading was verified by probing the blots an anti-GSK3 
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Fig 4.2.10. H. The effect of Rap1 siRNA on the phosphorylation of GSK3. PC12 
cells were transfected with control siRNA or Rap1 siRNA for 48 h before incubated 
with PACAP (100 nM) for the indicated time periods and then harvested. The whole 
cell lysates were subjected to Western blotting with phosphospecific GSK3 
(pGSK3) and anti-GSK3 (pGSK3) antibodies, respectively. The efficiency of 
siRNA was evaluated 48 h after transfection using an anti-Rap1 antibody and equal 
loading was revealed by -actin. The bands are representative of three independent 
experiments.                                                       
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4.2.10.5. The effect of GSK3 on PACAP-induced ERK1/2 activation  
 
Whether ERK1/2 and GSK3 phosphorylation were correlated in PACAP signaling, 
or whether ERK1/2 phosphorylation was the downstream (or upstream) event of 
GSK3 phosphorylation was examined. Different GSK3 inhibitors and activators 
were used to treat the PC12 cells. GSK3 and ERK1/2 phosphorylation levels were 
assured by Western blot. Inhibition of GSK3 constitutive activity by either lithium 
or valproate, which enhanced PACAP-induced GSK3 Ser-9 phosphorylation (Fig 
4.2.10.I, middle lower panel) potentiated PACAP-elicited ERK1/2 phosphorylation at 
both Thr-202 and Tyr-204 (Fig 4.2.10.I, upper panel). Contrastingly, activating of 
GSK3 by LY294002 or wortmannin, which reduced GSK3 phosphorylation level 
to the basal level (Fig 4.2.10.I, middle lower panel) decreased ERK1/2 activation by 
PACAP (Fig 4.2.10.I, upper panel), while total ERK1/2 was not affected (Fig 4.2.10.I, 
middle lower panel). In the absence of PACAP, lithium, valproate, LY294002 and 
wortmannin alone did not elicit ERK1/2 activation above basal level (Fig 4.2.10.I, 
upper panel). These data provide evidence that PACAP-evoked ERK1/2 activation 
was regulated by GSK3 phosphorylation. Consistent with this, the MEK1/2 inhibitor 
PD98059 did not change PACAP-elicited GSK3 phosphorylation (Fig 4.2.10.J). 
Taken together, ERK1/2 activation was most likely the downstream event of GSK3 
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Fig 4.2.10. I. The effect of GSK3 on the phosphorylation of ERK1/2. PC12 cells 
were treated with either GSK3 activity activators (LY294002 and wortmannin) or 
inhibitors (lithium and valproate) for 1 h before incubated with PACAP for 5 min and 
harvested. The whole cell lystates were subjected to Western blotting with a 
phosphospecific ERK1/2 (pERK1/2) antibody or a phosphospecific GSK3 (pGSK3) 
antibody. Equal loading was verified by probing the blots with an anti-ERK1/2 
(ERK1/2) or an anti-GSK3 (GSK3) antibody. The bands are representative of three 
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Fig 4.2.10. J.  The effect of ERK1/2 activity on the phosphorylation of GSK3. 
PC12 cells were treated with or without PD98059 (100 µM) for 1 h before incubated 
with or without PACAP (100 nM) for 5 min. The cells were harvested and subjected 
to Western blotting with a phosphospecific GSK3 (pGSK3) antibody. Equal 
loading was verified by probing the blots with an anti-GSK3 (GSK3) antibody. The 
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4.2.10.6. The effect of Ras on PACAP-induced GSK3 phosphorylation  
 
Lastly, the effect of Ras on the phosphorylation of GSK3 induced by PACAP was 
examined. Unlike the effect of Rap1, suppression of Ras activity by specific Ras 
farnesylation inhibitor FPTII at both concentrations applied (0.1 mM and 0.2 mM), 
did not affect either the phosphorylation or the total level of GSK3 elicited by 
PACAP (Fig 4.2.10.K). These results demonstrate that, unlike the positive effect of 
Rap1 on GSK3 phosphorylation, PACAP-induced GSK3 phosphorylation was not 
modulated by Ras activity in PC12 cells. 
 
Taken together, the above data demonstrate that GSK3 was involved in PACAP 
signaling pathways in PC12 cell by modulating ERK1/2 activation. On the other hand, 
GSK3 phosphorylation was downstream event of Rap1 and PKC activation as well 
as Ca2+ mobilization, however, it was independent of Ras activation. On top of this, 
perturbation of lipid rafts/caveolae affected PACAP-induced GSK3 phosphorylation 
in PC12 cells, indicative of the functional association of phosphorylation of GSK3 
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Fig 4.2.10. K. The effect of inhibition of Ras on the PACAP-induced GSK3 
phosphorylation. PC12 cells were treated with different concentrations (0.1, 0.2 mM) 
of Ras process inhibitor FPTII for 1 h before incubated with PACAP for 5 min. The 
cells were harvested and subjected to Western blotting with a phosphospecific 
GSK3 (pGSK3) antibody. Equal loading was verified by probing the blots with an 
anti-GSK3 (GSK3) antibody. The bands are representative of three independent 
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4.2.11. Perturbation of the lipid rafts/caveolae by caveolin-1 siRNA, 
which inhibits the PACAP-elicited neurite extension, increases ERK1/2 
activation 
 
ERK1/2 are members of MAP Kinases which are Ser/ Thr kinases involved in 
regulating of a variety of cellular functions, such as cell proliferation, growth, 
differentiation and apoptosis (Davis 1993; Nishida and Gotoh 1993; Lewis et al. 1998; 
Chang and Karin 2001; Pearson et al. 2001). Sustained activation of ERK1/2 is 
required for full neurite outgrowth induced by several factors (Perron and Bixby 1999; 
Yaka et al. 1998; Perron and Bixby 1999). Indeed, ERK1/2 phosphorylation was 
found to be essential in the process of differentiation in PC12 cells stimulated by 
PACAP (Fig 4.2.5.2). However, the level of activated ERK1/2 stimulated by PACAP 
was attenuated by perturbation of the integrity of lipid rafts/caveolae when the major 
lipid components were removed (Fig 4.2.5.3), which in turn, led to inhibited neurite 
outgrowth (Fig 3.2.1.1). In the studies that follow, the effects of caveolin-1 siRNA, 
also known to disrupt the lipid rafts/caveolae, on the PACAP-elicited ERK1/2 activity 







4.2.11.1. The effect of perturbation of lipid rafts/caveolae by caveolin-1 
siRNA on PACAP-induced ERK1/2 activation  
 
 As shown in Fig 4.2.11.A, the caveolin-1 expression level was remarkably inhibited 
(70%) in cells transfected with caveolin-1 siRNA compared to cells transfected with 
siRNA of random sequences or untreated cells. Interestingly, PACAP-elicited 
ERK1/2 activation was enhanced by a decrease in caveolin-1 expression, with more 
remarkable effect in the early stage of PACAP treatment (Fig 4.2.11.A and B), but the 
total ERK1/2 level was not affected. These data indicate that perturbation of lipid 
rafts integrity by caveolin-1 siRNA could increase the PACAP-evoked ERK1/2 
activation and this effect was sustainable. These results appeared to be in 
contradiction to what found before. Although the reason for the increase of the 
ERK1/2 phosphorylation upon caveolin-1 siRNA transfection was still vague, the 
discrepancy might be explained by the fact that cavoelin-1 possesses transformation 
prohibitive activity by binding to and inactivating the signaling molecules including 
ERK1/2 (Okamoto et al. 1998). Therefore, when the caveolin-1 was downregulated, 
this inhibitory effect of caveolin-1 on the ERK1/2 was removed. Moreover, this effect 
on the increase in ERK1/2 phosphorylation might surpass the opposite effect of 
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Fig 4.2.11. The effect of caveolin-1 siRNA on the PACAP-induced ERK1/2 
activation and on the function of membrane glycosphingolipids.  PC12 cells were 
treated with or without (control) caveolin-1 siRNA or control siRNA in the presence 
or absence of GM1 or NB-DNJ, followed by incubation with or without PACAP for 5 
min. (A). The cells were harvested and subjected to Western blotting with pERK1/2 
and ERK1/2 antibodies. Densitometry determination of pERK1/2 levels in control 
and caveolin-1 siRNA-treated cells in the presence of PACAP for the indicated time 
periods was shown in (B). The caveolin-1 expression level was evaluated 48 h after 
the caveolin-1 siRNA transfection (-actin as loading control). The bands are 
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4.2.11.2. The effect of caveolin-1 siRNA on the ERK1/2 nuclear 
translocation elicited by PACAP 
 
It is known that ERK1/2 must localize to the nucleus in order to execute its mitogenic 
function such as causing proliferation and differentiation (Brune et al. 1999). Many 
studies have reported that activation of the ERK1/2 pathway by diverse agonists 
results in its nuclear translocation of the active kinase (Lenormand et al. 1998). 
Therefore, a reason for the fact that increased ERK1/2 activation following caveolin-1 
siRNA transfection failed to cause promoted neurite outgrowth might be due to 
cytoplasmic sequestration and prevention of nuclear translocation of active ERK1/2. 
Indeed, PACAP-induced phosphorylation of ERK1/2 in nuclear fraction was 
significantly decreased in cells transfected with caveolin-1 siRNA compared to cells 
transfected with siRNA of random sequences or untreated cells (Fig 4.2.11.C upper 
panel), with un-affected total ERK1/2 levels (Fig 4.2.11.C middle upper panel). These 
results were further confirmed by the immunostaining with an anti-phospho-p42/44 
ERK1/2 antibody (Fig 4.2.11.D). Clearly, in cells transfected with the control siRNA 
sequence, majority of the phosphorylated ERK1/2 induced by PACAP was located in 
the nuclear fraction (indicated by Hoechst staining), while in caveolin-1 siRNA-
treated cells, the distribution of activated ERK1/2 was dispersed and the portion of 
phosphorylated ERK1/2 in the nuclei was much less than that in the control cells. 
Therefore, the nuclear translocation of PACAP-induced phosphorylated ERK1/2 was 
somehow inhibited by knock-down of caveolin-1 expression. Whether the decreased 
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amount of phosphorylated ERK1/2 allocated in nuclear fraction leads to decreased 
downstream transcription factor activation and subsequent attenuated neurite 
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Fig 4.2.11. C. The effect of caveolin-1 siRNA on the pERK1/2 level in the nuclei 
of PACAP-stimulated PC12 cells. PC12 cells were treated with or without caveolin-
1 siRNA or control siRNA before incubated with or without PACAP for 5 min. The 
cells were homogenized and the nuclear fractions of the cells were collected and 
subjected to Western blotting with pERK1/2 and ERK1/2 antibodies. The caveolin-1 
expression level was evaluated 48 h of caveolin-1 transfection (-actin as loading 
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Fig 4.2.11. D. The effect of caveolin-1 on the nuclear translocation of PACAP-
induced phosphorylated ERK1/2. PC12 cells were cultured on glass coverslips and 
were treated with or without caveolin-1 siRNA or control siRNA, respectively, 
followed by stimulation with PACAP (100 nM, 5 min), as indicated, before being 
fixed and stained with anti-phosphor-p42/44-ERK1/2 antibody. The cells were then 
cultured with goat-anti-rabbit IgG Alexa-488 secondary antibody (green) for 1 h, 
followed by staining with Hoechst33342 (blue) for 15 min at room temperature in the 
dark. The merged images were shown in right column. The micrographs shown are 







4.2.12. ERK1/2-mediated CREB and Elk phosphorylation upon PACAP 
stimulation is an essential step for transcriptional regulation required 
for lipid rafts/caveolae-mediated PC12 cell differentiation 
 
Many transcription factors, such as the phosphoprotein cyclic AMP response element 
binding protein (CREB) and ETS domain-containing protein (Elk), regulate gene 
expression in response to membrane depolarization, Ca2+ influx, cAMP-mediated 
second messenger systems, as well as MAPK activation. As mentioned previously, 
the nuclear translocation of ERK1/2 and phosphorylation of downstream transcription 
factors are essential for the activated ERK1/2 to affect different biological outcomes. 
Indeed, CREB is a major regulatory target of ERK1/2 signaling and may be pivotal 
for synaptic plasticity, neuronal survival and genesis of dendritic spines mediated by 
ERK1/2 (Montminy and Bilezikjian 1987; Impey et al., 1998 a, b; Bonni et al. 1999; 
Riccio et al. 1999; Waeber and Habener 1991; Lee 1997; Murphy and Segal 1997). 
Phosphorylation of CREB at Ser-133 is required for recruitment of the co-activator 
CREB-binding protein (CBP) and transcriptional activity (Gonzalez and Motminy 
1989; Chrivia et al.1993). Numerous signaling events can activate CREB through 
phosphorylation of Ser-133, which contributes to many vital processes. Elk1, a 
member of the Ets family of transcription factors, is another nuclear target of ERK1/2 
which is important for neuronal plasticity (Berman et al. 1998) and differentiation 
(Vossler et al. 1997). Elk is an important physiological substrate of ERKs and 
mediates serum-induced expression of immediate early genes (Marais et al. 1993). 
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The activation of ERKs can be assayed indirectly by measuring the transactivation of 
a 5× Gal4-E1b/luciferase reporter gene by an Elk-1/Gal4 chimera (Misra-Press et al. 
1995). ERK-mediated Elk phosphorylation upon NGF stimulation is an essential step 
for transcriptional regulation required for neuronal differentiation (Vossler et al. 
1997). Elk is phosphorylated by ERK at a cluster of Ser/Thr motifs at its C-terminus 
(Cruzalegui et al. 1999). Phosphorylation at these sites, particularly Ser-383, is 
critical for transcriptional activity of Elk1 (Marais et al. 1993; Zinck et al. 1993). 
However, evidence for CREB and Elk phosphorylation in response to lipid 
rafts/caveolae-mediated PACAP signaling is still lacking.  
 
4.2.12.1. The involvement of transcription factors Elk and CREB in the 
PACAP-induced signaling pathways 
 
In this study, the CREB and Elk activity was evaluated by Western blot using 
antibodies that recognize the phospho-Ser-133 of CREB, phospho-Ser-383 of Elk, 
CREB and Elk. As expected, PACAP stimulation increased both CREB (Fig 4.2.12.A) 
and Elk phosphorylation (Fig 4.2.12.B) compared to the unstimulated control cells. 
Blocking PKA activity by either H89 or PKI did not change the PACAP-induced 
CREB phosphorylation (Fig 4.2.12.A) or Elk phosphorylation (Fig 4.2.12.B). Since 
ERK1/2 phosphorylation levels were not influenced by PKA (Fig 4.2.6.B), it was not 
surprising that the downstream target transcription factors were not affected as well. 
However, blocking MEK1/2, cAMP, PLC and PKC by PD98059, RP-cAMP, U73122 
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and chelerythrine respectively, inhibited both the phosphorylation of CREB (Fig 
4.2.12.A) and Elk (Fig 4.2.12.B). These results were also consistent with previous 
data showing that MEK1/2 (Fig 4.2.5.2.A), cAMP (Fig 4.2.4.B), PLC (Fig 4.2.9.B) 
and PKC (Fig 4.2.9.G) inhibitors reduced ERK1/2 activation. There was therefore a 
strong correlation between ERK1/2 activation and CREB, Elk-1 phosphorylation in 
PACAP signaling.  
 
4.2.12.2. The role of lipid rafts/caveolae on Elk and CREB 
phosphorylation in PACAP-induced signaling pathways 
 
Furthermore, when the plasma membrane was enriched with exogenous GM1 or 
cholesterol, the phosphorylation of both CREB (Fig 4.2.12.E) and Elk (Fig 4.2.12.F) 
were enhanced. On the other hand, when glycosphinoglipid or cholesterol levels were 
reduced by NB-DNJ or U18666a respectively, the phosphorylation of CREB (Fig 
4.2.12.E) and Elk (Fig 4.2.12.F) were inhibited. Consistently, depletion of plasma 
membrane cholesterol by filipin, nystatin or methyl--cyclodextrin also attenuated the 
CREB (Fig 4.2.12.C) and Elk (Fig 4.2.12.D) activation. These results suggest that 
perturbation of lipid rafts/caveolae by modulating plasma membrane glycoshingolipid 
and cholesterol levels influenced the PACAP-stimulated phosphorylation of 
transcription factors CREB and Elk. Likewise, disrupting the caveolae/rafts by 
caveolin-1 siRNA (Fig 4.2.12.G) significantly inhibited PACAP-induced 
phosphorylation of CREB and Elk (Fig 4.2.12.G), with total CREB and Elk levels  
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Fig 4.2.12. The involvement of transcription factors, CREB and Elk, in the 
PACAP-induced signaling pathways. PC12 cells treated with or without H89, 
PD98059, U73122, Chelerythrine, RP-cAMP, EGTA, THG for 1 h before brief 
incubation with or without PACAP for 5 min. The cells were harvested and the 
samples were subjected to Western blotting using a phosphospecific CREB (pCREB) 
(A) or a phosphospecific Elk (pElk) (B) antibody. Equal loading was verified by 
probing the blots with an anti-CREB (CREB) (A) or an anti-Elk (Elk) (B) antibody. 
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Fig 4.2.12. The effect of integrity of lipid rafts/caveolae on the phosphorylation 
of transcription factors, CREB and Elk, in PACAP-induced signaling pathways. 
PC12 cells were treated with or without filipin, nystatin, cyclodextrin (CD) for 1 h 
before brief incubation with or without PACAP (100 nM) for 5 min. The cells were 
harvested and the samples were subjected to Western blotting using a phosphospecific 
CREB (pCREB) (C) or a phosphospecific Elk (pElk) (D) antibody. Equal loading 
was verified by probing the blots with an anti-CREB (CREB) (C) or an anti-Elk (Elk) 
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Fig 4.2.12. The effect of membrane glycosphingolipid and cholesterol levels on 
PACAP-induced CREB and Elk phosphorylation. PC12 cells were treated with or 
without GM1, NB-DNJ, Cholesterol-mCD or U18666a for 24 h before brief 
incubation with or without PACAP for 5 min. The cells were harvested and the 
nuclear fractions of the samples were prepared as described in Materials and Methods. 
The samples were subjected to Western blotting using a phosphospecific CREB 
(pCREB) (E) or a phosphospecific Elk (pElk) (F) antibody. Equal loading was 
verified by probing the blots with an anti-CREB (CREB) (E) or an anti-Elk (Elk) (F) 
















































unaffected. These data show that caveolin-1 siRNA attenuated downstream 
transcription factors activation, which could result from the inhibited nuclear 
translocation of phosphorylated ERK1/2 (Fig 4.2.11.C). Taken together, the above 
data confirm that perturbation of lipid rafts/caveolae affected PACAP-induced 
activation of Elk and CREB. 
 
That concomitant phosphorylation of Elk and CREB coincides with the activation of 
cAMP, PLC, PKC, Ca2+ as well as downstream ERK1/2 suggests that the activation 
of both Elk and CREB were essential at the gene transcription level that were  
necessary for the neuritogenesis upon PACAP stimulation. This notion was further 
supported by another finding indicating that GSK3, which was involved in PACAP 
signaling, is an inhibitory regulator of CREB. Inhibition of GSK3 blocks its 
inhibitory effect on the phosphorylation of CREB on Ser-133 (Grimes and Jope 2001). 
Therefore, Ser-9 phosphorylation of GSK3, which attenuates the inhibitory effect of 
GSK3, increases the phosphorylation of CREB. This conclusion was in agreement 
with previous finding in this study that increased GSK3 phosphorylation augmented 
ERK1/2 activation. This in turn, enhanced phosphorylation of downstream 
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Fig 4.2.12. G. The effect of caveolin-1 siRNA on PACAP-induced CREB and Elk 
phosphorylation.  PC12 cells were treated with caveolin-1 siRNA or control siRNA 
before incubated with or without PACAP for 5 min. The cells were homogenized and 
the nuclear fractions of the cells were collected and subjected to Western blotting 
with anti-pCREB and CREB antibodies or with anti-pElk and Elk antibodies. The 
caveolin-1 expression level was evaluated 48 h after caveolin-1 transfection (-actin 
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5.1. PACAP-induced translocation of its receptor PAC1R into 
lipid rafts/caveolae, leading to enhanced cAMP generation and 
neurite outgrowth in PC12 cells 
 
In PC12 cells, PACAP is known to activate the transmembrane adenylyl cyclase (AC) 
via its specific G-protein-coupled receptor PAC1R, resulting in an elevation of 
intracellular cAMP levels (Spengler et al. 1993). In the present study, I demonstrate 
that PACAP induces translocation of PAC1R into plasma membrane caveolae, where 
AC and the regulating G-proteins are localized (Schwencke et al. 1999; Ostrom et al. 
2000a; 2000b; Insel et al. 2005). This colocalization of PAC1R and AC appears to 
enhance their interactions and contributes to the elevation of cAMP synthesis and 
eventually leads to neuritogenesis in PC12 cells. The results of this study elucidate for 
the first time the molecular events between PAC1R activation and cAMP production. 
 
PC12 cells express PAC1R, and experience robust morphological changes following 
PACAP stimulation (Deutsch and Sun 1992; Ravni et al. 2006). Although PACAP 
has no significant effect on the expression of endogenous PAC1R mRNA (Cavallaro 
et al. 1995; Jamen et al. 2002), it slightly elevated cellular levels of PAC1R (Fig 
4.2.1), implying that PACAP signaling might influence the rate of PAC1R translation 
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or its turnover. It is interesting to note that this PACAP-induced up-regulation of 
PAC1R was not affected by a disruption of the integrity of caveolin-enriched 
microdomains (Fig 4.2.1), which retarded PACAP-induced neurite outgrowth (Figs 
3.2.1 and 3.2.2.A and C). This observation directly prompted us to examine the 
possible association of PAC1R with caveolae, where its effector proteins reside, 
following PACAP stimulation.  
 
Immunoblot analysis revealed that PAC1R was localized in both detergent-soluble 
and -insoluble fractions of PC12 cells (Fig 4.2.2.B). Triton X-100-insoluble fractions 
were enriched with the caveolae-specific structural protein, caveolin-1 (Fig 4.2.2.A). 
Our data support a model in which a portion of PAC1R, originally localized in the 
detergent-soluble region, was recruited into caveolae after PACAP stimulation. Since 
AC, the effector of PACAP signaling pathway, accumulates in caveolae, this 
translocation of PAC1R was expected to enhance its coupling with AC. This was 
indeed demonstrated by the increased degree of co-immunoprecipitation of PAC1R 
and AC (Fig 4.2.2.D). As a result of this increased interaction, the intracellular cAMP 
level was markedly elevated (Fig 4.2.4.A) and consequently the signaling pathway 
leading to neurite outgrowth of PC12 cells was activated. Exactly how PAC1R 
translocated into caveolae upon PACAP stimulation remains unclear in terms of 
biophysical details. Nevertheless, translocations of activated receptors into lipid 
rafts/caveolae as means to initiate signaling cascades were reported before (Higuchi et 




Caveolae are tiny (50 - 100 nm in diameter) plasma membrane invaginations enriched 
in cholesterol and glycosphingolipids. Nystatin and filipin disrupt caveolae by 
binding to cholesterol (Rothberg et al., 1992; Schnitzer et al., 1994; Orlandi and 
Fishman, 1998). These compounds blocked the redistribution of PAC1R (Fig 4.2.2.B) 
and retarded the neurite outgrowth of PC12 cells (Fig 3.2.2.A), suggesting that intact 
caveolae were necessary for the propagation of the PACAP signal. Clearly, activation 
of AC, the immediate downstream effector of PAC1R, was inhibited by treatments 
with these cholesterol-binding drugs, as demonstrated by the decrease in PACAP-
induced cAMP synthesis (Fig 4.2.4.A). The importance of caveolar integrity in 
PACAP signaling was further investigated through another set of complementary 
experiments, focusing on glycosphingolipids, another major lipid constituent of 
caveolae. The cellular glycosphingolipid composition can be modulated by 
administration of exogenous gangliosides (Farooqui et al. 1997; Simons et al. 1999; 
Crespo et al. 2002; Liu et al. 2004), transfection of cells with a glycosphingolipid 
synthase gene (Mitsuda et al. 2002; Nishio et al. 2004) or use of inhibitors of 
glycosphingolipid biosynthesis (Platt et al. 1994a; 1994b; Hynds et al. 2002; 
Nagafuku et al. 2003). The former two approaches are expected to increase 
glycosphingolipid level at the plasma membrane surface while the third will reduce it.  
In this study, the ganglioside GM1 level was modulated by exposure of the cells to 
exogenous GM1 or treatment with NB-DNJ, a glucosylceramide synthase inhibitor. 
Although quantitative roles of gangliosides in membrane microdomians such as 
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caveolae were unclear, it was believed that the carbohydrate-containing sphingolipids 
would affect the integrity and stability of these structures such that signaling proteins 
were excluded from or recruited into them (Simons et al. 1999; Mitsuda et al. 2002; 
Liu et al. 2004; Sottocornola et al. 2006). Apparently, increasing membrane 
gangliosides by addition of exogenous GM1 promoted translocation of PAC1R into 
the caveolin-1-enriched detergent-insoluble fractions, while reduction of membrane 
gangliosides inhibited this process (Fig 4.2.2.B). Although direct interactions between 
gangliosides and membrane proteins were reported before (Mutoh et al. 1995; Miljan 
et al. 2002), it is unknown at this stage whether the presence of more PAC1R in the 
detergent-insoluble fraction was due to GM1-induced stabilization and/or 
enlargement of the existing caveolae which could therefore accommodate more 
PAC1R molecules, or to direct interactions between GM1 and PAC1R which might 
help to retain more PAC1R in the caveolae.  
 
In agreement with the pharmacological evidence above, down-regulation of caveolin-
1 expression by siRNA confirmed that intact caveolae were necessary for PAC1R 
translocation and downstream PACAP signaling via cAMP. As a consequence of 
caveolin-1 knockdown, neurite outgrowth of PC12 cells was inhibited (Fig 3.2.2.C), 
PAC1R translocation was blocked (Fig 4.2.2.B) and PACAP-induced cAMP 
generation was diminished (Fig 4.2.4.A).  In vivo experiments with caveolin-1-null 
mice showed a remarkable lack of caveolae in various tissues (Drab et al. 2001; 
Razani et al. 2001; Le Lay and Kurzchalia 2005), implying that caveolin-1 is 
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necessary for the formation of caveolae in cells. Knockdown of caveolin-1 would 
therefore be expected to disrupt the structure of caveolae which might cause their 
ablation (Hong et al. 2004).  Taken together, these results provided compelling 
evidence that caveolae played a pivotal role in mediating PACAP signaling in PC12 
cells. 
 
Another important result in support of PACAP-induced caveolar translocation of 
PAC1R was the observation of patchy plasma membrane distribution of the receptors 
following PACAP stimulation, while those in untreated controls showed a rather 
uniformed distribution (Fig 4.2.3). Fluorescence staining of PAC1R and GM1, the 
marker lipid for caveolae, demonstrated their increased co-localization in the 
membranes of stimulated cells. This was in agreement with the observation by 
immunoprecipitation (Fig 4.2.2.B), where PACAP induced translocation of PAC1R 
into detergent-insoluble fractions. I also investigated the effects of glycosphingolipid 
concentration on the distribution pattern of PAC1R (Fig 4.2.3). As discussed above, 
the concentration of ganaglioside GM1 in the plasma membrane can be conveniently 
modulated and visualized. Clearly, PACAP-induced distribution of PAC1R into 
membrane patches was retained at increased GM1 concentrations, while treatment 
with NB-DNJ, which significantly decreased cellular ganglioside levels, resulted in 
dispersion of the patched PACAP receptors. These observations imply that the 
integrity of glycosphingolipid-enriched microdomains was essential for retaining 




AC6 (type 6 adenylyl cyclase, a calcium-inhibitable isoform) is the major adenylyl 
cyclase in PC12 cells and is co-localized in cholesterol- and sphingolipid-enriched 
microdomains (Oshikawa et al. 2003) with G-proteins (Schwencke et al. 1999; 
Ostrom et al. 2000b; Insel et al. 2005) and caveolin-1 (Peiro et al. 2000 and this 
study). Therefore, translocation of PAC1R into these microdomains serves as a 
determinant for effective coupling of the receptor to its effector molecule, AC6. 
Indeed, enhanced AC6 co-immunoprecipitation using anti-PAC1R antibody was 
observed following PACAP stimulation (Fig 4.2.2.D). The increased coupling 
efficacy appeared to contribute to the increased ability of PAC1R in stimulating AC6, 
leading to an elevation of intracellular cAMP levels (Fig 4.2.4.A). These data provide 
direct evidence for the functional significance of co-localization of PACAP signaling 
molecules in caveolin-enriched membrane microdomains. 
 
In conclusion, the current study on PACAP signaling transduction in PC12 cells 
demonstrates that, following PACAP stimulation, translocation of PAC1R into 
caveolae enhanced the efficacy of PAC1R-AC coupling, which in turn increased 
intracellular cAMP generation, leading to the activation of the downstream pathways 
for neurite outgrowth. On the other hand, it could be speculated that, in neurons 
lacking caveolae, similar mechanism might exist for caveolin-enriched microdomains 




5.2 Lipid rafts/caveolae-mediated PACAP signaling cascades 
and downstream events 
 
5.2.1. Modulation of the ERK pathway by EPAC and GTP-loaded Rap1 
involving the concomitant activation of Ras, PKC and Ca2+, resulting in 
nuclear transcription in PACAP signaling in PC12 cells 
 
Our present data indicate that PACAP activated the ERK pathway through the 
pleiotropic stimulation of several signaling pathways acting synergistically, leading to 
the overall effect of neurite outgrowth of PC12 cells. Cyclic AMP, upon activated by 
Gs-coupled GPCR-PACAP receptor type 1, amplifies the signaling by acting on its 
effector proteins. Formerly, PKA was thought to be the major effector for cAMP. 
However, in our system, PACAP-induced signaling was apparently independently of 
PKA (Fig 4.2.6). This observation was in line with similar findings by others 
(Lazarovici et al. 1998). The molecular events leading from PACAP-induced cAMP 
elevation to ERK1/2 activation were therefore lacking.  Instead, we observed that 
activation of EPAC, a Rap1 guanine nucleotide exchange factor that mediates Rap1 
activation by direct binding to cAMP, potentiated PACAP-stimulated ERK1/2 
activation and neurite elongation (Figs 4.2.7.B and C). These data were consistent 
with previous findings that EPAC agonist attenuated the inhibitory effect of AC 
inhibitors on the GPCR-stimulated ERK activation (Lin et al. 2003). EPAC was 
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therefore likely to be involved in PACAP signaling.  Furthermore, I found that 
PACAP stimulated GTP-loading of both Rap1 and Ras (Figs 4.2.8.1.A and 4.2.8.3.A). 
The stimulation on Rap1 was more pronounced and sustained than that on Ras, 
suggesting that Ras might primarily be involved in a transient stimulation of ERK 
while Rap1 was likely responsible for the prolonged activation of ERK and its 
subsequent nuclear translocation, which is known to be necessary for cell 
differentiation (Marshall 1996). However, how these GTP-binding proteins were 
activated upon PACAP stimulation, particularly, whether Rap1 activation was 
directly modulated by EPAC or whether Rap1 could be activated by other signaling 
intermediates are matters of interest for further investigations. 
 
Our findings suggest that Rap1 activation requires the proper function of lipid 
rafts/caveolae. Depletion of membrane rafts glycosphingolipid or cholesterol by the 
rafts disruptors reduced Rap1 activation, whilst enrichment with GM1 or cholesterol 
increased the GTP-loading of Rap1 (Fig 4.2.8.2.A). In addition, the distribution 
pattern of membrane-associated Rap1 at the plasma membrane changed upon PACAP 
stimulation and perturbation of rafts/caveolae (Fig 4.2.8.2.B). It was translocated to 
the caveolae fraction of plasma membrane upon induction of PACAP, where more 
receptors and signaling molecules are present. GM1, which stabilizes and maintains 
caveolae, enhanced this shift. On the other hand, caveolar disruptors dispersed Rap1 
to non-caveolae fractions. These observations suggest that lipid rafts/caveolae act as a 
biophysical hub for PACAP signaling, from the upstream receptor (PAC1R) 
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translocation and coupling of AC, to downstream signaling intermediates such as 
Rap1.  
 
Although PACAP-elicited cAMP elevation and subsequent EPAC activation were 
shown to be essential for PACAP-induced ERK1/2 stimulation (Fig 4.2.8.1), EPAC 
activation itself was not sufficient to induce neurite extension and efficient ERK1/2 
stimulation (Figs 4.2.7 A and C). The proximal effectors of PAC1R are AC and PLC, 
whose activations resulted in the stimulation of a set of kinases, directly controlled by 
second messengers, ie. cAMP, PKC and Ca2+. Indeed, I found that cAMP and PLC 
were both involved in some way. However, PAC1R might exert its major function 
through cAMP elevation rather than PLC or PKC activation. This hypothesis was 
supported by the fact that different extent of neurite outgrowth was induced by the 
cAMP analog db-cAMP, compared to that by the PKC activator PMA. cAMP on its 
own induced neurite elongation robustly (Fig 4.2.4.C), while PMA alone could not 
elicit the formation of long neurites (Fig 4.2.9). Nevertheless, PMA significantly 
enhanced PACAP-elicited neurite outgrowth. In addition, inhibition of PKC activity 
also attenuated neurite elongation (Fig 4.2.9.E) and ERK phosphorylation (Fig 
4.2.9.H) induced by PACAP in PC12 cells. These findings were in agreement with 
the results obtained by others (Bouschet et al. 2003), suggesting that PKC was 
involved in the activation of ERK1/2 by PACAP. PKC activation may therefore act to 
enhance cAMP signaling upon PACAP binding to PAC1R, and the cAMP and PKC 




It is known that activation of PLC results in the hydrolysis of phosphatidylinositol 
biphosphate (PIP2) and generation of IP3 and diacylglycerol, which activates PKC. IP3, 
in turn, stimulates the release of Ca2+ from the smooth ER and activates PKC through 
diacylglycerol.  Since PLC and PKC were both activated upon PACAP binding to 
PAC1R in PC12 cells, whether the intracellular Ca2+ mobilization also affects the 
PACAP signaling is worth checking. Indeed, treatment of the cells with either the 
extracellular Ca2+ chelator EGTA or the intracellular Ca2+ release promoter THG 
(Figs 4.2.9.E, F, G and 4.2.10.E) inhibited PACAP-induced neurite outgrowth and 
ERK1/2 phosphorylation. These results suggest that Ca2+ mobilization played a role 
in PACAP signaling in PC12 cells. Our data indicate that stimulation of PACAP 
signaling might elicit the concomitant activation of PLC, PKC and Ca2+ pathways, 
which engaged in collaboration with cAMP to potentiate the effect of GTP-loaded 
Rap1. For full neurite extension, all of these intermediates might exert their functions 
on ERK1/2 phosphorylation by regulating the activity of another signaling 
intermediate, GSK3 (Figs 4.2.10.G, H, I, J).  
 
GSK3 is an enzyme first characterized by its ability to phosphorylate and inhibit 
glycogen synthase (Embi et al. 1980; Rylatt et al.1980). It is now known to be a key 
component of several intracellular signaling pathways (Plyte et al. 1992; Grimes and 
Jope 2001; Kim and Kimmel 2000). The best characterized function of GSK3 is in 
the survival-promoting signaling pathways involving PI3K and Akt (Datta et al. 1999) 
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downstream of epidermal growth factor (EGF) and insulin-like growth factor (IGF) 
signaling. However, information on possible functions of GSK3 in neuronal 
differentiation is lacking. In the current study, I demonstrate a novel role for GSK3 
in both PACAP-induced ERK1/2 activation (Fig 4.2.10.I) and neurite outgrowth (Figs 
4.2.10.A, B, C, D) in PC12 cells. GSK3 appeared to be responsible for linking 
PACAP-elicited signaling to the downstream ERK1/2 activation. It is known that 
GSK3 also functions in regulation of transcription factors activation (Grimes and 
Jope 2001) and modulation of cytoskeleton stability (Hanger et al.1992; wagner et al. 
1996; Trivedi et al. 2005; Goold and Gordon-Weeks 2004; Yoshimura et al.2005). 
GSK3 is therefore conceivable as a signal transducer that is responsible for the 
effective neurite outgrowth induced by PACAP in PC12 cells. Consistent with this 
notion, GSK3 activity was regulated by Rap1 (Fig 4.2.10. H), PKC and Ca2+ (Fig 
4.2.10.G) in PACAP signaling. Moreover, intact caveolae microdomains were 
required for the proper function of GSK3 on the regulation of ERK1/2 activation 
(Figs 4.2.10.E and F). These data suggest a mechanism to control Rap1 activity by 
GPCRs and their downstream intermediates. 
 
Finally, the nuclear translocation of ERK1/2 and activation of downstream 
transcription factors are known to be essential for the neuronal plasticity and survival 
(Bonni et al. 1999; Riccio et al. 1999). Both the transcription factors, Elk and CREB, 
are important physiological substrates of ERKs and mediate immediate early genes 
(Marais et al. 1993). In NGF signaling, Elk phosphorylation is critical for neuronal 
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differentiation (Vossler et al. 1997). However, evidence of downstream transcription 
factor activation upon ERK1/2 phosphorylation stimulated by PACAP has been 
lacking. In this study, I demonstrate that PACAP-induced ERK1/2 activation 
participated in the regulation of both CREB- and Elk-dependent transcription (Figs 
4.2.12.A and B). The activation of these transcription factors required not only the 
necessary intermediates in the pathways (Figs 4.2.12.A and B), but also intact plasma 
membrane rafts/caveolae microdomains (Figs 4.2.12.C, D, E, F, G). Indeed, 
disruption of caveolae by caveolin-1 siRNA inhibited ERK1/2 nuclear translocation 
(Figs 4.2.11.C and D) and subsequent activation of CREB and Elk (Fig 4.2.12.G), 
although the cytoplasmic ERK1/2 phosphorylation was increased (Figs 4.2.11.A and 
B). As a result, PACAP-stimulated neurite elongation was eventually inhibited by 
caveolin-1 siRNA (Fig 3.2.5.A). However, reasons for the impairment of ERK1/2 
nuclear translocation after perturbation of caveolae by caveolin-1 siRNA are still 
unknown at this stage. Whether it was related to the malfunction of the endocytic 
function of membrane caveolae or the architecturally impaired nuclear membrane due 
to caveolin-1 knockdown, or resulted from other underlying mechanisms are of 
interest for further investigations. 
 
I have observed that cholesterol-chelators filipin, nystatin or methyl--cyclodextrin 
also increased PACAP-induced ERK1/2 activation (data not shown). One possible 
reason for these effects was that depletion of plasma membrane cholesterol results in 
ligand-independent activation of epidermal growth factor receptor (EGFR) and 
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subsequent activation of ERK1/2 by PI3K and Ras (Chen and Resh 2002). 
Accumulating evidence suggests that the primary function of EGFR is in the 
regulation of cell proliferation (Barnard et al. 1995; Khasharyasha et al. 1993; Kanae 
et al. 2005). Therefore, the enhanced ERK1/2 phosphorylation by cholesterol-
depletion might not be due to the induction of PACAP, but rather to the increased 
activation of EGFR. Whether the proliferation was indeed increased after cholesterol-
removing in PACAP-induced PC12 cells is of interest for further confirmation. If this 
is the case, this fraction of activated ERK1/2 would contribute to proliferation instead 
of differentiation. The elevated ERK1/2 phosphorylation is therefore not necessarily 
led to enhanced neurite extension. Rather, the specific receptor(s) and the signaling 
cascade(s) that stimulate ERK1/2 activation have a decisive influence on the outcome 
of the biological response. 
 
5.2.2. The inhibitory effect of cAMP on Ras activation in PACAP signaling 
 
One interesting finding obtained in this study is that RP-cAMP, an antagonist of 
cAMP, increased PACAP-elicited Ras GTP-loading (data not shown). The overall 
level of Ras activation was augmented after the inhibition of cAMP activity, 
suggesting that Ras activation was in fact counteracted by cAMP-EPAC-Rap1 
signaling in PACAP stimulation. Indeed, whether cAMP inhibits or enhances ERK 
activation is cell type dependent (Dumaz and Marais 2005). In PC12 cells, cAMP are 
thought to stimulate ERK in a B-Raf-dependent manner (Jaiswal et al. 1994). 
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However, the mechanisms by which ERK can be modulated by Raf protein and the 
crosstalk between cAMP-Rap1 and Ras are still unclear. One of the reported 
functions of Rap1 is its interaction with, and modulation of the Ser/ Thr kinases Raf1 
and B-Raf. This occurs through an interaction with both the Raf binding domain 
(RBD) and the adjacent cysteine-rich region (CRD) of Rap1 (Herrmann et al. 1996; 
Okada et al. 1999), resulting in the modulation of ERK and ERK-mediated 
transcriptions. Furthermore, Rap1 possesses an effector domain that is similar to that 
of Ras, indicating that both small GTPases might share common downstream 
effectors (Bos et al. 2001). Therefore, Rap1 may antagonize Ras-dependent ERK1/2 
signaling through competitive interaction with the RBD of B-Raf (a neuron-specific 
Raf isoform which is highly expressed in PC12 cells), and preventing it from 
activating Ras. Nevertheless, B-Raf has been suggested to block Raf-1 activation by 
Ras when over-expressed (Okada et al. 1999).  Another way how Rap1 might 
function to modulate Ras/ERK signaling is that Rap1 binds tightly to Raf-1 CRD, 
preventing it from interacting with Ras. Thus when both Ras and Rap1 interact with 
the RBD and the CRD respectively, the Raf activation complex might be locked in a 
refractory state (Hu et al. 1997). When Raf-1 CRD is replaced by the lower-affinity 
B-Raf RBD, Rap1 is converted into an activator. However, whether Rap1 modulate 
Ras/ERK signaling by trapping Raf isoforms in an inactive complex, and how the 
Raf-1 CRD is replaced by B-Raf RBD, requires further investigations. A previously 
uncharacterized feedback loop from ERK to Raf has also been proposed (Alessi et al. 
1995). Raf is activated by phosphorylation, which occurs when it is recruited to the 
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plasma membrane by Ras, suggesting a possible feedback regulation mediated by Ras 
in cAMP-Rap1 signaling.  
 
5.2.3. The essential role of cytoskeleton (actin and microtubule) stability 
for the neuritogenesis process induced by PACAP in PC12 cells  
 
It is known that a critical aspect of neuronal differentiation is the rearrangement of the 
neuronal cytoskeleton, leading to specific and directed elongation of microtubules 
into growing neuritic cytoplasmic extensions. Therefore, the involvement of GSK3, 
which regulated ERK1/2 activation and several cytoskeleton-associated molecules in 
the neuronal differentiation process, further illustrates the essential role of 
cytoskeleton played in PACAP-induced neurite elongation of PC12 cells. Since 
cytoskeletons are major and required constituent of neurites, and ERK1/2 may 
regulate the assembly and stability of neuritic cytoskeleton elements, the present 
observations that GSK3 was involved in PACAP-induced neurite outgrowth and 
ERK1/2 phosphorylation suggest a possible causal relationship between these two 
events. Moreover, sustained ERK activation leads to translocation of ERKs to the 
nucleus (Traverse et al. 1992; 1994; Nguyen et al.1993; Dikic et al. 1994) and 
subsequently activation of downstream transcription factors CREB and Elk (Fig 
4.2.13). The latter would result in the modulation of relevant gene transcription and 




The dynamic filamentous cytoskeleton actin network might also be linked to lipid 
rafts/caveolae and certain membrane-bound molecules. It has been found that 
perturbation the stability of the actin filament disrupted PACAP-elicited neurite 
elongation (data not shown). Demolishing the integrity of lipid rafts/caveolae by 
either cholesterol deprivation or caveolin-1 depletion, in turn, lead to the dysfunction 
of rafts-associated proteins and disruption of the cortical actin ring. Accordingly, it is 
likely that the detrimental effect of rafts/caveolae disruption might, at least in part, 
arise from an impairment of the signaling pathways associated with cytoskeleton 
stability. Therefore, it is comprehensible that without a functional cytoskeleton, 
neurite extension would be fundamentally retarded.  
 
5.3. Future directions 
 
The current study on PACAP signaling transduction in PC12 cells demonstrated that 
the neurotrophic factor PACAP binding to its specific receptor PAC1R enhanced its 
membrane association with lipid rafts/caveolae and subsequently facilitated the 
receptor and effector protein interaction. This coupling of PAC1-AC positively 
contributed to intracellular cAMP production, which subsequently regulated 
downstream signaling molecules ERK1/2 activation through Rap1 and GSK3. Rap1, 
as a membrane associated protein, targeted to lipid rafts/caveolae upon activation and 




On the other hand, Ras activity was also found to be involved in the PACAP-
stimulated neurite extension process. Several isoforms of Ras have been identified, 
such as H-Ras, K-Ras and N-Ras, and have multiple effector proteins (Raf-1, A-Raf, 
B-Raf, PI3K and Ral-GEF) (Sun et al. 2006). Targeting of specific Ras isoforms to 
distinct microdomains within the plasma membrane contribute to the different 
signaling capacities of Ras isoforms (Yan et al. 1998). The identification of specific 
isoform(s) of Ras that has (have) been activated upon PACAP stimulation and the 
mechanisms of how the Ras isoform(s) is (are) activated in this signaling, therefore, 
are worth further investigation. Particularly, the distribution pattern of Ras in different 
PM microdomains upon perturbation of the stability of lipid rafts/caveolae in PACAP 
signaling would be important to document. Conventionally, Ras activation was 
mediated by receptor tyrosine kinase (RTK).  Multiple pathways have recently been 
reported that could indirectly stimulate Ras-dependent ERK activation. For example, 
GPCR-mediated Ras activation through G of G protein, which subsequently 
recruits c-Src/PI3K, phosphorylates SHC and finally leads to Grb2/Sos1 recruitment 
and Ras activation (Marinissen and Gutkind 2001).  Gq of G protein could also 
indirectly activate Ras via Gq-PLC pathway (Lev et al 1995). In addition, Ras 
could also be activated by cAMP through direct binding to cyclic nucleotide Ras GEF 
(cNrasGEF) in response to elevated intracellular cAMP in a PKA-independent 
manner (Pham et al 2000). Therefore, it is worthwhile to investigate further the 
upstream events that activate Ras in PACAP signaling, which may lead to better 




In addition, EPAC was found to enhance the PACAP signaling in PC12 cells. 
However, it could not induce neurite outgrowth on its own (Fig 4.2.7), and the 
mechanisms of its function is not yet clear. It has been shown that EPAC could not 
activate ERK unless it was recruited to the plasma membrane (Wang et al 2006). 
Whether EPAC activates a pool of Rap1 that could induce downstream ERK 
activation through targeting to the plasma membrane, particularly lipid rafts, upon 
PACAP stimulation, is another interesting issue to be addressed.  
 
The current study on PACAP-induced differentiation transduction pathways in PC12 
cells shows that lipid rafts/ caveolae play essential role in the signaling cascade, from 
the upstream receptor translocation, coupling of effector protein AC to the 
downstream signaling molecules activation and targeting, such as Rap1. Whether the 




















Lipid rafts/caveolae microdomains differ from the rest of plasma membrane in being 
specifically enriched in glycosphingolipids, cholesterol and a myriad of intracellular 
signaling proteins (Simons and Ikonen 1997). These microdomains form relatively 
stable lipid matrix which act as an ordered support for receptor mediated signaling 
events. In this study, we aim to characterize the role of lipid rafts/caveolae in the 
neuritogenesis process induced by neuropeptide PACAP in PC12 cells, as well as the 
signaling pathways involved in this process.  
 
In the first part of this study, the effects of the major components of lipid 
rafts/caveolae: cholesterol and glycosphingolipid and the integrity of lipid 
rafts/caveolae on PACAP-induced neuritogenesis were examined in PC12 cells. 
These effects were implemented by either inhibition of de novo biosynthesis of 
glycosphingolipids, inhibition of cholesterol intracellular trafficking or depletion of 
cholesterol level on PC12 cells in the presence of PACAP. Treatment of the cells by 
the above inhibitory factors hindered neurite outgrowth, while supplementation of the 
cell plasma membrane with exogenous ganglioside GM1 or cholesterol restored 
neurite outgrowth. These data suggest that removing either cholesterol or 
glycosphingolipids of the lipid rafts/caveolae inhibits neurite outgrowth, and this 
inhibition is reversible once the cells are replenished with the depleted components. 
These data also indicate that the two major components of the lipid rafts/caveolae 
  
 214 
microdomains: glycosphingolipid and cholesterol were essential in promoting 
neuritogenesis. However, perturbation of the integrity of lipid rafts/caveolae by 
silencing the caveolar structural protein caveolin-1, the inhibitory effects on the 
PACAP-induced neurite outgrowth was irreversible, suggesting that the proper 
function of lipid rafts/caveolae was essential for PACAP-mediated neuritogenesis. 
 
To unveil the underlying mechanisms of lipid rafts/caveolae’s role in PC12 
neuritogenesis, the level of PACAP receptor type I (PAC1R) and the ratio of the 
PAC1R level in lipid rafts to non-raft fractions of the plasma membrane after the 
treatment of the cells with different caveolae disruptors were examined. It was found 
that PAC1R shifts to the caveolin-enriched Triton X-100-insoluble microdomains 
after PACAP induction. GM1, which promoted neurite extension, enhanced this shift. 
Perturbations of lipid rafts/caveolae, which retarded neurite outgrowth, prevented the 
translocation of PAC1R into the detergent-insoluble membrane microdomains. In 
addition, the altered membrane distribution of PAC1R facilitated its interaction with 
AC, the target enzyme located in caveolae and catalyzes the conversion of ATP to 
cAMP. Nevertheless, perturbation of caveolae did not significantly affect expression 
of PAC1R in PC12 cells. These results suggest that it was the PAC1R’s shift to the 
lipid rafts/caveolae fraction that results in the downstream signaling and eventual 




Based on the above results, further elucidations of the signaling pathway(s) 
downstream of the PAC1R and the effect of the lipid rafs/caveolae on the PACAP 
signaling would be important. Indeed, our results show that the translocation of 
PAC1R into caveolae lead to generation of cAMP and activation of PLC. However, 
instead of PKA, EPAC and Rap1 were activated upon cAMP elevation. These 
activations were favored the detergent-insoluble fraction upon PACAP induction, 
providing additional evidence for the importance of lipid rafts/caveolae in PACAP-
induced neurite differentiation of PC12 cells. Known as a plasma membrane-
associated protein, Rap1’s activation was correlated with the integrity of lipid 
rafts/caveolae. Rap1 regulated PACAP-induced neurite outgrowth through 
modulating GSK3 activity and subsequent MEK1/2-dependent ERK1/2 
phosphorylation. On the other hand, PKC and Ca2+ mobilization collaborated with the 
cAMP pathway of PACAP signaling by regulating GSK3 and ERK1/2 activity. In 
addition, PACAP-elicited Rap1 and Ras activation accounted for both the sustained 
and transient activation of downstream ERK1/2 phosphorylation and neurite 
extension. Activated ERK1/2 translocated to the nucleus and phosphorylated the 
transcription factors Elk and CREB. This was an essential step of transcriptional 
regulation required for rafts/caveolae-mediated PC12 cell differentiation. The results 
revealed novel components of PACAP-induced signaling cascades in PC12 cells that 




The present study shows that lipid rafts/caveolae microdomains act as a hub for the 
molecules involved in the PACAP-induced differentiating PC12 cells to gather upon 
receptor-ligand binding. Specifically, it demonstrates that the PAC1R receptor shifts 
to the rafts/caveolae once activated, and initiates downstream signaling. These 
findings are of importance since they show for the first time a general picture of the 
neuritogenesis process and underlying mechanisms in differentiating PC12 cells 
induced by PACAP as well as its signaling pathways. They also indicate that one key 
factor for neuritogenesis is the integrity of the lipid rafts/caveolae. However, further 
work is needed to confirm that these observations in PC12 cells are generally 
applicable to other cell lines, especially primary neurons. With a further 
understanding of the mechanisms of neuritogensis in general, the mechanisms 
underlying of neurodegeneration and neuronal regeneration after injury could be 
















Fig 5.1. A schema of the signaling transduction pathways of PACAP-induced 










































Adamou, J. E., N. Aiyar, S. Van Horn and N. A. Elshourbagy (1995). "Cloning and 
functional characterization of the human vasoactive intestinal peptide (VIP)-2 
receptor." Biochem Biophys Res Commun 209(2): 385-92. 
 
Ahmed, S. N., D. A. Brown and E. London (1997). "On the origin of 
sphingolipid/cholesterol-rich detergent-insoluble cell membranes: physiological 
concentrations of cholesterol and sphingolipid induce formation of a detergent-
insoluble, liquid-ordered lipid phase in model membranes." Biochemistry 36(36): 
10944-53. 
 
Alessi, D. R., A. Cuenda, P. Cohen, D. T. Dudley and A. R. Saltiel (1995). "PD 
098059 is a specific inhibitor of the activation of mitogen-activated protein kinase 
kinase in vitro and in vivo." J Biol Chem 270(46): 27489-94. 
 
Anderson, R. G. (1998). "The caveolae membrane system." Annu Rev Biochem 67: 
199-225. 
 
Anderson, R. G., B. A. Kamen, K. G. Rothberg and S. W. Lacey (1992). "Potocytosis: 
sequestration and transport of small molecules by caveolae." Science 255(5043): 410-
1. 
 
Anderson, S. T. and J. D. Curlewis (1998). "PACAP stimulates dopamine neuronal 
activity in the medial basal hypothalamus and inhibits prolactin." Brain Res 790(1-2): 
343-6. 
 
Andreasen, P. A., L. Sottrup-Jensen, L. Kjoller, A. Nykjaer, S. K. Moestrup, C. M. 
Petersen and J. Gliemann (1994). "Receptor-mediated endocytosis of plasminogen 
activators and activator/inhibitor complexes." FEBS Lett 338(3): 239-45. 
 
Arimura, A. (1998). "Perspectives on pituitary adenylate cyclase activating 
polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems." Jpn J 
Physiol 48(5): 301-31. 
 
Balbi, D. and J. M. Allen (1994). "Role of protein kinase C in mediating NGF effect 




Barnard, J. A., R. D. Beauchamp, W. E. Russell, R. N. Dubois and R. J. Coffey 
(1995). "Epidermal growth factor-related peptides and their relevance to 
gastrointestinal pathophysiology." Gastroenterology 108(2): 564-80. 
 
Barrie, A. P., A. M. Clohessy, C. S. Buensuceso, M. V. Rogers and J. M. Allen 
(1997). "Pituitary adenylyl cyclase-activating peptide stimulates extracellular signal-
regulated kinase 1 or 2 (ERK1/2) activity in a Ras-independent, mitogen-activated 
protein Kinase/ERK kinase 1 or 2-dependent manner in PC12 cells." J Biol Chem 
272(32): 19666-71. 
 
Basille, M., B. J. Gonzalez, L. Desrues, M. Demas, A. Fournier and H. Vaudry (1995). 
"Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates adenylyl 
cyclase and phospholipase C activity in rat cerebellar neuroblasts." J Neurochem 
65(3): 1318-24. 
 
Bender, F., M. Montoya, V. Monardes, L. Leyton and A. F. Quest (2002). "Caveolae 
and caveolae-like membrane domains in cellular signaling and disease: identification 
of downstream targets for the tumor suppressor protein caveolin-1." Biol Res 35(2): 
151-67. 
 
Berman, D. E., S. Hazvi, K. Rosenblum, R. Seger and Y. Dudai (1998). "Specific and 
differential activation of mitogen-activated protein kinase cascades by unfamiliar 
taste in the insular cortex of the behaving rat." J Neurosci 18(23): 10037-44. 
 
Bierkamper, G. G. and R. J. Cenedella (1978). "Induction of chronic epileptiform 
activity in the rat by an inhibitor of cholesterol synthesis, U18666A." Brain Res 
150(2): 343-51. 
 
Bilderback, T. R., V. R. Gazula, M. P. Lisanti and R. T. Dobrowsky (1999). 
"Caveolin interacts with Trk A and p75(NTR) and regulates neurotrophin signaling 
pathways." J Biol Chem 274(1): 257-63. 
 
Bilderback, T. R., R. J. Grigsby and R. T. Dobrowsky (1997). "Association of 
p75(NTR) with caveolin and localization of neurotrophin-induced sphingomyelin 
hydrolysis to caveolae." J Biol Chem 272(16): 10922-7. 
 
Bivona, T. G., H. H. Wiener, I. M. Ahearn, J. Silletti, V. K. Chiu and M. R. Philips 
(2004). "Rap1 up-regulation and activation on plasma membrane regulates T cell 
adhesion." J Cell Biol 164(3): 461-70. 
 
Bonni, A., A. Brunet, A. E. West, S. R. Datta, M. A. Takasu and M. E. Greenberg 
(1999). "Cell survival promoted by the Ras-MAPK signaling pathway by 




Bos, J. L., J. de Rooij and K. A. Reedquist (2001). "Rap1 signalling: adhering to new 
models." Nat Rev Mol Cell Biol 2(5): 369-77. 
 
Bouschet, T., V. Perez, C. Fernandez, J. Bockaert, A. Eychene and L. Journot (2003). 
"Stimulation of the ERK pathway by GTP-loaded Rap1 requires the concomitant 
activation of Ras, protein kinase C, and protein kinase A in neuronal cells." J Biol 
Chem 278(7): 4778-85. 
 
Braun, W., G. Wider, K. H. Lee and K. Wuthrich (1983). "Conformation of glucagon 
in a lipid-water interphase by 1H nuclear magnetic resonance." J Mol Biol 169(4): 
921-48. 
 
Brdickova, N., T. Brdicka, L. Andera, J. Spicka, P. Angelisova, S. L. Milgram and V. 
Horejsi (2001). "Interaction between two adapter proteins, PAG and EBP50: a 
possible link between membrane rafts and actin cytoskeleton." FEBS Lett 507(2): 
133-6. 
 
Brown, D. A. and E. London (1997). "Structure of detergent-resistant membrane 
domains: does phase separation occur in biological membranes?" Biochem Biophys 
Res Commun 240(1): 1-7. 
 
Brown, D. A. and E. London (1998a). "Structure and origin of ordered lipid domains 
in biological membranes." J Membr Biol 164(2): 103-14. 
 
Brown, D. A. and E. London (1998b). "Functions of lipid rafts in biological 
membranes." Annu Rev Cell Dev Biol 14: 111-36. 
 
Brunet, A., D. Roux, P. Lenormand, S. Dowd, S. Keyse and J. Pouyssegur (1999). 
"Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for 
growth factor-induced gene expression and cell cycle entry." Embo J 18(3): 664-74. 
 
Bubb, M. R., A. M. Senderowicz, E. A. Sausville, K. L. Duncan and E. D. Korn 
(1994). "Jasplakinolide, a cytotoxic natural product, induces actin polymerization and 
competitively inhibits the binding of phalloidin to F-actin." J Biol Chem 269(21): 
14869-71. 
 
Burry, R. W. and N. I. Perrone-Bizzozero (1993). "Nerve growth factor stimulates 
GAP-43 expression in PC12 cell clones independently of neurite outgrowth." J 
Neurosci Res 36(3): 241-51. 
 
Busca, R., P. Abbe, F. Mantoux, E. Aberdam, C. Peyssonnaux, A. Eychene, J. P. 
Ortonne and R. Ballotti (2000). "Ras mediates the cAMP-dependent activation of 





Buscail, L., P. Gourlet, A. Cauvin, P. De Neef, D. Gossen, A. Arimura, A. Miyata, D. 
H. Coy, P. Robberecht and J. Christophe (1990). "Presence of highly selective 
receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes 
from the rat pancreatic acinar cell line AR 4-2J." FEBS Lett 262(1): 77-81. 
 
Butler, J. D., J. Blanchette-Mackie, E. Goldin, R. R. O'Neill, G. Carstea, C. F. Roff, 
M. C. Patterson, S. Patel, M. E. Comly, A. Cooney and et al. (1992). "Progesterone 
blocks cholesterol translocation from lysosomes." J Biol Chem 267(33): 23797-805. 
 
Carver, L. A. and J. E. Schnitzer (2003). "Caveolae: mining little caves for new 
cancer targets." Nat Rev Cancer 3(8): 571-81. 
 
Carver, L. A., J. E. Schnitzer, R. G. Anderson and S. Mohla (2003). "Role of caveolae 
and lipid rafts in cancer: workshop summary and future needs." Cancer Res 63(20): 
6571-4. 
 
Casella, J. F., M. D. Flanagan and S. Lin (1981). "Cytochalasin D inhibits actin 
polymerization and induces depolymerization of actin filaments formed during 
platelet shape change." Nature 293(5830): 302-5. 
 
Casey, P. J., P. A. Solski, C. J. Der and J. E. Buss (1989). "p21ras is modified by a 
farnesyl isoprenoid." Proc Natl Acad Sci U S A 86(21): 8323-7. 
 
Cass, L. A., S. A. Summers, G. V. Prendergast, J. M. Backer, M. J. Birnbaum and J. 
L. Meinkoth (1999). "Protein kinase A-dependent and -independent signaling 
pathways contribute to cyclic AMP-stimulated proliferation." Mol Cell Biol 19(9): 
5882-91. 
 
Cauvin, A., L. Buscail, P. Gourlet, P. De Neef, D. Gossen, A. Arimura, A. Miyata, D. 
H. Coy, P. Robberecht and J. Christophe (1990). "The novel VIP-like hypothalamic 
polypeptide PACAP interacts with high affinity receptors in the human 
neuroblastoma cell line NB-OK." Peptides 11(4): 773-7. 
 
Cerneus, D. P., E. Ueffing, G. Posthuma, G. J. Strous and A. van der Ende (1993). 
"Detergent insolubility of alkaline phosphatase during biosynthetic transport and 
endocytosis. Role of cholesterol." J Biol Chem 268(5): 3150-5. 
 
Chang, L. and M. Karin (2001). "Mammalian MAP kinase signalling cascades." 
Nature 410(6824): 37-40. 
 
Chang, T. Y., P. C. Reid, S. Sugii, N. Ohgami, J. C. Cruz and C. C. Chang (2005). 





Chang, W. J., K. G. Rothberg, B. A. Kamen and R. G. Anderson (1992). "Lowering 
the cholesterol content of MA104 cells inhibits receptor-mediated transport of folate." 
J Cell Biol 118(1): 63-9. 
 
Chartrel, N., M. C. Tonon, H. Vaudry and J. M. Conlon (1991). "Primary structure of 
frog pituitary adenylate cyclase-activating polypeptide (PACAP) and effects of ovine 
PACAP on frog pituitary." Endocrinology 129(6): 3367-71. 
 
Chatterjee, T. K., X. Liu, R. L. Davisson and R. A. Fisher (1997). "Genomic 
organization of the rat pituitary adenylate cyclase-activating polypeptide receptor 
gene. Alternative splicing within the 5'-untranslated region." J Biol Chem 272(18): 
12122-31. 
 
Chatterjee, T. K., R. V. Sharma and R. A. Fisher (1996). "Molecular cloning of a 
novel variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) 
receptor that stimulates calcium influx by activation of L-type calcium channels." J 
Biol Chem 271(50): 32226-32. 
 
Chen, X. and M. D. Resh (2002). "Cholesterol depletion from the plasma membrane 
triggers ligand-independent activation of the epidermal growth factor receptor." J Biol 
Chem 277(51): 49631-7. 
 
Christensen, A. E., F. Selheim, J. de Rooij, S. Dremier, F. Schwede, K. K. Dao, A. 
Martinez, C. Maenhaut, J. L. Bos, H. G. Genieser and S. O. Doskeland (2003). 
"cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs 
demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell 
neurite extension." J Biol Chem 278(37): 35394-402. 
 
Chrivia, J. C., R. P. Kwok, N. Lamb, M. Hagiwara, M. R. Montminy and R. H. 
Goodman (1993). "Phosphorylated CREB binds specifically to the nuclear protein 
CBP." Nature 365(6449): 855-9. 
 
Chun, M., U. K. Liyanage, M. P. Lisanti and H. F. Lodish (1994). "Signal 
transduction of a G protein-coupled receptor in caveolae: colocalization of endothelin 
and its receptor with caveolin." Proc Natl Acad Sci U S A 91(24): 11728-32. 
 
Clemente, R., D. R. Jones, P. Ochoa, G. Romero, J. M. Mato and I. Varela-Nieto 
(1995). "Role of glycosyl-phosphatidylinositol hydrolysis as a mitogenic signal for 
epidermal growth factor." Cell Signal 7(4): 411-21. 
 
Cohen, A. W., R. Hnasko, W. Schubert and M. P. Lisanti (2004). "Role of caveolae 




Cohen, P. and M. Goedert (2004). "GSK3 inhibitors: development and therapeutic 
potential." Nat Rev Drug Discov 3(6): 479-87. 
 
Conese, M., A. Nykjaer, C. M. Petersen, O. Cremona, R. Pardi, P. A. Andreasen, J. 
Gliemann, E. I. Christensen and F. Blasi (1995). "alpha-2 Macroglobulin receptor/Ldl 
receptor-related protein(Lrp)-dependent internalization of the urokinase receptor." J 
Cell Biol 131(6 Pt 1): 1609-22. 
 
Costello, B., A. Meymandi and J. A. Freeman (1990). "Factors influencing GAP-43 
gene expression in PC12 pheochromocytoma cells." J Neurosci 10(4): 1398-406. 
 
Couet, J., M. Sargiacomo and M. P. Lisanti (1997). "Interaction of a receptor tyrosine 
kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and 
serine/threonine kinase activities." J Biol Chem 272(48): 30429-38. 
 
Crespo, P. M., A. R. Zurita and J. L. Daniotti (2002). "Effect of gangliosides on the 
distribution of a glycosylphosphatidylinositol-anchored protein in plasma membrane 
from Chinese hamster ovary-K1 cells." J Biol Chem 277(47): 44731-9. 
 
Cross, D. A., D. R. Alessi, P. Cohen, M. Andjelkovich and B. A. Hemmings (1995). 
"Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B." 
Nature 378(6559): 785-9. 
 
Cruzalegui, F. H., E. Cano and R. Treisman (1999). "ERK activation induces 
phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry." Oncogene 
18(56): 7948-57. 
 
Datta, S. R., A. Brunet and M. E. Greenberg (1999). "Cellular survival: a play in three 
Akts." Genes Dev 13(22): 2905-27. 
 
Dautzenberg, F. M., G. Mevenkamp, S. Wille and R. L. Hauger (1999). "N-terminal 
splice variants of the type I PACAP receptor: isolation, characterization and ligand 
binding/selectivity determinants." J Neuroendocrinol 11(12): 941-9. 
 
Davies, J. P., F. W. Chen and Y. A. Ioannou (2000). "Transmembrane molecular 
pump activity of Niemann-Pick C1 protein." Science 290(5500): 2295-8. 
 
Davis, R. J. (1993). "The mitogen-activated protein kinase signal transduction 
pathway." J Biol Chem 268(20): 14553-6. 
 
de Rooij, J., F. J. Zwartkruis, M. H. Verheijen, R. H. Cool, S. M. Nijman, A. 
Wittinghofer and J. L. Bos (1998). "Epac is a Rap1 guanine-nucleotide-exchange 




De Sarno, P., X. Li and R. S. Jope (2002). "Regulation of Akt and glycogen synthase 
kinase-3 beta phosphorylation by sodium valproate and lithium." Neuropharmacology 
43(7): 1158-64. 
 
de Weerd, W. F. and L. M. Leeb-Lundberg (1997). "Bradykinin sequesters B2 
bradykinin receptors and the receptor-coupled Galpha subunits Galphaq and Galphai 
in caveolae in DDT1 MF-2 smooth muscle cells." J Biol Chem 272(28): 17858-66. 
 
Delgado, M., E. Garrido, M. de la Fuente and R. P. Gomariz (1996). "Pituitary 
adenylate cyclase-activating polypeptide (PACAP-38) stimulates rat peritoneal 
macrophage functions." Peptides 17(7): 1097-105. 
 
Deutsch, P. J. and Y. Sun (1992). "The 38-amino acid form of pituitary adenylate 
cyclase-activating polypeptide stimulates dual signaling cascades in PC12 cells and 
promotes neurite outgrowth." J Biol Chem 267(8): 5108-13. 
 
Dietzen, D. J., W. R. Hastings and D. M. Lublin (1995). "Caveolin is palmitoylated 
on multiple cysteine residues. Palmitoylation is not necessary for localization of 
caveolin to caveolae." J Biol Chem 270(12): 6838-42. 
 
Dikic, I., J. Schlessinger and I. Lax (1994). "PC12 cells overexpressing the insulin 
receptor undergo insulin-dependent neuronal differentiation." Curr Biol 4(8): 702-8. 
 
Doble, B. W. and J. R. Woodgett (2003). "GSK-3: tricks of the trade for a multi-
tasking kinase." J Cell Sci 116(Pt 7): 1175-86. 
 
Drab, M., P. Verkade, M. Elger, M. Kasper, M. Lohn, B. Lauterbach, J. Menne, C. 
Lindschau, F. Mende, F. C. Luft, A. Schedl, H. Haller and T. V. Kurzchalia (2001). 
"Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-
disrupted mice." Science 293(5539): 2449-52. 
 
Draber, P. and L. Draberova (2002). "Lipid rafts in mast cell signaling." Mol Immunol 
38(16-18): 1247-52. 
 
Dremier, S., V. Pohl, C. Poteet-Smith, P. P. Roger, J. Corbin, S. O. Doskeland, J. E. 
Dumont and C. Maenhaut (1997). "Activation of cyclic AMP-dependent kinase is 
required but may not be sufficient to mimic cyclic AMP-dependent DNA synthesis 
and thyroglobulin expression in dog thyroid cells." Mol Cell Biol 17(11): 6717-26. 
 
Dumaz, N. and R. Marais (2005). "Integrating signals between cAMP and the 
RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the 
Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 




Dykstra, M. L., A. Cherukuri and S. K. Pierce (2001). "Floating the raft hypothesis 
for immune receptors: access to rafts controls receptor signaling and trafficking." 
Traffic 2(3): 160-6. 
 
Edidin, M. (2003). "The state of lipid rafts: from model membranes to cells." Annu 
Rev Biophys Biomol Struct 32: 257-83. 
 
Ehrhardt, A., G. R. Ehrhardt, X. Guo and J. W. Schrader (2002). "Ras and relatives--
job sharing and networking keep an old family together." Exp Hematol 30(10): 1089-
106. 
 
Eickholt, B. J., F. S. Walsh and P. Doherty (2002). "An inactive pool of GSK-3 at the 
leading edge of growth cones is implicated in Semaphorin 3A signaling." J Cell Biol 
157(2): 211-7. 
 
Embi, N., D. B. Rylatt and P. Cohen (1980). "Glycogen synthase kinase-3 from rabbit 
skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and 
phosphorylase kinase." Eur J Biochem 107(2): 519-27. 
 
Enserink, J. M., A. E. Christensen, J. de Rooij, M. van Triest, F. Schwede, H. G. 
Genieser, S. O. Doskeland, J. L. Blank and J. L. Bos (2002). "A novel Epac-specific 
cAMP analogue demonstrates independent regulation of Rap1 and ERK." Nat Cell 
Biol 4(11): 901-6. 
 
Fan, J., S. G. Mansfield, T. Redmond, P. R. Gordon-Weeks and J. A. Raper (1993). 
"The organization of F-actin and microtubules in growth cones exposed to a brain-
derived collapsing factor." J Cell Biol 121(4): 867-78. 
 
Fang, X., S. Yu, J. L. Tanyi, Y. Lu, J. R. Woodgett and G. B. Mills (2002). 
"Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg 
receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through 
a protein kinase C-dependent intracellular pathway." Mol Cell Biol 22(7): 2099-110. 
 
Fang, X., S. X. Yu, Y. Lu, R. C. Bast, Jr., J. R. Woodgett and G. B. Mills (2000). 
"Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase 
A." Proc Natl Acad Sci U S A 97(22): 11960-5. 
 
Farooqui, T., T. Franklin, D. K. Pearl and A. J. Yates (1997). "Ganglioside GM1 
enhances induction by nerve growth factor of a putative dimer of TrkA." J 
Neurochem 68(6): 2348-55. 
 
Feany, M. B. and W. G. Quinn (1995). "A neuropeptide gene defined by the 




Feron, O., L. Belhassen, L. Kobzik, T. W. Smith, R. A. Kelly and T. Michel (1996). 
"Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with 
caveolin isoforms in cardiac myocytes and endothelial cells." J Biol Chem 271(37): 
22810-4. 
 
Fiedler, K., R. G. Parton, R. Kellner, T. Etzold and K. Simons (1994). "VIP36, a 
novel component of glycolipid rafts and exocytic carrier vesicles in epithelial cells." 
Embo J 13(7): 1729-40. 
 
Fielding, C. J., A. Bist and P. E. Fielding (1997). "Caveolin mRNA levels are up-
regulated by free cholesterol and down-regulated by oxysterols in fibroblast 
monolayers." Proc Natl Acad Sci U S A 94(8): 3753-8. 
 
Forscher, P. and S. J. Smith (1988). "Actions of cytochalasins on the organization of 
actin filaments and microtubules in a neuronal growth cone." J Cell Biol 107(4): 
1505-16. 
 
Fra, A. M., M. Masserini, P. Palestini, S. Sonnino and K. Simons (1995b). "A photo-
reactive derivative of ganglioside GM1 specifically cross-links VIP21-caveolin on the 
cell surface." FEBS Lett 375(1-2): 11-4. 
 
Fra, A. M., E. Williamson, K. Simons and R. G. Parton (1995a). "De novo formation 
of caveolae in lymphocytes by expression of VIP21-caveolin." Proc Natl Acad Sci U 
S A 92(19): 8655-9. 
 
Fredriksson, R., M. C. Lagerstrom, L. G. Lundin and H. B. Schioth (2003). "The G-
protein-coupled receptors in the human genome form five main families. 
Phylogenetic analysis, paralogon groups, and fingerprints." Mol Pharmacol 63(6): 
1256-72. 
 
Friedrichson, T. and T. V. Kurzchalia (1998). "Microdomains of GPI-anchored 
proteins in living cells revealed by crosslinking." Nature 394(6695): 802-5. 
 
Frodin, M., P. Peraldi and E. Van Obberghen (1994). "Cyclic AMP activates the 
mitogen-activated protein kinase cascade in PC12 cells." J Biol Chem 269(8): 6207-
14. 
 
Fujimoto, T. (1993). "Calcium pump of the plasma membrane is localized in 
caveolae." J Cell Biol 120(5): 1147-57. 
 
Fujimoto, T., S. Nakade, A. Miyawaki, K. Mikoshiba and K. Ogawa (1992). 
"Localization of inositol 1,4,5-trisphosphate receptor-like protein in plasmalemmal 




Fukuda, M., Y. Gotoh, T. Tachibana, K. Dell, S. Hattori, Y. Yoneda and E. Nishida 
(1995). "Induction of neurite outgrowth by MAP kinase in PC12 cells." Oncogene 
11(2): 239-44. 
 
Funatsu, N., H. Kumanogoh, Y. Sokawa and S. Maekawa (2000). "Identification of 
gelsolin as an actin regulatory component in a triton insoluble low density fraction 
(raft) of newborn bovine brain." Neurosci Res 36(4): 311-7. 
 
Gagnon, A. W., N. Aiyar and N. A. Elshourbagy (1994). "Molecular cloning and 
functional characterization of a human liver vasoactive intestinal peptide receptor." 
Cell Signal 6(3): 321-33. 
 
Galbiati, F., D. Volonte, J. A. Engelman, G. Watanabe, R. Burk, R. G. Pestell and M. 
P. Lisanti (1998). "Targeted downregulation of caveolin-1 is sufficient to drive cell 
transformation and hyperactivate the p42/44 MAP kinase cascade." Embo J 17(22): 
6633-48. 
 
Garcia-Cardena, G., R. Fan, D. F. Stern, J. Liu and W. C. Sessa (1996a). "Endothelial 
nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with 
caveolin-1." J Biol Chem 271(44): 27237-40. 
 
Garcia-Cardena, G., P. Oh, J. Liu, J. E. Schnitzer and W. C. Sessa (1996b). 
"Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: 
implications for nitric oxide signaling." Proc Natl Acad Sci U S A 93(13): 6448-53. 
 
Gibbs, J. B. (1991). "Ras C-terminal processing enzymes--new drug targets?" Cell 
65(1): 1-4. 
 
Glenney, J. (1986). "Two related but distinct forms of the Mr 36,000 tyrosine kinase 
substrate (calpactin) that interact with phospholipid and actin in a Ca2+-dependent 
manner." Proc Natl Acad Sci U S A 83(12): 4258-62. 
 
Glenney, J. R., Jr. (1989). "Tyrosine phosphorylation of a 22-kDa protein is 
correlated with transformation by Rous sarcoma virus." J Biol Chem 264(34): 20163-
6. 
 
Glenney, J. R., Jr. (1992). "The sequence of human caveolin reveals identity with 
VIP21, a component of transport vesicles." FEBS Lett 314(1): 45-8. 
 
Glenney, J. R., Jr. and L. Zokas (1989). "Novel tyrosine kinase substrates from Rous 





Gliemann, J., A. Nykjaer, C. M. Petersen, K. E. Jorgensen, M. Nielsen, P. A. 
Andreasen, E. I. Christensen, A. Lookene, G. Olivecrona and S. K. Moestrup (1994). 
"The multiligand alpha 2-macroglobulin receptor/low density lipoprotein receptor-
related protein (alpha 2MR/LRP). Binding and endocytosis of fluid phase and 
membrane-associated ligands." Ann N Y Acad Sci 737: 20-38. 
 
Goebel, J., K. Forrest, L. Morford and T. L. Roszman (2002). "Differential 
localization of IL-2- and -15 receptor chains in membrane rafts of human T cells." J 
Leukoc Biol 72(1): 199-206. 
 
Gonzalez, G. A. and M. R. Montminy (1989). "Cyclic AMP stimulates somatostatin 
gene transcription by phosphorylation of CREB at serine 133." Cell 59(4): 675-80. 
 
Goold, R. G. and P. R. Gordon-Weeks (2001). "Microtubule-associated protein 1B 
phosphorylation by glycogen synthase kinase 3beta is induced during PC12 cell 
differentiation." J Cell Sci 114(Pt 23): 4273-84. 
 
Goold, R. G. and P. R. Gordon-Weeks (2004). "Glycogen synthase kinase 3beta and 
the regulation of axon growth." Biochem Soc Trans 32(Pt 5): 809-11. 
 
Gottschall, P. E., I. Tatsuno and A. Arimura (1991). "Hypothalamic binding sites for 
pituitary adenylate cyclase activating polypeptide: characterization and molecular 
identification." Faseb J 5(2): 194-9. 
 
Gottschall, P. E., I. Tatsuno, A. Miyata and A. Arimura (1990). "Characterization and 
distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-
activating polypeptide." Endocrinology 127(1): 272-7. 
 
Grimes, C. A. and R. S. Jope (2001). "CREB DNA binding activity is inhibited by 
glycogen synthase kinase-3 beta and facilitated by lithium." J Neurochem 78(6): 
1219-32. 
 
Gronenborn, A. M., G. Bovermann and G. M. Clore (1987). "A 1H-NMR study of the 
solution conformation of secretin. Resonance assignment and secondary structure." 
FEBS Lett 215(1): 88-94. 
 
Gunning, P. W., G. E. Landreth, M. A. Bothwell and E. M. Shooter (1981). 
"Differential and synergistic actions of nerve growth factor and cyclic AMP in PC12 
cells." J Cell Biol 89(2): 240-5. 
 
Hailstones, D., L. S. Sleer, R. G. Parton and K. K. Stanley (1998). "Regulation of 




Hall, A. M., L. Krishnamoorthy and S. J. Orlow (2003). "Accumulation of tyrosinase 
in the endolysosomal compartment is induced by U18666A." Pigment Cell Res 16(2): 
149-58. 
 
Hamelink, C., H. W. Lee, Y. Chen, M. Grimaldi and L. E. Eiden (2002). "Coincident 
elevation of cAMP and calcium influx by PACAP-27 synergistically regulates 
vasoactive intestinal polypeptide gene transcription through a novel PKA-
independent signaling pathway." J Neurosci 22(13): 5310-20. 
 
Hancock, J. F., A. I. Magee, J. E. Childs and C. J. Marshall (1989). "All ras proteins 
are polyisoprenylated but only some are palmitoylated." Cell 57(7): 1167-77. 
 
Hancock, W. W., L. Wang, Q. Ye, R. Han and I. Lee (2003). "Chemokines and their 
receptors as markers of allograft rejection and targets for immunosuppression." Curr 
Opin Immunol 15(5): 479-86. 
 
Hanger, D. P., K. Hughes, J. R. Woodgett, J. P. Brion and B. H. Anderton (1992). 
"Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: 
generation of paired helical filament epitopes and neuronal localisation of the kinase." 
Neurosci Lett 147(1): 58-62. 
 
Harder, T., P. Scheiffele, P. Verkade and K. Simons (1998). "Lipid domain structure 
of the plasma membrane revealed by patching of membrane components." J Cell Biol 
141(4): 929-42. 
 
Harder, T. and K. Simons (1997). "Caveolae, DIGs, and the dynamics of 
sphingolipid-cholesterol microdomains." Curr Opin Cell Biol 9(4): 534-42. 
 
Hashimoto, H., T. Ishihara, R. Shigemoto, K. Mori and S. Nagata (1993). "Molecular 
cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating 
polypeptide." Neuron 11(2): 333-42. 
 
Hashimoto, H., K. Yamamoto, N. Hagigara, N. Ogawa, A. Nishino, H. Aino, H. Nogi, 
K. Imanishi, T. Matsuda and A. Baba (1996). "cDNA cloning of a mouse pituitary 
adenylate cyclase-activating polypeptide receptor." Biochim Biophys Acta 1281(2): 
129-33. 
 
Head, B. P. and P. A. Insel (2007). "Do caveolins regulate cells by actions outside of 
caveolae?" Trends Cell Biol 17(2): 51-7. 
 
Herbert, J. M., J. M. Augereau, J. Gleye and J. P. Maffrand (1990). "Chelerythrine is 





Hernandez, A., B. Kimball, G. Romanchuk and M. W. Mulholland (1995). "Pituitary 
adenylate cyclase-activating peptide stimulates neurite growth in PC12 cells." 
Peptides 16(5): 927-32. 
 
Herrmann, C., G. Horn, M. Spaargaren and A. Wittinghofer (1996). "Differential 
interaction of the ras family GTP-binding proteins H-Ras, Rap1A, and R-Ras with the 
putative effector molecules Raf kinase and Ral-guanine nucleotide exchange factor." 
J Biol Chem 271(12): 6794-800. 
 
Hiol, A., P. C. Davey, J. L. Osterhout, A. A. Waheed, E. R. Fischer, C. K. Chen, G. 
Milligan, K. M. Druey and T. L. Jones (2003). "Palmitoylation regulates regulators of 
G-protein signaling (RGS) 16 function. I. Mutation of amino-terminal cysteine 
residues on RGS16 prevents its targeting to lipid rafts and palmitoylation of an 
internal cysteine residue." J Biol Chem 278(21): 19301-8. 
 
Hogg, N. and B. Leitinger (2001). "Shape and shift changes related to the function of 
leukocyte integrins LFA-1 and Mac-1." J Leukoc Biol 69(6): 893-8. 
 
Hope, H. R. and L. J. Pike (1996). "Phosphoinositides and phosphoinositide-utilizing 
enzymes in detergent-insoluble lipid domains." Mol Biol Cell 7(6): 843-51. 
 
Hosoya, M., C. Kimura, K. Ogi, S. Ohkubo, Y. Miyamoto, H. Kugoh, M. Shimizu, H. 
Onda, M. Oshimura, A. Arimura and et al. (1992). "Structure of the human pituitary 
adenylate cyclase activating polypeptide (PACAP) gene." Biochim Biophys Acta 
1129(2): 199-206. 
 
Hosoya, M., H. Onda, K. Ogi, Y. Masuda, Y. Miyamoto, T. Ohtaki, H. Okazaki, A. 
Arimura and M. Fujino (1993). "Molecular cloning and functional expression of rat 
cDNAs encoding the receptor for pituitary adenylate cyclase activating polypeptide 
(PACAP)." Biochem Biophys Res Commun 194(1): 133-43. 
 
Hu, C. D., K. Kariya, G. Kotani, M. Shirouzu, S. Yokoyama and T. Kataoka (1997). 
"Coassociation of Rap1A and Ha-Ras with Raf-1 N-terminal region interferes with 
ras-dependent activation of Raf-1." J Biol Chem 272(18): 11702-5. 
 
Huang, C. S., J. Zhou, A. K. Feng, C. C. Lynch, J. Klumperman, S. J. DeArmond and 
W. C. Mobley (1999). "Nerve growth factor signaling in caveolae-like domains at the 
plasma membrane." J Biol Chem 274(51): 36707-14. 
 
Hunter, T. (2000). "Signaling--2000 and beyond." Cell 100(1): 113-27. 
 
Hur, E. M., Y. S. Park, B. D. Lee, I. H. Jang, H. S. Kim, T. D. Kim, P. G. Suh, S. H. 
Ryu and K. T. Kim (2004). "Sensitization of epidermal growth factor-induced 
  
 231 
signaling by bradykinin is mediated by c-Src. Implications for a role of lipid 
microdomains." J Biol Chem 279(7): 5852-60. 
 
Impey, S., K. Obrietan, S. T. Wong, S. Poser, S. Yano, G. Wayman, J. C. Deloulme, 
G. Chan and D. R. Storm (1998a). "Cross talk between ERK and PKA is required for 
Ca2+ stimulation of CREB-dependent transcription and ERK nuclear translocation." 
Neuron 21(4): 869-83. 
 
Impey, S., D. M. Smith, K. Obrietan, R. Donahue, C. Wade and D. R. Storm (1998b). 
"Stimulation of cAMP response element (CRE)-mediated transcription during 
contextual learning." Nat Neurosci 1(7): 595-601. 
 
Ishizaka, N., K. K. Griendling, B. Lassegue and R. W. Alexander (1998). 
"Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial 
agonist stimulation." Hypertension 32(3): 459-66. 
 
Jaiswal, R. K., S. A. Moodie, A. Wolfman and G. E. Landreth (1994). "The mitogen-
activated protein kinase cascade is activated by B-Raf in response to nerve growth 
factor through interaction with p21ras." Mol Cell Biol 14(10): 6944-53. 
 
Janes, P. W., S. C. Ley and A. I. Magee (1999). "Aggregation of lipid rafts 
accompanies signaling via the T cell antigen receptor." J Cell Biol 147(2): 447-61. 
 
Jeong, J. and A. P. McMahon (2002). "Cholesterol modification of Hedgehog family 
proteins." J Clin Invest 110(5): 591-6. 
 
Jiang, H., W. Guo, X. Liang and Y. Rao (2005). "Both the establishment and the 
maintenance of neuronal polarity require active mechanisms: critical roles of GSK-
3beta and its upstream regulators." Cell 120(1): 123-35. 
 
Journot, L., D. Spengler, C. Pantaloni, A. Dumuis, M. Sebben and J. Bockaert (1994). 
"The PACAP receptor: generation by alternative splicing of functional diversity 
among G protein-coupled receptors in nerve cells." Semin Cell Biol 5(4): 263-72. 
 
Kato, K., A. D. Cox, M. M. Hisaka, S. M. Graham, J. E. Buss and C. J. Der (1992). 
"Isoprenoid addition to Ras protein is the critical modification for its membrane 
association and transforming activity." Proc Natl Acad Sci U S A 89(14): 6403-7. 
 
Kawasaki, H., G. M. Springett, N. Mochizuki, S. Toki, M. Nakaya, M. Matsuda, D. E. 
Housman and A. M. Graybiel (1998). "A family of cAMP-binding proteins that 




Keller, G. A., M. W. Siegel and I. W. Caras (1992). "Endocytosis of 
glycophospholipid-anchored and transmembrane forms of CD4 by different endocytic 
pathways." Embo J 11(3): 863-74. 
 
Khazaie, K., V. Schirrmacher and R. B. Lichtner (1993). "EGF receptor in neoplasia 
and metastasis." Cancer Metastasis Rev 12(3-4): 255-74. 
 
Kim, J., R. M. Adam, K. R. Solomon and M. R. Freeman (2004). "Involvement of 
cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of 
LNCaP prostate cancer cells." Endocrinology 145(2): 613-9.  
 
Kim, L. and A. R. Kimmel (2000). "GSK3, a master switch regulating cell-fate 
specification and tumorigenesis." Curr Opin Genet Dev 10(5): 508-14. 
 
Kirshenboim, N., B. Plotkin, S. B. Shlomo, O. Kaidanovich-Beilin and H. Eldar-
Finkelman (2004). "Lithium-mediated phosphorylation of glycogen synthase kinase-
3beta involves PI3 kinase-dependent activation of protein kinase C-alpha." J Mol 
Neurosci 24(2): 237-45. 
 
Klein, U., G. Gimpl and F. Fahrenholz (1995). "Alteration of the myometrial plasma 
membrane cholesterol content with beta-cyclodextrin modulates the binding affinity 
of the oxytocin receptor." Biochemistry 34(42): 13784-93. 
 
Krajewska, W. M. and I. Maslowska (2004). "Caveolins: structure and function in 
signal transduction." Cell Mol Biol Lett 9(2): 195-220. 
 
Krisch, B., J. Feindt and R. Mentlein (1998). "Immunoelectronmicroscopic analysis 
of the ligand-induced internalization of the somatostatin receptor subtype 2 in 
cultured human glioma cells." J Histochem Cytochem 46(11): 1233-42. 
 
Kurzchalia, T. V., P. Dupree and S. Monier (1994). "VIP21-Caveolin, a protein of the 
trans-Golgi network and caveolae." FEBS Lett 346(1): 88-91. 
 
Kurzchalia, T. V., P. Dupree, R. G. Parton, R. Kellner, H. Virta, M. Lehnert and K. 
Simons (1992). "VIP21, a 21-kD membrane protein is an integral component of trans-
Golgi-network-derived transport vesicles." J Cell Biol 118(5): 1003-14. 
 
Lai, C. and L. Feng (2004). "Neuregulin induces proliferation of neural progenitor 
cells via PLC/PKC pathway." Biochem Biophys Res Commun 319(2): 603-11. 
 





Lam, H. C., K. Takahashi, M. A. Ghatei, S. M. Kanse, J. M. Polak and S. R. Bloom 
(1990). "Binding sites of a novel neuropeptide pituitary-adenylate-cyclase-activating 
polypeptide in the rat brain and lung." Eur J Biochem 193(3): 725-9. 
 
Lander, H. M., A. T. Jacovina, R. J. Davis and J. M. Tauras (1996). "Differential 
activation of mitogen-activated protein kinases by nitric oxide-related species." J Biol 
Chem 271(33): 19705-9. 
 
Lange, Y., J. Ye, M. Rigney and T. Steck (2000). "Cholesterol movement in 
Niemann-Pick type C cells and in cells treated with amphiphiles." J Biol Chem 
275(23): 17468-75. 
 
Lange, Y., J. Ye, M. Rigney and T. L. Steck (2002). "Dynamics of lysosomal 
cholesterol in Niemann-Pick type C and normal human fibroblasts." J Lipid Res 43(2): 
198-204. 
 
Lazarovici, P. and D. Fink, Jr. (1999). "Heterologous upregulation of nerve growth 
factor-TrkA receptors in PC12 cells by pituitary adenylate cyclase-activating 
polypeptide (PACAP)." Mol Cell Biol Res Commun 2(2): 97-102. 
 
Lazarovici, P., H. Jiang and D. Fink, Jr. (1998). "The 38-amino-acid form of pituitary 
adenylate cyclase-activating polypeptide induces neurite outgrowth in PC12 cells that 
is dependent on protein kinase C and extracellular signal-regulated kinase but not on 
protein kinase A, nerve growth factor receptor tyrosine kinase, p21(ras) G protein, 
and pp60(c-src) cytoplasmic tyrosine kinase." Mol Pharmacol 54(3): 547-58. 
 
Lee, J. E. (1997). "Basic helix-loop-helix genes in neural development." Curr Opin 
Neurobiol 7(1): 13-20. 
 
Lefkowitz, R. J. (1998). "G protein-coupled receptors. III. New roles for receptor 
kinases and beta-arrestins in receptor signaling and desensitization." J Biol Chem 
273(30): 18677-80. 
 
Le Lay, S. and T. V. Kurzchalia (2005). "Getting rid of caveolins: phenotypes of 
caveolin-deficient animals." Biochim Biophys Acta 1746(3): 322-33. 
 
Lenormand, P., J. M. Brondello, A. Brunet and J. Pouyssegur (1998). "Growth factor-
induced p42/p44 MAPK nuclear translocation and retention requires both MAPK 
activation and neosynthesis of nuclear anchoring proteins." J Cell Biol 142(3): 625-33. 
 
Leroy, K. and J. P. Brion (1999). "Developmental expression and localization of 




Lev, S., H. Moreno, R. Martinez, P. Canoll, E. Peles, J. M. Musacchio, G. D. 
Plowman, B. Rudy and J. Schlessinger (1995). "Protein tyrosine kinase PYK2 
involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions." 
Nature 376(6543): 737-45. 
 
Levi-Montalcini, R. (1965). "Growth regulation of sympathetic nerve cells." Arch Ital 
Biol 103(4): 832-46. 
 
Lewis, T. S., P. S. Shapiro and N. G. Ahn (1998). "Signal transduction through MAP 
kinase cascades." Adv Cancer Res 74: 49-139. 
 
Li, M., X. Wang, M. K. Meintzer, T. Laessig, M. J. Birnbaum and K. A. Heidenreich 
(2000). "Cyclic AMP promotes neuronal survival by phosphorylation of glycogen 
synthase kinase 3beta." Mol Cell Biol 20(24): 9356-63. 
 
Li, S., J. Couet and M. P. Lisanti (1996b). "Src tyrosine kinases, Galpha subunits, and 
H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin 
binding negatively regulates the auto-activation of Src tyrosine kinases." J Biol Chem 
271(46): 29182-90. 
 
Li, S., T. Okamoto, M. Chun, M. Sargiacomo, J. E. Casanova, S. H. Hansen, I. 
Nishimoto and M. P. Lisanti (1995). "Evidence for a regulated interaction between 
heterotrimeric G proteins and caveolin." J Biol Chem 270(26): 15693-701. 
 
Li, S., K. S. Song and M. P. Lisanti (1996a). "Expression and characterization of 
recombinant caveolin. Purification by polyhistidine tagging and cholesterol-
dependent incorporation into defined lipid membranes." J Biol Chem 271(1): 568-73. 
 
Li, Y., S. Asuri, J. F. Rebhun, A. F. Castro, N. C. Paranavitana and L. A. Quilliam 
(2006). "The RAP1 guanine nucleotide exchange factor Epac2 couples cyclic AMP 
and Ras signals at the plasma membrane." J Biol Chem 281(5): 2506-14. 
 
Lin, C. H. and P. Forscher (1993). "Cytoskeletal remodeling during growth cone-
target interactions." J Cell Biol 121(6): 1369-83. 
 
Lin, S. L., N. N. Johnson-Farley, D. R. Lubinsky and D. S. Cowen (2003). "Coupling 
of neuronal 5-HT7 receptors to activation of extracellular-regulated kinase through a 
protein kinase A-independent pathway that can utilize Epac." J Neurochem 87(5): 
1076-85. 
 
Lisanti, M. P., P. E. Scherer, J. Vidugiriene, Z. Tang, A. Hermanowski-Vosatka, Y. H. 
Tu, R. F. Cook and M. Sargiacomo (1994). "Characterization of caveolin-rich 
membrane domains isolated from an endothelial-rich source: implications for human 




Liscum, L. and G. J. Collins (1991). "Characterization of Chinese hamster ovary cells 
that are resistant to 3-beta-[2-(diethylamino)ethoxy]androst-5-en-17-one inhibition of 
low density lipoprotein-derived cholesterol metabolism." J Biol Chem 266(25): 
16599-606. 
 
Liscum, L. and J. R. Faust (1989). "The intracellular transport of low density 
lipoprotein-derived cholesterol is inhibited in Chinese hamster ovary cells cultured 
with 3-beta-[2-(diethylamino)ethoxy]androst-5-en-17-one." J Biol Chem 264(20): 
11796-806. 
 
Liu, C. W., G. Lee and D. G. Jay (1999). "Tau is required for neurite outgrowth and 
growth cone motility of chick sensory neurons." Cell Motil Cytoskeleton 43(3): 232-
42. 
 
Liu, J., G. Garcia-Cardena and W. C. Sessa (1996). "Palmitoylation of endothelial 
nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: 
implications for caveolae localization." Biochemistry 35(41): 13277-81. 
 
Liu, P. and R. G. Anderson (1995). "Compartmentalized production of ceramide at 
the cell surface." J Biol Chem 270(45): 27179-85. 
 
Liu, P., Y. Ying and R. G. Anderson (1997). "Platelet-derived growth factor activates 
mitogen-activated protein kinase in isolated caveolae." Proc Natl Acad Sci U S A 
94(25): 13666-70. 
 
Liu, P., Y. Ying, Y. G. Ko and R. G. Anderson (1996). "Localization of platelet-
derived growth factor-stimulated phosphorylation cascade to caveolae." J Biol Chem 
271(17): 10299-303. 
 
Liu, Y., R. Li and S. Ladisch (2004). "Exogenous ganglioside GD1a enhances 
epidermal growth factor receptor binding and dimerization." J Biol Chem 279(35): 
36481-9. 
 
Lu, N., R. Zhou and E. DiCicco-Bloom (1998). "Opposing mitogenic regulation by 
PACAP in sympathetic and cerebral cortical precursors correlates with differential 
expression of PACAP receptor (PAC1-R) isoforms." J Neurosci Res 53(6): 651-62. 
 
Magee, T., N. Pirinen, J. Adler, S. N. Pagakis and I. Parmryd (2002). "Lipid rafts: cell 
surface platforms for T cell signaling." Biol Res 35(2): 127-31. 
 
Manes, S., R. A. Lacalle, C. Gomez-Mouton, G. del Real, E. Mira and A. C. Martinez 
(2001). "Membrane raft microdomains in chemokine receptor function." Semin 




Marais, R., J. Wynne and R. Treisman (1993). "The SRF accessory protein Elk-1 
contains a growth factor-regulated transcriptional activation domain." Cell 73(2): 
381-93. 
 
Maridonneau-Parini, I. and J. de Gunzburg (1992). "Association of rap1 and rap2 
proteins with the specific granules of human neutrophils. Translocation to the plasma 
membrane during cell activation." J Biol Chem 267(9): 6396-402. 
 
Marinissen, M. J. and J. S. Gutkind (2001). "G-protein-coupled receptors and 
signaling networks: emerging paradigms." Trends Pharmacol Sci 22(7): 368-76. 
 
Marmor, M. D. and M. Julius (2001). "Role for lipid rafts in regulating interleukin-2 
receptor signaling." Blood 98(5): 1489-97. 
 
Marshall, C. J. (1995). "Specificity of receptor tyrosine kinase signaling: transient 
versus sustained extracellular signal-regulated kinase activation." Cell 80(2): 179-85. 
 
Mastick, C. C., M. J. Brady and A. R. Saltiel (1995). "Insulin stimulates the tyrosine 
phosphorylation of caveolin." J Cell Biol 129(6): 1523-31. 
 
Matsuda, K., Y. Takei, J. Katoh, S. Shioda, A. Arimura and M. Uchiyama (1997). 
"Isolation and structural characterization of pituitary adenylate cyclase activating 
polypeptide (PACAP)-like peptide from the brain of a teleost, stargazer, Uranoscopus 
japonicus." Peptides 18(5): 723-7. 
 
Matsuda, K., T. Yoshida, Y. Nagano, K. Kashimoto, T. Yatohgo, H. Shimomura, S. 
Shioda, A. Arimura and M. Uchiyama (1998). "Purification and primary structure of 
pituitary adenylate cyclase activating polypeptide (PACAP) from the brain of an 
elasmobranch, stingray, Dasyatis akajei." Peptides 19(9): 1489-95. 
 
Matthies, H. J., H. C. Palfrey, L. D. Hirning and R. J. Miller (1987). "Down 
regulation of protein kinase C in neuronal cells: effects on neurotransmitter release." J 
Neurosci 7(4): 1198-206. 
 
McCulloch, D. A., E. M. Lutz, M. S. Johnson, D. N. Robertson, C. J. MacKenzie, P. J. 
Holland and R. Mitchell (2001). "ADP-ribosylation factor-dependent phospholipase 
D activation by VPAC receptors and a PAC(1) receptor splice variant." Mol 
Pharmacol 59(6): 1523-32. 
 
McRory, J. E., D. B. Parker, S. Ngamvongchon and N. M. Sherwood (1995). 
"Sequence and expression of cDNA for pituitary adenylate cyclase activating 
polypeptide (PACAP) and growth hormone-releasing hormone (GHRH)-like peptide 




McRory, J. E., R. L. Parker and N. M. Sherwood (1997). "Expression and alternative 
processing of a chicken gene encoding both growth hormone-releasing hormone and 
pituitary adenylate cyclase-activating polypeptide." DNA Cell Biol 16(1): 95-102. 
 
Meijering, E., M. Jacob, J. C. Sarria, P. Steiner, H. Hirling and M. Unser (2004). 
"Design and validation of a tool for neurite tracing and analysis in fluorescence 
microscopy images." Cytometry A 58(2): 167-76. 
 
Mentlein, R., J. Held-Feindt and B. Krisch (2001). "Topology of the signal 
transduction of the G protein-coupled somatostatin receptor sst2 in human glioma 
cells." Cell Tissue Res 303(1): 27-34. 
 
Mercer, A., H. Ronnholm, J. Holmberg, H. Lundh, J. Heidrich, O. Zachrisson, A. 
Ossoinak, J. Frisen and C. Patrone (2004). "PACAP promotes neural stem cell 
proliferation in adult mouse brain." J Neurosci Res 76(2): 205-15. 
 
Michel, J. B. and T. Michel (1997). "The role of palmitoyl-protein thioesterase in the 
palmitoylation of endothelial nitric oxide synthase." FEBS Lett 405(3): 356-62. 
 
Milligan, G., M. Parenti and A. I. Magee (1995). "The dynamic role of palmitoylation 
in signal transduction." Trends Biochem Sci 20(5): 181-7. 
 
Mineo, C., G. N. Gill and R. G. Anderson (1999). "Regulated migration of epidermal 
growth factor receptor from caveolae." J Biol Chem 274(43): 30636-43. 
 
Mineo, C., G. L. James, E. J. Smart and R. G. Anderson (1996). "Localization of 
epidermal growth factor-stimulated Ras/Raf-1 interaction to caveolae membrane." J 
Biol Chem 271(20): 11930-5. 
 
Misra-Press, A., C. S. Rim, H. Yao, M. S. Roberson and P. J. Stork (1995). "A novel 
mitogen-activated protein kinase phosphatase. Structure, expression, and regulation." 
J Biol Chem 270(24): 14587-96. 
 
Mitsuda, T., K. Furukawa, S. Fukumoto, H. Miyazaki and T. Urano (2002). 
"Overexpression of ganglioside GM1 results in the dispersion of platelet-derived 
growth factor receptor from glycolipid-enriched microdomains and in the suppression 
of cell growth signals." J Biol Chem 277(13): 11239-46. 
 
Miyamoto, Y., Y. Habata, T. Ohtaki, Y. Masuda, K. Ogi, H. Onda and M. Fujino 
(1994). "Cloning and expression of a complementary DNA encoding the bovine 
receptor for pituitary adenylate cyclase-activating polypeptide (PACAP)." Biochim 




Miyata, A., A. Arimura, R. R. Dahl, N. Minamino, A. Uehara, L. Jiang, M. D. Culler 
and D. H. Coy (1989). "Isolation of a novel 38 residue-hypothalamic polypeptide 
which stimulates adenylate cyclase in pituitary cells." Biochem Biophys Res Commun 
164(1): 567-74. 
 
Moffett, S., D. A. Brown and M. E. Linder (2000). "Lipid-dependent targeting of G 
proteins into rafts." J Biol Chem 275(3): 2191-8. 
 
Mohammadi, A., R. J. Perry, M. K. Storey, H. W. Cook, D. M. Byers and N. D. 
Ridgway (2001). "Golgi localization and phosphorylation of oxysterol binding protein 
in Niemann-Pick C and U18666A-treated cells." J Lipid Res 42(7): 1062-71. 
 
Monier, S., D. J. Dietzen, W. R. Hastings, D. M. Lublin and T. V. Kurzchalia (1996). 
"Oligomerization of VIP21-caveolin in vitro is stabilized by long chain fatty acylation 
or cholesterol." FEBS Lett 388(2-3): 143-9. 
 
Montixi, C., C. Langlet, A. M. Bernard, J. Thimonier, C. Dubois, M. A. Wurbel, J. P. 
Chauvin, M. Pierres and H. T. He (1998). "Engagement of T cell receptor triggers its 
recruitment to low-density detergent-insoluble membrane domains." Embo J 17(18): 
5334-48. 
 
Montminy, M. R. and L. M. Bilezikjian (1987). "Binding of a nuclear protein to the 
cyclic-AMP response element of the somatostatin gene." Nature 328(6126): 175-8. 
 
Morgan, B. P., C. W. van den Berg, E. V. Davies, M. B. Hallett and V. Horejsi (1993). 
"Cross-linking of CD59 and of other glycosyl phosphatidylinositol-anchored 
molecules on neutrophils triggers cell activation via tyrosine kinase." Eur J Immunol 
23(11): 2841-50. 
 
Morrow, J. A., E. M. Lutz, K. M. West, G. Fink and A. J. Harmar (1993). "Molecular 
cloning and expression of a cDNA encoding a receptor for pituitary adenylate cyclase 
activating polypeptide (PACAP)." FEBS Lett 329(1-2): 99-105. 
 
Mukai, F., K. Ishiguro, Y. Sano and S. C. Fujita (2002). "Alternative splicing isoform 
of tau protein kinase I/glycogen synthase kinase 3beta." J Neurochem 81(5): 1073-83. 
 
Murata, M., J. Peranen, R. Schreiner, F. Wieland, T. V. Kurzchalia and K. Simons 
(1995). "VIP21/caveolin is a cholesterol-binding protein." Proc Natl Acad Sci U S A 
92(22): 10339-43. 
 
Murphy, D. D. and M. Segal (1997). "Morphological plasticity of dendritic spines in 
central neurons is mediated by activation of cAMP response element binding 




Nagafuku, M., K. Kabayama, D. Oka, A. Kato, S. Tani-ichi, Y. Shimada, Y. Ohno-
Iwashita, S. Yamasaki, T. Saito, K. Iwabuchi, T. Hamaoka, J. Inokuchi and A. Kosugi 
(2003). "Reduction of glycosphingolipid levels in lipid rafts affects the expression 
state and function of glycosylphosphatidylinositol-anchored proteins but does not 
impair signal transduction via the T cell receptor." J Biol Chem 278(51): 51920-7. 
 
Neufeld, E. B., A. M. Cooney, J. Pitha, E. A. Dawidowicz, N. K. Dwyer, P. G. 
Pentchev and E. J. Blanchette-Mackie (1996). "Intracellular trafficking of cholesterol 
monitored with a cyclodextrin." J Biol Chem 271(35): 21604-13. 
 
Nguyen, T. T., J. C. Scimeca, C. Filloux, P. Peraldi, J. L. Carpentier and E. Van 
Obberghen (1993). "Co-regulation of the mitogen-activated protein kinase, 
extracellular signal-regulated kinase 1, and the 90-kDa ribosomal S6 kinase in PC12 
cells. Distinct effects of the neurotrophic factor, nerve growth factor, and the 
mitogenic factor, epidermal growth factor." J Biol Chem 268(13): 9803-10. 
 
Nicot, A. and E. DiCicco-Bloom (2001). "Regulation of neuroblast mitosis is 
determined by PACAP receptor isoform expression." Proc Natl Acad Sci U S A 98(8): 
4758-63. 
 
Nishida, E. and Y. Gotoh (1993). "The MAP kinase cascade is essential for diverse 
signal transduction pathways." Trends Biochem Sci 18(4): 128-31. 
 
Nishio, M., S. Fukumoto, K. Furukawa, A. Ichimura, H. Miyazaki, S. Kusunoki and 
T. Urano (2004). "Overexpressed GM1 suppresses nerve growth factor (NGF) signals 
by modulating the intracellular localization of NGF receptors and membrane fluidity 
in PC12 cells." J Biol Chem 279(32): 33368-78. 
 
Nyasae, L. K., A. L. Hubbard and P. L. Tuma (2003). "Transcytotic efflux from early 
endosomes is dependent on cholesterol and glycosphingolipids in polarized hepatic 
cells." Mol Biol Cell 14(7): 2689-705. 
 
O'Connor, T. P. and D. Bentley (1993). "Accumulation of actin in subsets of pioneer 
growth cone filopodia in response to neural and epithelial guidance cues in situ." J 
Cell Biol 123(4): 935-48. 
 
Oda, K., Y. Matsuoka, A. Funahashi and H. Kitano (2005). "A comprehensive 
pathway map of epidermal growth factor receptor signaling." Mol Syst Biol 1: 2005 
0010. 
 
Ogi, K., C. Kimura, H. Onda, A. Arimura and M. Fujino (1990). "Molecular cloning 
and characterization of cDNA for the precursor of rat pituitary adenylate cyclase 




Ogi, K., Y. Miyamoto, Y. Masuda, Y. Habata, M. Hosoya, T. Ohtaki, Y. Masuo, H. 
Onda and M. Fujino (1993). "Molecular cloning and functional expression of a cDNA 
encoding a human pituitary adenylate cyclase activating polypeptide receptor." 
Biochem Biophys Res Commun 196(3): 1511-21. 
 
Ohkubo, S., C. Kimura, K. Ogi, K. Okazaki, M. Hosoya, H. Onda, A. Miyata, A. 
Arimura and M. Fujino (1992). "Primary structure and characterization of the 
precursor to human pituitary adenylate cyclase activating polypeptide." DNA Cell 
Biol 11(1): 21-30. 
 
Okada, T., C. D. Hu, T. G. Jin, K. Kariya, Y. Yamawaki-Kataoka and T. Kataoka 
(1999). "The strength of interaction at the Raf cysteine-rich domain is a critical 
determinant of response of Raf to Ras family small GTPases." Mol Cell Biol 19(9): 
6057-64. 
 
Okamoto, T., A. Schlegel, P. E. Scherer and M. P. Lisanti (1998). "Caveolins, a 
family of scaffolding proteins for organizing "preassembled signaling complexes" at 
the plasma membrane." J Biol Chem 273(10): 5419-22. 
 
Okazaki, K., Y. Itoh, K. Ogi, S. Ohkubo and H. Onda (1995). "Characterization of 
murine PACAP mRNA." Peptides 16(7): 1295-9. 
 
Orlandi, P. A. and P. H. Fishman (1998). "Filipin-dependent inhibition of cholera 
toxin: evidence for toxin internalization and activation through caveolae-like 
domains." J Cell Biol 141(4): 905-15. 
 
Oshikawa, J., Y. Toya, T. Fujita, M. Egawa, J. Kawabe, S. Umemura and Y. Ishikawa 
(2003). "Nicotinic acetylcholine receptor alpha 7 regulates cAMP signal within lipid 
rafts." Am J Physiol Cell Physiol 285(3): C567-74. 
 
Osipenko, O. N., A. P. Barrie, J. M. Allen and A. M. Gurney (2000). "Pituitary 
adenylyl cyclase-activating peptide activates multiple intracellular signaling pathways 
to regulate ion channels in PC12 cells." J Biol Chem 275(22): 16626-31. 
 
Palade, G. E. (1953). "An electron microscope study of the mitochondrial structure." 
J Histochem Cytochem 1(4): 188-211. 
 
Pantaloni, C., P. Brabet, B. Bilanges, A. Dumuis, S. Houssami, D. Spengler, J. 
Bockaert and L. Journot (1996). "Alternative splicing in the N-terminal extracellular 
domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor 
modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in 




Parat, M. O. and P. L. Fox (2001). "Palmitoylation of caveolin-1 in endothelial cells 
is post-translational but irreversible." J Biol Chem 276(19): 15776-82. 
 
Parker, D. B., I. R. Coe, G. H. Dixon and N. M. Sherwood (1993). "Two salmon 
neuropeptides encoded by one brain cDNA are structurally related to members of the 
glucagon superfamily." Eur J Biochem 215(2): 439-48. 
 
Parton, R. G. (1996). "Caveolae and caveolins." Curr Opin Cell Biol 8(4): 542-8. 
 
Parton, R. G., M. Way, N. Zorzi and E. Stang (1997). "Caveolin-3 associates with 
developing T-tubules during muscle differentiation." J Cell Biol 136(1): 137-54. 
 
Pearson, G., F. Robinson, T. Beers Gibson, B. E. Xu, M. Karandikar, K. Berman and 
M. H. Cobb (2001). "Mitogen-activated protein (MAP) kinase pathways: regulation 
and physiological functions." Endocr Rev 22(2): 153-83. 
 
Peiro, S., J. X. Comella, C. Enrich, D. Martin-Zanca and N. Rocamora (2000). "PC12 
cells have caveolae that contain TrkA. Caveolae-disrupting drugs inhibit nerve 
growth factor-induced, but not epidermal growth factor-induced, MAPK 
phosphorylation." J Biol Chem 275(48): 37846-52. 
 
Perron, J. C. and J. L. Bixby (1999). "Distinct neurite outgrowth signaling pathways 
converge on ERK activation." Mol Cell Neurosci 13(5): 362-78. 
 
Perrone-Bizzozero, N. I., V. V. Cansino and D. T. Kohn (1993). "Posttranscriptional 
regulation of GAP-43 gene expression in PC12 cells through protein kinase C-
dependent stabilization of the mRNA." J Cell Biol 120(5): 1263-70. 
 
Pham, N., I. Cheglakov, C. A. Koch, C. L. de Hoog, M. F. Moran and D. Rotin 
(2000). "The guanine nucleotide exchange factor CNrasGEF activates ras in response 
to cAMP and cGMP." Curr Biol 10(9): 555-8. 
 
Pike, L. J. and L. Casey (1996). "Localization and turnover of phosphatidylinositol 
4,5-bisphosphate in caveolin-enriched membrane domains." J Biol Chem 271(43): 
26453-6. 
 
Pisegna, J. R. and S. A. Wank (1996). "Cloning and characterization of the signal 
transduction of four splice variants of the human pituitary adenylate cyclase 
activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and 
phospholipase C." J Biol Chem 271(29): 17267-74. 
 
Platt, F. M., G. R. Neises, R. A. Dwek and T. D. Butters (1994a). "N-





Platt, F. M., G. R. Neises, G. B. Karlsson, R. A. Dwek and T. D. Butters (1994b). "N-
butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-
linked oligosaccharide processing." J Biol Chem 269(43): 27108-14. 
 
Plyte, S. E., K. Hughes, E. Nikolakaki, B. J. Pulverer and J. R. Woodgett (1992). 
"Glycogen synthase kinase-3: functions in oncogenesis and development." Biochim 
Biophys Acta 1114(2-3): 147-62. 
 
Pohl, M. and S. A. Wank (1998). "Molecular cloning of the helodermin and exendin-
4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary 
adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence 
against the existence of mammalian homologues." J Biol Chem 273(16): 9778-84. 
 
Pol, A., R. Luetterforst, M. Lindsay, S. Heino, E. Ikonen and R. G. Parton (2001). "A 
caveolin dominant negative mutant associates with lipid bodies and induces 
intracellular cholesterol imbalance." J Cell Biol 152(5): 1057-70. 
 
Pozo, D., M. Delgado, C. Martinez, R. P. Gomariz, J. M. Guerrero and J. R. Calvo 
(1997). "Functional characterization and mRNA expression of pituitary adenylate 
cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal 
macrophages." Biochim Biophys Acta 1359(3): 250-62. 
 
Pralle, A., P. Keller, E. L. Florin, K. Simons and J. K. Horber (2000). "Sphingolipid-
cholesterol rafts diffuse as small entities in the plasma membrane of mammalian 
cells." J Cell Biol 148(5): 997-1008. 
 
Quest, A. F., L. Leyton and M. Parraga (2004). "Caveolins, caveolae, and lipid rafts 
in cellular transport, signaling, and disease." Biochem Cell Biol 82(1): 129-44. 
 
Qui, M. S. and S. H. Green (1992). "PC12 cell neuronal differentiation is associated 
with prolonged p21ras activity and consequent prolonged ERK activity." Neuron 9(4): 
705-17. 
 
Quilliam, L. A., J. F. Rebhun and A. F. Castro (2002). "A growing family of guanine 
nucleotide exchange factors is responsible for activation of Ras-family GTPases." 
Prog Nucleic Acid Res Mol Biol 71: 391-444. 
 
Raposo, G., I. Dunia, C. Delavier-Klutchko, S. Kaveri, A. D. Strosberg and E. L. 
Benedetti (1989). "Internalization of beta-adrenergic receptor in A431 cells involves 
non-coated vesicles." Eur J Cell Biol 50(2): 340-52. 
 
Raposo, G., I. Dunia, S. Marullo, C. Andre, J. G. Guillet, A. D. Strosberg, E. L. 
Benedetti and J. Hoebeke (1987). "Redistribution of muscarinic acetylcholine 
  
 243 
receptors on human fibroblasts induced by regulatory ligands." Biol Cell 60(2): 117-
23. 
 
Ravni, A., S. Bourgault, A. Lebon, P. Chan, L. Galas, A. Fournier, H. Vaudry, B. 
Gonzalez, L. E. Eiden and D. Vaudry (2006). "The neurotrophic effects of PACAP in 
PC12 cells: control by multiple transduction pathways." J Neurochem 98(2): 321-9. 
 
Razani, B., S. E. Woodman and M. P. Lisanti (2002). "Caveolae: from cell biology to 
animal physiology." Pharmacol Rev 54(3): 431-67. 
 
Reglodi, D., A. Somogyvari-Vigh, S. Vigh, J. L. Maderdrut and A. Arimura (2000). 
"Neuroprotective effects of PACAP38 in a rat model of transient focal ischemia under 
various experimental conditions." Ann N Y Acad Sci 921: 119-28. 
 
Reinhold, D. S. and K. E. Neet (1989). "The lack of a role for protein kinase C in 
neurite extension and in the induction of ornithine decarboxylase by nerve growth 
factor in PC12 cells." J Biol Chem 264(6): 3538-44. 
 
Riccio, A., S. Ahn, C. M. Davenport, J. A. Blendy and D. D. Ginty (1999). 
"Mediation by a CREB family transcription factor of NGF-dependent survival of 
sympathetic neurons." Science 286(5448): 2358-61. 
 
Ritter, T. E., O. Fajardo, H. Matsue, R. G. Anderson and S. W. Lacey (1995). "Folate 
receptors targeted to clathrin-coated pits cannot regulate vitamin uptake." Proc Natl 
Acad Sci U S A 92(9): 3824-8. 
 
Robbins, S. M., N. A. Quintrell and J. M. Bishop (1995). "Myristoylation and 
differential palmitoylation of the HCK protein-tyrosine kinases govern their 
attachment to membranes and association with caveolae." Mol Cell Biol 15(7): 3507-
15. 
 
Rodal, S. K., G. Skretting, O. Garred, F. Vilhardt, B. van Deurs and K. Sandvig 
(1999). "Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation 
of clathrin-coated endocytic vesicles." Mol Biol Cell 10(4): 961-74. 
 
Rothberg, K. G., J. E. Heuser, W. C. Donzell, Y. S. Ying, J. R. Glenney and R. G. 
Anderson (1992). "Caveolin, a protein component of caveolae membrane coats." Cell 
68(4): 673-82. 
 
Rothberg, K. G., Y. S. Ying, B. A. Kamen and R. G. Anderson (1990). "Cholesterol 
controls the clustering of the glycophospholipid-anchored membrane receptor for 5-




Runz, H., J. Rietdorf, I. Tomic, M. de Bernard, K. Beyreuther, R. Pepperkok and T. 
Hartmann (2002). "Inhibition of intracellular cholesterol transport alters presenilin 
localization and amyloid precursor protein processing in neuronal cells." J Neurosci 
22(5): 1679-89. 
 
Rybin, V. O., X. Xu, M. P. Lisanti and S. F. Steinberg (2000). "Differential targeting 
of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. 
A mechanism to functionally regulate the cAMP signaling pathway." J Biol Chem 
275(52): 41447-57. 
 
Rylatt, D. B., A. Aitken, T. Bilham, G. D. Condon, N. Embi and P. Cohen (1980). 
"Glycogen synthase from rabbit skeletal muscle. Amino acid sequence at the sites 
phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal 
sequence containing the site phosphorylated by phosphorylase kinase." Eur J 
Biochem 107(2): 529-37. 
 
Sacchetti, B., C. A. Lorenzini, E. Baldi, C. Bucherelli, M. Roberto, G. Tassoni and M. 
Brunelli (2001). "Pituitary adenylate cyclase-activating polypeptide hormone 
(PACAP) at very low dosages improves memory in the rat." Neurobiol Learn Mem 
76(1): 1-6. 
 
Sakai, Y., H. Hashimoto, N. Shintani, A. Ichibori, S. Tomimoto, K. Tanaka, M. 
Hirose and A. Baba (2002). "Involvement of intracellular Ca2+ elevation but not 
cyclic AMP in PACAP-induced p38 MAP kinase activation in PC12 cells." Regul 
Pept 109(1-3): 149-53. 
 
Sargiacomo, M., M. Sudol, Z. Tang and M. P. Lisanti (1993). "Signal transducing 
molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich 
insoluble complex in MDCK cells." J Cell Biol 122(4): 789-807. 
 
Sayas, C. L., J. Avila and F. Wandosell (2002). "Regulation of neuronal cytoskeleton 
by lysophosphatidic acid: role of GSK-3." Biochim Biophys Acta 1582(1-3): 144-53. 
 
Schaffer, B., M. Wiedau-Pazos and D. H. Geschwind (2003). "Gene structure and 
alternative splicing of glycogen synthase kinase 3 beta (GSK-3beta) in neural and 
non-neural tissues." Gene 302(1-2): 73-81. 
 
Scherer, P. E., T. Okamoto, M. Chun, I. Nishimoto, H. F. Lodish and M. P. Lisanti 
(1996). "Identification, sequence, and expression of caveolin-2 defines a caveolin 
gene family." Proc Natl Acad Sci U S A 93(1): 131-5. 
 
Scherer, P. E., Z. Tang, M. Chun, M. Sargiacomo, H. F. Lodish and M. P. Lisanti 
(1995). "Caveolin isoforms differ in their N-terminal protein sequence and subcellular 
  
 245 
distribution. Identification and epitope mapping of an isoform-specific monoclonal 
antibody probe." J Biol Chem 270(27): 16395-401. 
 
Schnitzer, J. E., P. Oh, B. S. Jacobson and A. M. Dvorak (1995). "Caveolae from 
luminal plasmalemma of rat lung endothelium: microdomains enriched in caveolin, 
Ca(2+)-ATPase, and inositol trisphosphate receptor." Proc Natl Acad Sci U S A 92(5): 
1759-63. 
 
Schnitzer, J. E., P. Oh, E. Pinney and J. Allard (1994). "Filipin-sensitive caveolae-
mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and 
capillary permeability of select macromolecules." J Cell Biol 127(5): 1217-32. 
 
Schroeder, F., A. M. Gallegos, B. P. Atshaves, S. M. Storey, A. L. McIntosh, A. D. 
Petrescu, H. Huang, O. Starodub, H. Chao, H. Yang, A. Frolov and A. B. Kier (2001). 
"Recent advances in membrane microdomains: rafts, caveolae, and intracellular 
cholesterol trafficking." Exp Biol Med (Maywood) 226(10): 873-90. 
 
Schroeder, R., E. London and D. Brown (1994). "Interactions between saturated acyl 
chains confer detergent resistance on lipids and glycosylphosphatidylinositol (GPI)-
anchored proteins: GPI-anchored proteins in liposomes and cells show similar 
behavior." Proc Natl Acad Sci U S A 91(25): 12130-4. 
 
Schroeder, R. J., S. N. Ahmed, Y. Zhu, E. London and D. A. Brown (1998). 
"Cholesterol and sphingolipid enhance the Triton X-100 insolubility of 
glycosylphosphatidylinositol-anchored proteins by promoting the formation of 
detergent-insoluble ordered membrane domains." J Biol Chem 273(2): 1150-7. 
 
Schuck, S., M. Honsho, K. Ekroos, A. Shevchenko and K. Simons (2003). 
"Resistance of cell membranes to different detergents." Proc Natl Acad Sci U S A 
100(10): 5795-800. 
 
Schwencke, C., S. Okumura, M. Yamamoto, Y. J. Geng and Y. Ishikawa (1999). 
"Colocalization of beta-adrenergic receptors and caveolin within the plasma 
membrane." J Cell Biochem 75(1): 64-72. 
 
Scott, J. D., E. H. Fischer, J. G. Demaille and E. G. Krebs (1985). "Identification of 
an inhibitory region of the heat-stable protein inhibitor of the cAMP-dependent 
protein kinase." Proc Natl Acad Sci U S A 82(13): 4379-83. 
 
Sedwick, C. E. and A. Altman (2002). "Ordered just so: lipid rafts and lymphocyte 




Sexton, R. C., S. R. Panini, F. Azran and H. Rudney (1983). "Effects of 3 beta-[2-
(diethylamino)ethoxy]androst-5-en-17-one on the synthesis of cholesterol and 
ubiquinone in rat intestinal epithelial cell cultures." Biochemistry 22(25): 5687-92. 
 
Shaul, P. W., E. J. Smart, L. J. Robinson, Z. German, I. S. Yuhanna, Y. Ying, R. G. 
Anderson and T. Michel (1996). "Acylation targets emdothelial nitric-oxide synthase 
to plasmalemmal caveolae." J Biol Chem 271(11): 6518-22. 
 
Shenoy-Scaria, A. M., D. J. Dietzen, J. Kwong, D. C. Link and D. M. Lublin (1994). 
"Cysteine3 of Src family protein tyrosine kinase determines palmitoylation and 
localization in caveolae." J Cell Biol 126(2): 353-63. 
 
Shogomori, H. and A. H. Futerman (2001). "Cholera toxin is found in detergent-
insoluble rafts/domains at the cell surface of hippocampal neurons but is internalized 
via a raft-independent mechanism." J Biol Chem 276(12): 9182-8. 
 
Simons, K. and R. Ehehalt (2002). "Cholesterol, lipid rafts, and disease." J Clin Invest 
110(5): 597-603. 
 
Simons, K. and E. Ikonen (1997). "Functional rafts in cell membranes." Nature 
387(6633): 569-72. 
 
Simons, K. and D. Toomre (2000). "Lipid rafts and signal transduction." Nat Rev Mol 
Cell Biol 1(1): 31-9. 
 
Simons, M., T. Friedrichson, J. B. Schulz, M. Pitto, M. Masserini and T. V. 
Kurzchalia (1999). "Exogenous administration of gangliosides displaces GPI-
anchored proteins from lipid microdomains in living cells." Mol Biol Cell 10(10): 
3187-96. 
 
Singh, K. R., L. K. Taylor, X. Z. Campbell, A. P. Fields and K. E. Neet (1994). "A 
bryostatin-sensitive protein kinase C required for nerve growth factor activity." 
Biochemistry 33(2): 542-51. 
 
Smart, E. J., D. C. Foster, Y. S. Ying, B. A. Kamen and R. G. Anderson (1994). 
"Protein kinase C activators inhibit receptor-mediated potocytosis by preventing 
internalization of caveolae." J Cell Biol 124(3): 307-13. 
 
Smart, E. J., C. Mineo and R. G. Anderson (1996a). "Clustered folate receptors 





Smart, E. J., Y. Ying, W. C. Donzell and R. G. Anderson (1996b). "A role for 
caveolin in transport of cholesterol from endoplasmic reticulum to plasma 
membrane." J Biol Chem 271(46): 29427-35. 
 
Smart, E. J., Y. S. Ying, C. Mineo and R. G. Anderson (1995). "A detergent-free 
method for purifying caveolae membrane from tissue culture cells." Proc Natl Acad 
Sci U S A 92(22): 10104-8. 
 
Somogyvari-Vigh, A. and D. Reglodi (2004). "Pituitary adenylate cyclase activating 
polypeptide: a potential neuroprotective peptide." Curr Pharm Des 10(23): 2861-89. 
 
Song, K. S., P. E. Scherer, Z. Tang, T. Okamoto, S. Li, M. Chafel, C. Chu, D. S. 
Kohtz and M. P. Lisanti (1996). "Expression of caveolin-3 in skeletal, cardiac, and 
smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-
fractionates with dystrophin and dystrophin-associated glycoproteins." J Biol Chem 
271(25): 15160-5. 
 
Spengler, D., C. Waeber, C. Pantaloni, F. Holsboer, J. Bockaert, P. H. Seeburg and L. 
Journot (1993). "Differential signal transduction by five splice variants of the PACAP 
receptor." Nature 365(6442): 170-5. 
 
Stahl, A. and B. M. Mueller (1995). "The urokinase-type plasminogen activator 
receptor, a GPI-linked protein, is localized in caveolae." J Cell Biol 129(2): 335-44. 
 
Stefanova, I., V. Horejsi, I. J. Ansotegui, W. Knapp and H. Stockinger (1991). "GPI-
anchored cell-surface molecules complexed to protein tyrosine kinases." Science 
254(5034): 1016-9. 
 
Stork, P. J. (2003). "Does Rap1 deserve a bad Rap?" Trends Biochem Sci 28(5): 267-
75. 
 
Stralfors, P. (1997). "Insulin second messengers." Bioessays 19(4): 327-35. 
 
Strohmeier, G. R., W. I. Lencer, T. W. Patapoff, L. F. Thompson, S. L. Carlson, S. J. 
Moe, D. K. Carnes, R. J. Mrsny and J. L. Madara (1997). "Surface expression, 
polarization, and functional significance of CD73 in human intestinal epithelia." J 
Clin Invest 99(11): 2588-601. 
 
Subramaniam, P. S. and H. M. Johnson (2002). "Lipid microdomains are required 
sites for the selective endocytosis and nuclear translocation of IFN-gamma, its 
receptor chain IFN-gamma receptor-1, and the phosphorylation and nuclear 




Suda, K., D. M. Smith, M. A. Ghatei and S. R. Bloom (1992). "Investigation of the 
interaction of VIP binding sites with VIP and PACAP in human brain." Neurosci Lett 
137(1): 19-23. 
 
Sun, P., H. Watanabe, K. Takano, T. Yokoyama, J. Fujisawa and T. Endo (2006). 
"Sustained activation of M-Ras induced by nerve growth factor is essential for 
neuronal differentiation of PC12 cells." Genes Cells 11(9): 1097-113. 
 
Svoboda, M., M. Tastenoy, E. Ciccarelli, M. Stievenart and J. Christophe (1993). 
"Cloning of a splice variant of the pituitary adenylate cyclase-activating polypeptide 
(PACAP) type I receptor." Biochem Biophys Res Commun 195(2): 881-8. 
 
Takahashi, M., K. Tomizawa, R. Kato, K. Sato, T. Uchida, S. C. Fujita and K. 
Imahori (1994). "Localization and developmental changes of tau protein kinase 
I/glycogen synthase kinase-3 beta in rat brain." J Neurochem 63(1): 245-55. 
 
Tang, Z., P. E. Scherer, T. Okamoto, K. Song, C. Chu, D. S. Kohtz, I. Nishimoto, H. 
F. Lodish and M. P. Lisanti (1996). "Molecular cloning of caveolin-3, a novel 
member of the caveolin gene family expressed predominantly in muscle." J Biol 
Chem 271(4): 2255-61. 
 
Traverse, S., N. Gomez, H. Paterson, C. Marshall and P. Cohen (1992). "Sustained 
activation of the mitogen-activated protein (MAP) kinase cascade may be required for 
differentiation of PC12 cells. Comparison of the effects of nerve growth factor and 
epidermal growth factor." Biochem J 288 ( Pt 2): 351-5. 
 
Traverse, S., K. Seedorf, H. Paterson, C. J. Marshall, P. Cohen and A. Ullrich (1994). 
"EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF 
receptor." Curr Biol 4(8): 694-701. 
 
Treisman, R. (1996). "Regulation of transcription by MAP kinase cascades." Curr 
Opin Cell Biol 8(2): 205-15. 
 
Trivedi, N., P. Marsh, R. G. Goold, A. Wood-Kaczmar and P. R. Gordon-Weeks 
(2005). "Glycogen synthase kinase-3beta phosphorylation of MAP1B at Ser1260 and 
Thr1265 is spatially restricted to growing axons." J Cell Sci 118(Pt 5): 993-1005. 
 
Uchida, D., A. Arimura, A. Somogyvari-Vigh, S. Shioda and W. A. Banks (1996). 
"Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate 
cyclase activating polypeptide." Brain Res 736(1-2): 280-6. 
 
Vallejo, I. and M. Vallejo (2002). "Pituitary adenylate cyclase-activating polypeptide 
induces astrocyte differentiation of precursor cells from developing cerebral cortex." 




van den Berg, C. W., T. Cinek, M. B. Hallett, V. Horejsi and B. P. Morgan (1995). 
"Exogenous glycosyl phosphatidylinositol-anchored CD59 associates with kinases in 
membrane clusters on U937 cells and becomes Ca(2+)-signaling competent." J Cell 
Biol 131(3): 669-77. 
 
Varma, R. and S. Mayor (1998). "GPI-anchored proteins are organized in submicron 
domains at the cell surface." Nature 394(6695): 798-801. 
 
Vaudry, D., Y. Chen, C. M. Hsu and L. E. Eiden (2002a). "PC12 cells as a model to 
study the neurotrophic activities of PACAP." Ann N Y Acad Sci 971: 491-6. 
 
Vaudry, D., Y. Chen, A. Ravni, C. Hamelink, A. G. Elkahloun and L. E. Eiden 
(2002b). "Analysis of the PC12 cell transcriptome after differentiation with pituitary 
adenylate cyclase-activating polypeptide (PACAP)." J Neurochem 83(6): 1272-84. 
 
Vaudry, D., B. J. Gonzalez, M. Basille, L. Yon, A. Fournier and H. Vaudry (2000). 
"Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to 
functions." Pharmacol Rev 52(2): 269-324. 
 
Vereb, G., J. Matko, G. Vamosi, S. M. Ibrahim, E. Magyar, S. Varga, J. Szollosi, A. 
Jenei, R. Gaspar, Jr., T. A. Waldmann and S. Damjanovich (2000). "Cholesterol-
dependent clustering of IL-2Ralpha and its colocalization with HLA and CD48 on T 
lymphoma cells suggest their functional association with lipid rafts." Proc Natl Acad 
Sci U S A 97(11): 6013-8. 
 
Vertongen, P., E. Ciccarelli, M. C. Woussen-Colle, P. De Neef, P. Robberecht and A. 
Cauvin (1994). "Pituitary adenylate cyclase-activating polypeptide receptors of types 
I and II and glucagon-like peptide-I receptors are expressed in the rat medullary 
carcinoma of the thyroid cell line 6/23." Endocrinology 135(4): 1537-42. 
 
Vertongen, P., P. De Clerck, J. C. Fournet, H. Martelli, P. Helardot, C. Devalck, T. 
Peeters, E. Sariban and P. Robberecht (1997). "Comparison between vasoactive 
intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in 
neuroblastoma tumour tissues." Neuropeptides 31(5): 409-13. 
 
Vist, M. R. and J. H. Davis (1990). "Phase equilibria of 
cholesterol/dipalmitoylphosphatidylcholine mixtures: 2H nuclear magnetic resonance 
and differential scanning calorimetry." Biochemistry 29(2): 451-64. 
 
Vossler, M. R., H. Yao, R. D. York, M. G. Pan, C. S. Rim and P. J. Stork (1997). 
"cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent 




Waeber, G. and J. F. Habener (1991). "Nuclear translocation and DNA recognition 
signals colocalized within the bZIP domain of cyclic adenosine 3',5'-monophosphate 
response element-binding protein CREB." Mol Endocrinol 5(10): 1431-8. 
 
Wagner, R. C., P. Kreiner, R. J. Barrnett and M. W. Bitensky (1972). "Biochemical 
characterization and cytochemical localization of a catecholamine-sensitive adenylate 
cyclase in isolated capillary endothelium." Proc Natl Acad Sci U S A 69(11): 3175-9. 
 
Wagner, U., M. Utton, J. M. Gallo and C. C. Miller (1996). "Cellular phosphorylation 
of tau by GSK-3 beta influences tau binding to microtubules and microtubule 
organisation." J Cell Sci 109 ( Pt 6): 1537-43. 
 
Wang, H., S. W. Yu, D. W. Koh, J. Lew, C. Coombs, W. Bowers, H. J. Federoff, G. 
G. Poirier, T. M. Dawson and V. L. Dawson (2004). "Apoptosis-inducing factor 
substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death." 
J Neurosci 24(48): 10963-73. 
 
Wang, J., F. Shen, W. Yan, M. Wu and M. Ratnam (1997). "Proteolysis of the 
carboxyl-terminal GPI signal independent of GPI modification as a mechanism for 
selective protein secretion." Biochemistry 36(47): 14583-92. 
 
Wang, Q. M., C. J. Fiol, A. A. DePaoli-Roach and P. J. Roach (1994). "Glycogen 
synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine 
and serine/threonine phosphorylation." J Biol Chem 269(20): 14566-74. 
 
Wang, Z., T. J. Dillon, V. Pokala, S. Mishra, K. Labudda, B. Hunter and P. J. Stork 
(2006). "Rap1-mediated activation of extracellular signal-regulated kinases by cyclic 
AMP is dependent on the mode of Rap1 activation." Mol Cell Biol 26(6): 2130-45. 
 
Wary, K. K., F. Mainiero, S. J. Isakoff, E. E. Marcantonio and F. G. Giancotti (1996). 
"The adaptor protein Shc couples a class of integrins to the control of cell cycle 
progression." Cell 87(4): 733-43. 
 
Waschek, J. A. (2002). "Multiple actions of pituitary adenylyl cyclase activating 
peptide in nervous system development and regeneration." Dev Neurosci 24(1): 14-23. 
 
Wassler, M., I. Jonasson, R. Persson and E. Fries (1987). "Differential 
permeabilization of membranes by saponin treatment of isolated rat hepatocytes. 
Release of secretory proteins." Biochem J 247(2): 407-15. 
 
Watanabe, T., T. Ohtaki, C. Kitada, M. Tsuda and M. Fujino (1990). "Adrenal 
pheochromocytoma PC12h cells respond to pituitary adenylate cyclase activating 




Way, M. and R. G. Parton (1996). "M-caveolin, a muscle-specific caveolin-related 
protein." FEBS Lett 378(1): 108-12. 
 
Wedegaertner, P. B., P. T. Wilson and H. R. Bourne (1995). "Lipid modifications of 
trimeric G proteins." J Biol Chem 270(2): 503-6. 
 
Wei, Y. and S. Mojsov (1996a). "Distribution of GLP-1 and PACAP receptors in 
human tissues." Acta Physiol Scand 157(3): 355-7. 
 
Wei, Y. and S. Mojsov (1996b). "Tissue specific expression of different human 
receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive 
intestinal polypeptide: implications for their role in human physiology." J 
Neuroendocrinol 8(11): 811-7. 
 
Werlen, G. and E. Palmer (2002). "The T-cell receptor signalosome: a dynamic 
structure with expanding complexity." Curr Opin Immunol 14(3): 299-305. 
 
Westover, E. J., D. F. Covey, H. L. Brockman, R. E. Brown and L. J. Pike (2003). 
"Cholesterol depletion results in site-specific increases in epidermal growth factor 
receptor phosphorylation due to membrane level effects. Studies with cholesterol 
enantiomers." J Biol Chem 278(51): 51125-33. 
 
Williams, R. S. and A. J. Harwood (2000). "Lithium therapy and signal transduction." 
Trends Pharmacol Sci 21(2): 61-4. 
 
Williams, T. M. and M. P. Lisanti (2005). "Caveolin-1 in oncogenic transformation, 
cancer, and metastasis." Am J Physiol Cell Physiol 288(3): C494-506. 
 
Wilson, B. S., J. R. Pfeiffer and J. M. Oliver (2000). "Observing FcepsilonRI 
signaling from the inside of the mast cell membrane." J Cell Biol 149(5): 1131-42. 
 
Wojtanik, K. M. and L. Liscum (2003). "The transport of low density lipoprotein-
derived cholesterol to the plasma membrane is defective in NPC1 cells." J Biol Chem 
278(17): 14850-6. 
 
Wong, A. O., M. Y. Leung, W. L. Shea, L. Y. Tse, J. P. Chang and B. K. Chow 
(1998). "Hypophysiotropic action of pituitary adenylate cyclase-activating 
polypeptide (PACAP) in the goldfish: immunohistochemical demonstration of 
PACAP in the pituitary, PACAP stimulation of growth hormone release from 
pituitary cells, and molecular cloning of pituitary type I PACAP receptor." 
Endocrinology 139(8): 3465-79. 
 
Woodgett, J. R. (1990). "Molecular cloning and expression of glycogen synthase 




Wray, V., C. Kakoschke, K. Nokihara and S. Naruse (1993). "Solution structure of 
pituitary adenylate cyclase activating polypeptide by nuclear magnetic resonance 
spectroscopy." Biochemistry 32(22): 5832-41. 
 
Wu, C., S. Butz, Y. Ying and R. G. Anderson (1997). "Tyrosine kinase receptors 
concentrated in caveolae-like domains from neuronal plasma membrane." J Biol 
Chem 272(6): 3554-9. 
 
Wyse, B. D., I. A. Prior, H. Qian, I. C. Morrow, S. Nixon, C. Muncke, T. V. 
Kurzchalia, W. G. Thomas, R. G. Parton and J. F. Hancock (2003). "Caveolin 
interacts with the angiotensin II type 1 receptor during exocytic transport but not at 
the plasma membrane." J Biol Chem 278(26): 23738-46. 
 
Yaka, R., A. Gamliel, D. Gurwitz and R. Stein (1998). "NGF induces transient but not 
sustained activation of ERK in PC12 mutant cells incapable of differentiating." J Cell 
Biochem 70(3): 425-32. 
 
Yamada, E. (1955). "The fine structure of the gall bladder epithelium of the mouse." J 
Biophys Biochem Cytol 1(5): 445-58. 
 
Yamamoto, M., Y. Toya, R. A. Jensen and Y. Ishikawa (1999). "Caveolin is an 
inhibitor of platelet-derived growth factor receptor signaling." Exp Cell Res 247(2): 
380-8. 
 
Yan, J., S. Roy, A. Apolloni, A. Lane and J. F. Hancock (1998). "Ras isoforms vary 
in their ability to activate Raf-1 and phosphoinositide 3-kinase." J Biol Chem 273(37): 
24052-6. 
 
York, R. D., D. C. Molliver, S. S. Grewal, P. E. Stenberg, E. W. McCleskey and P. J. 
Stork (2000). "Role of phosphoinositide 3-kinase and endocytosis in nerve growth 
factor-induced extracellular signal-regulated kinase activation via Ras and Rap1." 
Mol Cell Biol 20(21): 8069-83. 
 
York, R. D., H. Yao, T. Dillon, C. L. Ellig, S. P. Eckert, E. W. McCleskey and P. J. 
Stork (1998). "Rap1 mediates sustained MAP kinase activation induced by nerve 
growth factor." Nature 392(6676): 622-6. 
 
Yoshimura, T., Y. Kawano, N. Arimura, S. Kawabata, A. Kikuchi and K. Kaibuchi 
(2005). "GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity." 
Cell 120(1): 137-49. 
 
Young, S. W., M. Dickens and J. M. Tavare (1994). "Differentiation of PC12 cells in 
response to a cAMP analogue is accompanied by sustained activation of mitogen-
  
 253 
activated protein kinase. Comparison with the effects of insulin, growth factors and 
phorbol esters." FEBS Lett 338(2): 212-6. 
 
Zacharias, D. A., J. D. Violin, A. C. Newton and R. Y. Tsien (2002). "Partitioning of 
lipid-modified monomeric GFPs into membrane microdomains of live cells." Science 
296(5569): 913-6. 
 
Zhang, F., B. Crise, B. Su, Y. Hou, J. K. Rose, A. Bothwell and K. Jacobson (1991). 
"Lateral diffusion of membrane-spanning and glycosylphosphatidylinositol-linked 
proteins: toward establishing rules governing the lateral mobility of membrane 
proteins." J Cell Biol 115(1): 75-84. 
 
Zhou, F. Q. and W. D. Snider (2005). "Cell biology. GSK-3beta and microtubule 
assembly in axons." Science 308(5719): 211-4. 
 
Zhou, F. Q., J. Zhou, S. Dedhar, Y. H. Wu and W. D. Snider (2004). "NGF-induced 
axon growth is mediated by localized inactivation of GSK-3beta and functions of the 
microtubule plus end binding protein APC." Neuron 42(6): 897-912. 
 
Zinck, R., R. A. Hipskind, V. Pingoud and A. Nordheim (1993). "c-fos transcriptional 
activation and repression correlate temporally with the phosphorylation status of 
TCF." Embo J 12(6): 2377-87. 
 
Zolkiewska, A. and J. Moss (1993). "Integrin alpha 7 as substrate for a 
glycosylphosphatidylinositol-anchored ADP-ribosyltransferase on the surface of 





































RPMI 1640 medium supplemented with 10% (v/v) horse serum and 5% (v/v) heat- 
inactivated fetal bovine serum.  
 




RPMI 1640 medium supplemented with 40% (v/v) heat-inactivated fetal bovine 










































4 × Stacking gel buffer 
 
 








10% SDS, 50% sucrose, 0.1% electrophoresis purity reagent bromophenol blue, 1 M 

















10% (v/v) 10 × Transfer buffer supplemented with 70% (v/v) distilled water and 20% 














































250 mM sucrose, 3 mM imidazole, 1 mM EDTA and protease inhibitor cocktail (1 
tablet /10 ml HB), pH 7.4  
 
 




10% sucrose, 3 mM imidazole, 1 mM EDTA and protease inhibitor cocktail (1 tablet / 








40 % sucrose, 3 mM imidazole, 1 mM EDTA and protease inhibitor cocktail (1 tablet 
/ 10 ml HB), pH 7.4  
 
 
 
